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This thesis describes work conducted to enable Robot Scientist Eve to 
autonomously evaluate drug-like chemicals during high throughput experiments.  
Eve tests libraries of chemical compounds against yeast-based targets expressing 
parasite and host (human) proteins (i.e. DHFR, NMT & PGK); the parasites included 
in this study are responsible for an array of neglected tropical diseases. 
The raw data for yeast growth curves from an initial screen were evaluated, and 
decision tree rules were constructed to describe the relative activity and toxicity of 
compounds.  These rules were verified, and versions were subsequently developed 
for application to routine mass and confirmation screens.  Consequently, many 
potential lead drug-like candidates have been identified in the Maybridge Hitfinder 
library; several compounds from an approved drug library (the Johns Hopkins 
Clinical Compound Library) have also been confirmed as exhibiting activity against 
these yeast-based targets.  Further in vivo study of some JHCCL compounds is in 
progress using extracted parasite proteins; preliminary results indicate the potential 
for repositioning Triclosan and Tnp-470 as having anti-malarial behaviour based on 
their interaction with Plasmodium sp. DHFR proteins. 
In the second phase of the programme, a prototype Active Learning strategy was 
applied (active k-optimisation) to partial mass screen data as a seed; this allowed 
Eve to select compounds by assessing and predicting quantitative structure activity 
relationships (QSAR) between seed and unknown compounds.  Simulations of 
learning and testing QSAR cycles showed that Eve would be able to select active 
compounds more efficiently under such a regime.  Other strategies have been 
developed that further improve selection efficiency for active compounds, and also 
promote the ability to find rare category compounds.  An econometric model has 
been developed to demonstrate the potential beneficial impact of Active Learning 
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One of the greatest benefactors of all lifekind was a man who couldn't keep his mind on the 
job in hand.  
Brilliant?  
Certainly.  
One of the foremost genetic engineers of his or any other generation, including a number he 
had designed himself?  
Without a doubt.  
The problem was that he was far too interested in things which he shouldn't be interested in, 
at least, as people would tell him, not now.  
He was also, partly because of this, of a rather irritable disposition.  
So when his world was threatened by terrible invaders from a distant star, who were still a 
fair way off but travelling fast, he, Blart Versenwald III (his name was Blart Versenwald III, 
which is not strictly relevant, but quite interesting because --- never mind, that was his name 
and we can talk about why it's interesting later), was sent into guarded seclusion by the 
masters of his race with instructions to design a breed of fanatical superwarriors to resist 
and vanquish the feared invaders, do it quickly and, they told him, ``Concentrate!''  
So he sat by a window and looked out at a summer lawn and designed and designed and 
designed, but inevitably got a little distracted by things, and by the time the invaders were 
practically in orbit round them, had come up with a remarkable new breed of super-fly that 
could, unaided, figure out how to fly through the open half of a half-open window, and also 
an off-switch for children. Celebrations of these remarkable achievements seemed doomed to 
be shortlived because disaster was imminent as the alien ships were landing. But 
astoundingly, the fearsome invaders who, like most warlike races were only on the rampage 
because they couldn't cope with things at home, were stunned by Versenwald's extraordinary 
breakthroughs, joined in the celebrations and were instantly prevailed upon to sign a wide-
ranging series of trading agreements and set up a programme of cultural exchanges. And, in 
an astonishing reversal of normal practice in the conduct of such matters, everybody 
concerned lived happily ever after.  
There was a point to this story, but it has temporarily escaped the chronicler's mind. ” 
 









Adventures with yeast, part 1 of 7:  Khorasan loaves 
 
Dough starter: 
5 grams fresh yeast 
135 ml  cold water 
100 grams strong white bread flour 
100 grams Khorasan flour 
Whisk the yeast into the water.  Add the flours and mix, then store in a warm place for at 
least six hours. 
Main dough 
680 ml  warm water 
940 grams strong white bread flour 
130 grams  Khorasan flour 
15 grams sea salt 
22 grams fresh yeast 
Mix the water into the starter.  Add this mixture to the flours and other ingredients, and 
knead for 10 minutes.  Allow it to rise in a warm place for one hour or longer, then knock 
back, shape into two loaves, and leave to rise again for 30 minutes.  Dust with flour, and 





The process for drug discovery and development is expensive and of high risk, and 
largely the preserve of pharmaceutical companies (Morgan et al., 2011).  Whilst 
independent and specialised discovery research groups do exist in small companies 
and academia, the long and expensive registration process almost invariably means 
that larger companies usually step in once potentially successful candidate drugs 
have been identified. 
The underlying problem in the discovery phase is to find lead compounds that 
maximise the probability of discovering an effective pharmaceutical.  This problem is 
not only limited by scientific knowledge and its application, but is also strongly 
affected by resource management, balancing the costs of time and money 
associated with this process against the expected benefits of profit and health 
improvements. 
Simple candidate selection of drug-like compounds is linear and iterative, where 
compounds from a large library are individually tested against a target based on a 
micro-organism to find those with notable activity.  An alternative approach is to 
make use of quantitative structure-activity relationship (QSAR) techniques where 
existing seed/lead chemical compounds are used as indicators of possible 
alternative candidates.  Once lead compounds have been identified their structures 
can be scrutinised by an expert, and modified if necessary to further improve their 
drug-like properties. 
It is proposed that a further enhancement would be to have a continuous learning 
process to incorporate all information obtained during the experiments, thereby 
enabling re-modelling of the selection process as more data becomes available.  
This becomes a problem suited to Active Learning (AL) techniques, where AL is a 
branch of machine learning in which algorithms are designed to continuously select 
the next best examples to test.  AL has previously been applied only sparingly to 
QSAR analysis (Warmuth et al., 2003; De Grave et al., 2008a), most likely due to 
insufficient public domain compound/target data available for effective models to be 
built.  The proposed development programme for Robot Scientist Eve (Sparkes et 
al., 2010) explicitly included AL methods as part of its structure, with one aim being 
that Eve would conduct fully automated drug screening and discovery experiments. 
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1.2 The Robot Scientist project 
Originally based in Aberystwyth University, with Professor Ross King as the founder 
and Principal Investigator (King et al., 2009), the Robot Scientist project moved to 
the Manchester Interdisciplinary Biocentre (MIB), University of Manchester in 2012. 
The concept is to fully automate scientific method by linking up and automating the 
steps that form the scientific discovery process, applying rules and procedures with 
absolute objectivity and without bias; a Robot Scientist should be able to generate 
hypotheses, devise and run repeatable experiments to test them, interpret the results 
and refine each hypothesis.  This cycle is repeated until a satisfactory outcome is 
reached, and all methods and results are recorded in order that the work can be 
reproduced by others. 
Adam was the first Robot Scientist in the programme; it was a combination of 
laboratory worker and data analyst, and has shown its capacity for independent 
hypothesis-led experimentation by discovering novel gene function in yeast strains 
(King et al., 2004).  The system was designed to run microbial growth experiments 
to explore the amino acid pathway of the yeast Saccharomyces cerevisiae, with all 
liquid handling, growth measurements and analyses as linked up automated steps, 
requiring minimal human intervention after the initial set up. 
Robot Scientist Eve has been developed specifically to run high throughput 
experimentation (HTE) for testing the activity of libraries of drug-like compounds 
against genetically modified yeast assays (Sparkes et al., 2010); the yeast strains 
used to date have been developed by the School of Biological Sciences, University 
of Cambridge (Bilsland et al., 2011).  The strains have been modified to include 
enzymes from parasites responsible for certain neglected tropical diseases; these 
targets are evaluated alongside orthologue human strains, with the aim of identifying 




1.3 Drug-like compound selection processes 
Mass screening work conducted on Eve is limited to using a collection of drug-like 
compounds provided by the Maybridge Hitfinder library (www.maybridge.com); this 
collection is small compared to commercial libraries but is designed to be chemically 
diverse, covering a wide range of pharmaceutical functionality.  Analysis of the large 
array of chemical and biological assay data generated in each screen has needed to 
be formalised as part of this thesis, and has been fundamental in developing Robot 
Scientist Eve as a prototype drug discovery system.  These data are then used to 
identify potential drug-like activity. 
When isolating lead drug-like compounds it would be ideal if the next selected 
candidate showed strong activity with minimal toxicity to the human host, but in early 
stages strong candidates with notable toxicity might be also of value as indicators of 
similar structures with potentially strong activity.  However, when building and 
applying Active Learning routines, there are several other criteria to consider when 
selecting the next untested candidate compound within the screening process: e.g. 
should it be the one with maximum predicted variance, the maximally optimistic one, 
the one with maximum predicted mean value, the one offering the maximum 
predicted improvement?  All these criteria have conflicting effects, and building a 
balanced AL model depends on consideration of their relative importance. 
It was planned that Eve‟s prototype AL selections would use the active k-optimisation 
strategy (De Grave et al., 2008a), and be compared to Pfizer‟s Naive Bayesian 
approach (company confidential).  These could be benchmarks for additional 
models, to be designed using simple chemical knowledge.  Finalised models should 
select the next 𝑛 best candidates from a list of untested compounds, whilst allowing 
the model to develop and search the wider chemical space.  The ability to search 
much larger libraries must also be considered, together with an eye on exploring the 
space outside constraints applied by the library; this latter aspect might further 
develop the Robot Scientist project, where activity predictions for novel molecules 
could be made before they are synthesised and tested. 
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1.4 Challenges and goals 
The primary intent for this thesis was to find novel ways to carry out drug discovery; 
the scope of this work was beyond simply providing support to Eve‟s development, 
and it was intended that AL strategies devised would have much more widespread 
applicability.  The final strategies were based on simple inputs (standard chemical 
fingerprint techniques, and classification of drug-like activity) that could readily be 
applicable to many systems or problems.  Robot Scientist Eve was to provide the 
data sets upon which these methods would be developed. 
The novelty of Eve and the associated yeast strain targets meant that very specific 
problems would need to be solved before moving on to develop the Active Learning 
algorithms that would satisfy the primary intent.  
The verification of several aspects of Eve‟s processes eventually fell under the remit 
of this thesis: 
 It needed to be shown that the growth of the yeast-based targets could be 
measured consistently and objectively in a high throughput system. 
 Discrimination needed to be proven between active and inactive treatments, 
as provided in the form of positive and negative controls. 
 The results generated by Eve needed to be shown to be consistent and 
significant on a continuous basis across all screens; this would show that Eve 
is capable of consistently running good quality high throughput experiments. 
Once good quality datasets had been built, the Active Learning phase would hold the 
following challenges: 
 The prototype methods for Active Learning needed to be shown as offering 
improvements over simple, linear, methods for candidate identification, and a 
means of measuring these benefits needed to be designed. 
 Alternative AL approaches needed to be found that might offer further 
enhancements over the prototype method. 
These AL methods would be tested using Eve‟s data, but would be designed with 
general results in mind to enable wider applications.   
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In addition, the combined effect of meeting the above targets would allow Eve to 
operate as a standalone entity for the drug discovery process, whilst also compiling 
specific empirical datasets for the drug-like compounds/target combinations that 
might prove useful to other researchers. 
 
1.5 Thesis organisation and structure 
This thesis follows the pathways of the processes built for Eve, initially for isolating 
and identifying activity levels against different modified yeast targets, then for the 
tools that enable the Active Learning routines to be designed and evaluated. 
Chapter 2 is a review of the building blocks required in conventional drug discovery 
processes.  The general nature of pharmaceutical research is discussed, together 
with current techniques such as QSAR (quantitative structural activity relationships).  
Details are given of the yeast targets, and the parasites responsible for the neglected 
tropical diseases for which they will provide analogues.  This chapter includes an 
examination of the types of tool available to the computational chemist, albeit from a 
perspective based on open source software, and will start to identify areas where 
Robot Scientist Eve group might provide benefits.  Machine learning and other 
computational techniques are reviewed, with a bias towards modelling datasets from 
chemical problems 
Active Learning techniques are described, together with their possible application to 
drug discovery.  Variations that can boost the performance of AL are investigated, 
with a leaning towards finding regions of the chemical space less oft explored. 
In Chapter 3 the raw data generated by Eve is analysed, and rules are built to extract 
and simplify the relative activity of compounds.  Mass screen data are used to 
generate candidates for confirmatory testing, and lists of active candidates are built.  
Work conducted on existing drug therapies from the Johns Hopkins Clinical 
Compounds Library is reported 
Chapter 4 devises a scheme for using mass screen data as a proxy for confirmation 
screen data, thereby allowing in silico simulations of Active Learning algorithms.  AL 
processes are refined to incorporate either numerical or classification data, thereby 
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expanding the options away from the prototype AL method.  Commentary on 
different approaches is provided, with variations in clustering methods, transfer 
learning and rare category detection being considered. 
Chapter 5 reports the results of the simulations for each AL method, and makes a 
detailed comparison of their performances. 
Chapter 6 expands on the AL simulation studies by incorporating an econometric 
model.  The potential for improving the efficiency of drug discovery is discussed 
when using data handling processes similar to those developed using Eve‟s 
experiments. 
Chapter 7 summarises the highlights of the work conducted in support of this thesis. 
Conclusions are drawn on the approaches used, and ideas are provided for further 
work and possible additional publications. 
Appendix A provides data drawn from mass and confirmation screens reported in 
Chapter 3; it includes lists of all compounds with suggested activity versus the yeast 
analogues of parasitic organism enzymes. 
Appendix B is a compilation of all simulations run using the Active Learning 
algorithms described in Chapter 5. 
Appendix C gives details of the data file structure provided by Eve, and the hardware 




1.6 Contributions to knowledge, and related work 
Contributions to knowledge 
Details of the main achievements of this programme are given in Sections 7.1 & 7.2.  
Active Learning strategies based on classification of drug-like activity have been 
developed successfully; by using simple input data, these strategies should be 
readily adaptable to other drug discovery regimes, and will also have applicability for 
dealing with other problems where rare category detection is required. 
Specifically, this work has enabled Robot Scientist Eve to autonomously evaluate 
drug-like chemicals, moving between mass screen and confirmation screen modes. 
It has also been shown by simulation that Eve might switch from mass screening to 
an intelligent screening mode, with distinct improvement in the rate of detection of 
active compounds.  Similarly, it has been shown that active compounds with rare 
structures (i.e. dissimilar to compounds known to be active) can be promoted and 
found at earlier stages compared to simple search protocols. 
Eve‟s confirmation work on existing drug therapies suggests potential activity against 
neglected parasitic diseases for 14 of these, and also suggests a possible mode of 
parasite growth inhibition for two candidates with previously identified in vivo effects. 
Publications 
The work on the Robot Scientist Eve programme was ring-fenced in order to support 
major publications, hence it was not possible to publish intermediate studies.  
A poster (The Robot Scientist Eve: selection and confirmation of chemical 
compounds with potential for activity against parasites causing neglected tropical 
diseases, Williams et al.) was presented at the SLAS exhibition in San Diego in 
February 2012.  This was supported by an academic travel award from SLAS under 
their Tony B. Award programme for new researchers. 
Some results from the data analysis for Robot Eve have now been published in 
(Bilsland et al., 2013). 
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The work on applied machine learning for mass & confirmation screens, and the 
prototype active k-optimisation algorithm is in an advanced draft; this publication will 
include evidence of possible drug repositioning for JHCCL compounds. 
A further publication with specific drug repositioning for Triclosan is also in an 
advanced draft. 
The two papers currently under revision were originally submitted in the form of a 
single publication to Science:  
Cheaper Faster Drug Development Validated by the Targeted Repositioning of 
Triclosan against Dihydrofolate Reductase in Malarial Parasites (Kevin Williams, 
Elizabeth Bilsland, Andrew Sparkes, Wayne Aubrey, Michael Young, Larisa N. 
Soldatova, Kurt De Grave, Jan Ramon, Liisa Van Vliet, Jack E. Feltham, Florian 
Hollfelder, Michaela de Clare, Worachart Sirawaraporn, Victoria Jackson, Stephen 







Background knowledge for drug discovery and Active 
Learning 
Adventures with yeast, part 2 of 7:  Ninja wine 
 
1 kg  fresh root ginger 
5 kg  white sugar 
1 kg  sultanas 
3  juiced lemons 
1 cup  strong black tea 
1 teaspoon Marmite 
1 packet desert wine yeast 
 
Whilst generally following all the normal steps for home wine making...  
Macerate or finely chop the ginger, and add to 5 litres of water.  Heat the mixture to near 
boiling point, then allow it to cool to room temperature over a couple of hours. 
Add the marmite and 3 kg of sugar to 5 litres of water; heat this until the sugar is dissolved, 
then allow to cool to room temperature. 
When cooled, combine the two mixtures in a sanitised container.  Add the lemon juice and 
tea.  Macerate the sultanas and add these to the mixture with stirring. Make up to 15 litres 
with cold water.  Sprinkle the yeast onto the mixture, and mix in after 15 minutes.   
After two days of fermentation, add 1 kg of sugar to the mixture with stirring.  After two 
further days, add the remaining sugar with stirring. 
12 
 
2.1 Drug development from academia’s perspective 
Success in the field of drug design can be readily quantified, but less readily 
predicted.  The drug development process is exposed to rigorous approval steps, 
and failure is common at each way point; a pharmaceutical company may start trials 
with several tens or hundreds of compounds to treat a certain condition, with the 
hope of finding one commercially feasible molecule. 
A candidate compound will need to pass through a minimum of the following steps: 
 Finding the chemical lead compounds (in silico, in vitro) 
 Pre-clinical trials: testing for absorption, distribution, metabolism, and 
excretion (ADME) properties (in vitro, in vivo) 
 Clinical trials: Phase I (safety), II (effectiveness) & III (definitive) trials (in vivo) 
 There may also be Phase 0 (micro dose in humans to understand 
pharmacokinetic properties) and Phase IV trials (post-approval monitoring). 
The full process will take many years and many $100m to complete for a single 
therapeutic agent.  Selection of the starting point of the work will have a strong 
influence on the relative success of the development programme. 
The power of computational techniques has improved over time, resulting in a shift in 
the methods for finding lead compounds from in vitro experimentation towards 
in silico work.  (Goodford, 1984) gave a synopsis of the previous two decades' work 
in drug design using a receptor fit approach, and also pointed to potential future 
developments (e.g. drugs tuned to the individual requirements of patients based on 
their genetic code).   
Christopher Lipinski‟s (of Pfizer) work has been pivotal in identifying fundamental 
properties expected of drug-like compounds, and mooted a series of rules for drug 
discovery when using computational and experimental modelling (Lipinski et al., 
1997).  He argues that the empirical approach to drug design has been replaced by 
rational approaches, largely due to extensions in the knowledge base from HTE.  In 
vitro HTE has allowed a dramatic change to the previous process of lead compound 
selection consistent with historically orally active compounds; large libraries can now 
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be examined initially for hits, with screening for other properties such as IC50 
(inhibition concentration of a drug at which biological activity is halved) and solubility 
now taking place at a later time.  Subsequently, new lead compounds do not 
necessarily fit the classical “active” profile in vivo.  Other properties now come to the 
fore, allowing a wider scope of compounds to be tested in vitro thanks to improved 
solvation systems (Patel and Gordon, 1996).  Any leads from this work can be 
examined for relevance and possible modification to improve their usability.  One 
downside of this approach is that very active, but otherwise unsuitable, compounds 
might eclipse compounds with lower potency but favourable therapeutic profiles. 
2.2 Organic chemical structures and general drug-like properties 
The predictive models for drug development (see sections 2.10 & 2.11 for an 
expansion of these techniques) make use of a wide range of structural and 
physicochemical parameters to describe the behaviour of seed and candidate 
molecules.  Earlier predictive work used simpler datasets, largely using 2D structural 
modelling techniques in addition to activity and solubility measurements such as: 
IC50 Half maximal inhibitory concentration: the concentration of a 
drug at which the activity of a biological process is halved.  High 
potency is much preferred, as this minimises the impact of 
weaker factors elsewhere. 
Molecular weight Small molecules are preferred at the early stages of 
development, as they have a tendency to diffuse more 
effectively after application. 
Solubility Drug-like molecules need to be transported in the aqueous 
blood phase, and be able to pass through lipid cell membranes. 
Lipophilicity A measurement of relative solubility in the lipid phase, using the 
logarithm of the octanol:aqueous solubility partition coefficient 
(log P). 
C log P A computationally predicted version of log P. 
M log P A measured version of log P from experiments. 
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H-bond donor Increased numbers of hydrogen bond donors in a molecule 
generally improves aqueous solubility at the expense of lipid 
solubility, and helps to define the relative ease with which the 
compound passes through different membranes, e.g. cell walls; 
blood-brain barrier. 
More recently, it is computationally feasible that several hundred parameters might 
be measurable or predicted for each molecule and its activity within an experiment, 
and these data used in the model.  Complex 3D structures of candidate molecules 
and targets may now be constructed, in order to predict interactions. 
2.3 Discovery methods based on drug-like properties 
Compounds listed in the Derwent World Drugs Index (WDI) that reached Phase II 
trials have been systematically analysed for parameters influencing efficacy: 
molecular weight, lipophilicity (octanol solubility:aqueous solubility) as C log P and/or 
M log P, hydrogen bond donor and acceptor groups.  Analysis of these parameters 
led to generation of “The Rule of 5”, such that poor absorption and permeation are 
more likely when: 
 There are more than 5 hydrogen bond donors (sum of –NH and –OH) 
 The molecular weight is greater than 500 
 log P  > 5  (or  M log P  > 4.15) 
 There are more than 10 hydrogen bond acceptors (sum of Ns and Os) 
Some compound classes contain notable exceptions to “The Rule of 5”, e.g. 
substrates for biological transporters (antibiotics, antifungals, vitamins, cardiac 
glycosides). 
Compounds reaching Phase II trials that had exceeded two or more parameters 
occupied at most 10% of the data set for any combination.  If a drug-like compound 
doesn‟t fit these rules it is likely to need a high activity to be useful (a function of 
dose, solubility and permeability to describe potency); the Rule of 5 doesn‟t allow for 
this factor as it is based on simplified limits rather than such combination effects. 
The “Rule of 5” was extended to describe the properties required of an effective 
pharmaceutical molecule and the distribution of families of such compounds across 
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the whole domain of medium sized organic chemicals (Lipinski, 2000).  At that time, 
the number of drug-like compounds in existence was estimated at 10000, with an 
estimated number of targets as 500 strong (Drews, 2000). 
In theory there are more than 1050 molecules up to molecular weight 600 that contain 
the atoms commonly found in drugs (Lipinski, 2000); this is an immense space, but 
it is Lipinski‟s opinion that pharmacologically active compounds only occupy discrete 
areas in this space, and that random screening across it amounts to a lottery.  Drug 
companies duly take a conservative approach, and stay close to existing knowledge 
families; this suggests that alternative rational searches of other areas of the 
chemical space might be beneficial if suitable starting points could be identified. 
(Lipinski, 2006) also discusses a demarcation between how commercial and 
academic research organisations should go about their work.  He argues that, almost 
by definition, pharmaceutical and biotechnology companies are unlikely to take large 
strides into unknown territory as there is too much risk for it to be fruitful; this leaves 
such areas open for academia to investigate, and yet there is seemingly insufficient 
support for them to do so.  The cycle by which academia acquires research funding 
and generates papers seems to produce an almost equally conservative approach; 
the push for universities to claim chunks of intellectual property is seemingly 
compounding this effect, with the academic now having further bureaucratic hurdles 
to jump, and making external relationships more difficult to forge. 
Lipinski suggests that the main areas of academic interest for drug screening/design 
should be those away from the mainstream, or in areas where there is little or no 
potential profit (e.g. Neglected Tropical Diseases); he argues that university 
Intellectual Property officers may not realise that trying to protect IP in neglected, low 
profit areas is fairly pointless, and its pursuit will only harm potential partnerships. 
An area that should be of most interest to academia is the use of small molecules for 
verification of screening tests and/or investigating biological pathways, and these 
tasks are far removed from drug discovery.  It is in this type of work that “big pharma” 
and academia need to have better links as the former have large databases of what 
doesn't work (and why) and can help to eliminate studies doomed to later difficulties; 
this needs openness and trust in both directions, which in turn is an approach that is 
becoming increasingly difficult to foster. 
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2.4 Parasites responsible for ‘Neglected Tropical Diseases’ 
Neglected Tropical Diseases (NTD) are largely defined and described by chronic 
impacts in impoverished communities through their debilitating effects on health and 
development (Feasey et al., 2010).  The term is effectively a catch-all for diseases 
that have lain outside the scope of development programmes of pharmaceutical 
companies, largely due to limited impacts on targeted commercial markets and 
hence limited immediate profitability. 
The last decade has seen greater recognition of the need to combat NTDs, and to 
assist those communities affected by helping with prevention, education, control and 
treatment.  Traditional academic funding in this area is increasingly augmented by 
national and philanthropic bodies, e.g. U.S. National Institutes of Health (NIH); Bill & 
Melinda Gates Foundation; Wellcome Trust (Moran, 2011), and dedicated high 
profile journals also now exist (e.g. PLOS Neglected Tropical Diseases, established 
in 2007). 
The infectious parasitic diseases within the scope of the Robot Scientist programme 
are caused by either protozoa (unicellular eukaryotic organisms) or helminths 
(parasitic worms); existing therapies suffer from restrictions due to varying 
combinations of increased drug resistance, low effectiveness, difficult side effects, 
and high expense.  Current information for each of the parasites/diseases can be 
gleaned from (www.who.org).   
Malaria (wild and drug-resistant strains of Plasmodium falciparum and P.vivax in this 
study) is a major problem for developing countries with an estimated 219 million 
cases in 2010, leading to ~660,000 deaths, mostly among African children.  Existing 
drug therapies are effective for the wild-type strains, but increasing incidence of drug 
resistance (artemisinin and derivatives) is a growing concern (Dondorp, 2009). 
The protozoa responsible for Chagas disease, Typanosoma cruzi (de Souza et al., 
2010), is endemic in a large reservoir of wild animals in Central and South America, 
and the parasite cannot be eradicated.  Infection is estimated at 7 to 8 million people, 
mostly in Latin America.  Whilst effective treatments exist, they need to be employed 
soon after infection and have adverse side effects in a significant number of patients 
(reported up to 40%). 
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Sleeping sickness (Human African trypanosomiasis) is transmitted by the bite of 
infected tsetse flies in sub-Saharan Africa.  Two subspecies of the Trypanosoma 
brucei parasite cause the disease (Steverding, 2010): untreated, those infected with 
the far commoner T. b. Gambiense have a possible survival time of several years, 
whereas T. b. Rhodesiense will cause death within months.  Different treatments are 
required at the first (asymptomatic) and second stages, with those effective in the 
latter being significantly more toxic. 
Leishmaniasis is transmitted by bites from the infected female phlebotomine sandfly.  
There are some twenty species of leishmania protozoa, causing various problems 
ranging from the fatal visceral form (caused by L. Donovani) to skin lesions (Melby 
et al., 1992).  1.3 million cases are estimated per annum, with 20-30,000 deaths.   
Schistosomiasis is caused by Schistosoma spp. blood flukes.  In sub-Saharan Africa, 
more than 200,000 deaths are due to infection with S.mansoni.  Praziquantel is an 
effective treatment for all forms of Schistosomiasis, but is seemingly only available to 
12% of the estimated 243 million infected people (2011 figures), and there are 
concerns that drug-resistant parasites may develop (Melman et al., 2009). 
2.5 Protein targets and yeast strains  
For this project, the yeast Saccharomyces cerevisiae has been genetically 
engineered to contain drugable enzyme targets from the parasite strains.  The yeast 
strains for Eve were developed by Dr E Bilsland, School of Biological Sciences, 
University of Cambridge (Bilsland et al., 2011).   
These modified yeasts have been used as targets to counter significant problems 
that would arise in high throughput drug screening if whole parasites were otherwise 
under test.  Three drugable protein targets have been used for this work:  
 Dihydrofolate reductase (DHFR) is the enzyme responsible for conversion of 
dihydrofolate into tetrahydrofolate (Bertino, 2009), an essential process in the 
growth of all organism types. 
 Phosphoglycerate kinase (PGK) is an essential enzyme for parasites in their 
development stage in the host‟s blood (Michels et al., 2006). 
 N-myristoyltransferase (NMT) is a protein modifier, which allows parasites to 
target certain membranes (Frearson et al., 2010). 
18 
 
The human and parasite protein strain have been used to replace the equivalent 
function in wild-type yeast. 
The three strains chosen for each assay needed to fluoresce at discrete wavelengths 
in order to be measured without interference; this was achieved by Dr Bilsland by 
attaching different fluorophores to the strains.  The three fluorophores used to date 
are labelled as mcherry (580 nm excitation wavelength, 612 nm emission), sapphire 
(405/510 nm) and venus (500/540 nm).  Initial trials with Eve used pairs of yeast 
strains, but quickly progressed to the triple strain approach used for the main body of 
the experiments.  It was proposed that Eve might operate using four strains with 
discrete fluorophores, but this has not been attempted to date. 











-    Human 
-    Plasmodium vivax 
-    Drug resistant P.vivax 
-    P.falciparum 
-    Drug resistant P.falciparum  
-    Schistosomiasis mansoni 
-    Trypanosoma brucei 
-    Trypanosoma cruzi 
-    Leishmania major 
PGKpdr5 Hs, Pv, Sm, Tb, Tc 
NMTpdr5 Hs, Pv, Sm, Tb, Tc 
Table 2.1:  Modified target yeast strains for Robot Eve 
The drug resistant PvRdhfr strain is a triple mutant for residues S58R, S117N, and 
I173L; the resistant PfRdhfr strain is a triple mutant for N51I, C59R & S108N.  
Several other drug resistant double, triple and quadruple mutants of PvDHFR and 






2.6 Mutations and drug resistance 
Drug resistance in parasites occurs through selection in the population.  The drug 
removes those strains susceptible to its actions, leaving the field clear for less 
susceptible strains of the organism to flourish.  If the drug target site embedded in 
the structure of the protein is obscured by mutation, the ligands from the drug might 
be blocked from binding.  Within any population, parasites will exist where these 
mutated structures occur, but under normal circumstances will be out-competed by 
the more successful, unmutated organism (by definition).  As an example, a study of 
relative effectiveness of antifolates in a wide range of examples of P.vivax where the 
DHFR protein is mutated has shown that enzyme efficiency is distinctly adversely 
affected with increased mutation (Auliff et al., 2010); these mutated strains would 
easily be out-competed by unmodified examples. 
Drug resistance in P.falciparum is a serious problem.  The anti-folate mechanism by 
which pyrimethamine is an effective drug, was shown to be disrupted by mutation of 
the DHFR structure (Peterson et al., 1988).  The range of artemisinin-based 
antimalarials is also reported to be experiencing resistance in some areas of South 
East Asia (Dondorp et al., 2009). 
For P.falciparum, the structure of the DHFR domain consists of ~198 amino acids, 
and the wild-type drug-sensitive strain is labelled as 3D7.  A mutant version having 
pyrimethamine resistance (labelled HB3) exists where a single amino acid residue at 
position 108 has changed from serine (S) to aspargine (N), and is thus referred to as 
the S108N mutant. 
Other prevalent double and triple mutant strains are (Cowman et al., 1988): 
7G8 double mutant (S108N, N51I) 
*Csl-2 triple  (S108N, C59R, I164L) Thailand 
*K-1 double  (S108N, C59R)  Thailand 
*V-1 double  (S108N, C59R)  Vietnam 
Palo-Alto double (S108T, A16V)  Uganda 
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The strains marked * were ~100 times more resistant to pyrimethamine than 3D7, 
with the others showing intermediate resistance.  The Palo-Alto strain is resistant to 
cycloguanil (Sirawaraporn et al., 1997), relating to the local use of this drug. 
Work on alternative therapies has focussed on identifying the changes to the DHFR 
structure, and proposing alternative ligands.  One earlier interesting compound, 
WR99210, was found to have activity in various mutations of the PfDHFR protein, 
including a quadruple mutant (Yuvaniyama et al., 2003).  Another compound, 
QN254, also showed promise against such targets, but later mouse and rat 
modelling suggested too small a therapeutic window (Nzila et al., 2010).  
Similarly, work on P.vivax strains has indicated that the para-chlorine atom on 
pyrimethamine causes steric hindrance in the double mutant SP21 (S58R, S117N; 
note: this corresponds to C59R and S108N in P.falciparum).  An analogue of 
pyrimethamine with the chlorine atom removed has a seven-fold improvement in the 
inhibition of SP21 (Kongsaeree et al., 2005).  Further knowledge of modes of 
mutation might assist with the idea of using multiple therapies with opposing modes 
of selection (Ridley, 2002).   
For the experiments on Eve, the drug resistant PvR DHFR strain is a triple mutant 
(S58R, S117N, I173L); the resistant PfR DHFR strain is a triple mutant (N51I, C59R, 
S108N) (Bilsland et al., 2013).   
 
Studies of leishmania and trypanosoma spp. (Chakravarty and Sundar, 2010; 
Baker et al., 2013) have identified drug resistant mutations, and other work on 
helminths (James et al., 2009) suggests that both changes in genes and their 




2.7 2D representations of organic chemical structures 
The methods used in this project for representing chemical structures (SMILES 
codes), and the tools used for similarity searching across the available chemical 
space (Tanimoto Similarity coefficients) were chosen to fit in with those used for the 
prototype Active Learning method.  This approach was decided to reduce the level of 
variability when comparing different AL algorithms, as it these which were to be 
examined rather than the overall efficacy of the compound selection processes.   
The scaffold structure of an organic chemical lends itself to be codified.  The 
presentation of atoms and bonds follow physical rules; the forces and interactions 
within a molecule can be calculated, which in turn allow 3D representations to be 
built.  However, in terms of the predictive modelling requirements for HTE, a 2D 
representation of molecular structure is far simpler to work with; SMILES codes, 
SMARTS patterns (James et al., 1997), InChI strings (Heller and McNaught, 2009), 
MACCS keys and ILP processes are amongst variants which have successfully 
helped to model chemical compound activity within groups of molecules. 
SMILES codes (Simplified Molecular Line Entry System) 
The 2D representation of an organic molecule can be codified into a linear sequence 
that represents the atoms, bonds and chirality of its structure.  SMILES are one such 
means of depicting this information.  The initial work on producing the SMILES 
specification for coding organic structures was conducted in the 1980s (Weininger, 
1988; Weininger et al., 1989).  This work was built on extensively and was launched 
as an open standard in 2007, along with a large resource of web-based software for 
chemical informatics (Tetko et al, 2005; Tetko, 2005; Guha et al., 2006).  There is a 
significant amount of prior experience in chemoinformatic analyses that show the 
usefulness of using SMILES codes as a generalised coding system, and its adoption 
has been fairly widespread.  SMILES also offer benefits over key-based systems 
developed for pharmaceutical studies (e.g. MACCS, InChI) due to their adaptability; 
it can be speculated that this might allow identification of unusual patterns that might 




Another open source project, Open Babel (Babel), allows the chemist to search, 
convert, analyze, or store data from molecular modelling, chemistry, solid-state 
materials, biochemistry, or related areas.  One application available in Open Babel is 
to convert SMILES codes into a fingerprint (Daylight FP2), generating an output 
vector that describes fragments that make up the molecule.   
 
 
   Molecular formula:  C12H13ClN4 
   SMILES code:   Clc2ccc(c1c(nc(nc1CC)N)N)cc2 
Figure 2.1:  A SMILES code example: Pyrimethamine 
 
Aromatic atoms are coded in lower case (c, n) with non-aromatic atoms are in upper 
case (C, N, Cl).  Hydrogen atoms are not coded, but are assumed to occupy all 
remaining available bonding sites. 
As an example, the chlorobenzene fragment is coded as a chlorine atom attached to 
an aromatic ring, which in turn is attached to another aromatic ring at the para 
location.  The numbers „1‟ and „2‟ in the SMILES code mark the beginning and end of 
the first and second rings. 
 
Clc2ccc(rest_of_structure)cc2 
        1      2  3 4                                                          5 6 
 
 
Figure 2.2:  Encoding a SMILES code fragment 
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SMARTS (SMiles ARbitrary Target Specification) 
SMARTS patterns are an extension of the SMILES notation, and can be used to 
describe substructures in the molecule.  This allows precise substructural searches 
to be made in a compound database, and it follows that the exact matching of 
moieties (functional groups) will enable the clustering of compounds that are similar 
in such respects. 
Two further fingerprints (FP3 and FP4) using 55 and 307 SMARTS patterns can be 
created in OpenBabel that can then be used to run substructure searches. 
InChI strings (International Chemical Identifier) 
Unlike SMILES codes, every structure has a unique InChI string, and it is possible to 
convey more structural information with their use.  The structure is described in 
several layers which record the chemical structure, charges, stereochemistry, and 
isotope variations. 
InChI keys 
These keys are a condensed digital representation of InChI strings, introduced to 
improve how searches are handled for InChI strings.  The keys are limited to a fixed 
length of 25 characters, with the first 14 characters used for the chemical structure, 9 
representing the other description layers, and two for the version number and 
checksum.  It is possible (but likely to be extremely rare) that two compounds can be 
represented by the same key.   
InChI strings cannot be rebuilt from InChI keys, and therefore need to be fully linked 
to the appropriate records when used for searching.  
MACCS keys 
These are keys provide a 166 bit fingerprint for the structure, based on 166 
fragments considered important in medicinal chemistry.  Again, this fingerprint can 




2.8 Similarity searching using SMILES codes 
Once an indicator compound has been identified, there is a need to find structurally 
similar molecules as these are more likely to exhibit similar properties than those 
chosen by stochastic processes.  In order to achieve this, several techniques have 
been developed through that might be used to describe the similarity between 
SMILES strings e.g. Tanimoto similarity (Tanimoto, 1957), Dice coefficients (Willett 
et al., 1998), Monte Carlo simulations (Toropov et al., 2009) and digital 
compression (Melville et al., 2007); in some instances these techniques can also be 
applied to substructure similarity searches. 
For this project, the Tanimoto coefficient was adopted as a similarity measurement to 
maintain a consistent approach to earlier research from which the prototype Active 
Learning algorithm was developed. 
How can SMILES codes be used for similarity searching? 
The coded SMILES representation can be split into fragments; this allows a 
fingerprint to be built of the active groups attached to the molecule.  One such 
fingerprint, Daylight FP2 (James et al., 1995), is compiled using the following rules: 
1. Linear small molecule fragments up to 7 atoms in length are recorded. 
2. Single atom fragments of C, N, O are ignored. 
3. The fragment is terminated when the atoms form a ring. 
4. There is only one record of each fragment type, including those listed in 
reverse order. 
5. Each fragment is numbered from 0 to 1020; this is used to identify it in a 1024 
bit vector. 
The fingerprint information extracted and collated in the 1024 bit vector for each 
molecule can then be usefully evaluated by comparing it to that of another molecule.  
One common method of comparison is the Tanimoto Similarity coefficient 
(Tanimoto, 1957), which is calculated from the number of „on‟ bits of information in 






0 1 Total 
Object A 
0 d b d+b 
1 a c a+c 
Total a+d b+c n 
Figure 2.3: Comparison of encoded information for two objects 
 
    𝑇𝑎𝑛𝑖𝑚𝑜𝑡𝑜 𝑆𝑖𝑚𝑖𝑙𝑎𝑟𝑖𝑡𝑦 =  
𝑐
(𝑎+𝑏+𝑐)
    (1) 
Other methods defining the similarity between two fingerprints have been developed 
e.g. the Dice coefficient where the number of „on‟ bits in the intersection of the two 
sets is divided by the average size of the features:      
    𝐷𝑖𝑐𝑒 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡 =  
2𝑐
(𝑎+𝑏)
     (2) 
The Dice equation is monotonic with Tanimoto, i.e. it will give the same ranking order 
of molecules based on the same fingerprints, but will return different values for the 
coefficients. 
Other approaches take the number of „off‟ bits into consideration, on the basis that 
these offer further information: 
   𝑀𝑎𝑡𝑐𝑕𝑖𝑛𝑔 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡 =  
𝑐+𝑑
(𝑎+𝑏+𝑐+𝑑)
    (3) 
It has been argued that the maximum fragment size (7 atoms) represented by the 
standard Daylight 0/7 FP2 fingerprint is too low to represent some significant 
structures within the molecule, and Daylight 3/10 has been proposed as an 
alternative (McGaughey et al., 2007) where fragments of 3 to 10 atoms are used.  
OpenBabel fingerprints are limited in this respect, but there are alternative sources of 
open source software e.g. RCDK (Guha, 2007; Guha and Guha, 2013) that allow 




SMILES codes have been used to find similarity between molecules by 
fragmentation, and subsequently predict relative chemical activity (Bringmann and 
Karwath, 2004; Karwath and De Raedt, 2006); such techniques yield simple, 
interpretable patterns, and can provide powerful results when used alongside other 
tools for extracting information from chemical databases.  Fragmentation fingerprints 
will also have the advantage of smaller size, and this is beneficial when searching a 
large chemical space. 
Similarity searching using the FP3 or FP4 fingerprints from the SMARTS patterns 
might be used alongside FP2 similarity searches; combining methods should give 
search results that are more relevant to potential druglike compounds, and these 
results could then be added to datasets for parameters depicted by the “Rule of 5”. 
Monte Carlo simulations for similarity searching 
Monte Carlo simulations are iterative computational techniques that can be used in 
optimisation problems.  Several attempts to build Quantitative Structure Activity 
Relationships (QSAR) using SMILES strings and standard data sets have been 
reported as promising: 
For example, a standard set of 𝑙𝑜𝑔𝑇𝐴100 mutagenicity data for 48 nitrated polycyclic 
hydrocarbons (PAHs) has been used to develop a number of QSAR models (see 
section 2.10).  One such technique based on Monte Carlo simulation employed an 
alternative use for SMILES codes (Toropov et al., 2009); this built on earlier work 
(Toropov and Benfenati, 2004 & 2007; Toropov and Schultz, 2003).   
When investigating potential for similarity searching for this thesis, the Monte Carlo 
technique was found to be simple to describe and understand, and appears to give 
powerful results.  However, there was no indication of its computational needs or the 
extent of the chemical space across which the model could be used.  It would be 
difficult to predict how it might scale up to requirements for HTE.  Also, prior work 
was with small, specific data sets so might have been susceptible to overfitting. 
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2.9 Large compound libraries for drug development 
Pharmaceutical companies each hold their own collections of drug-like compounds, 
and it is estimated that more than 20 million diverse compounds now exist for 
development work.  On a smaller and more accessible scale, commercially available 
libraries have also been built; these include the Maybridge Hitfinder Library and the 
ChemBridge collections.  Commercial drug libraries are available in standard 384 
well plates, and can be used to build application-specific daughter libraries. 
Maybridge Hitfinder Library 
This is a collection of 14,400 compounds, selected to provide a diverse range of 
pharmacophores (active fragments) in a relatively low number of candidates.  The 
library closely follows Lipinski‟s “Rule of 5”, and the full Maybridge collection of 
53,000 compounds represents some 87% of the 400,000 pharmacophores estimated 
to be in existence, and the Hitfinder library has also been shown as highly diverse 
(McGregor and Pallai, 1997).  The Maybridge Hitfinder library was used by Eve as 
its main source of chemicals; it was used to prove the robot‟s ability to independently 
discover drug activity, at a much lower cost than other alternatives (which might in 
turn have given a richer collection of hits). 
ChemBridge MicroFormat Library 
ChemBridge offer a number of libraries both for high throughput studies and for 
highly specific screens; their full list is in excess of 850,000 compounds.  The 
ChemBridge MicroFormat library contains 180,000 components covering a wide 
chemical space. 
Many other libraries exist, largely for specialised applications.  In addition, interest in 
examining natural products is also growing (Koehn and Carter, 2005), leading to the 
development of such initiatives as the 5000 plant extracts compiled for the University 
of Strathclyde‟s Worldwide Natural Product Library (SIDR) (Harvey et al., 2010).  
This is ostensibly similar in design to libraries of drug-like compounds (i.e. 96 well 
plates), but each well/plant extract might represent several active ingredients which 
in turn would need to be isolated in the case of hit identification. 
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2.10 Libraries of late clinical stage pharmaceuticals 
The Comprehensive Medicinal Chemistry database listed 6683 compounds 
(McGregor and Pallai, 1997) that had been evaluated as therapeutic agents in 
humans, and was estimated to be growing by approximately 250 compounds per 
annum.  Data associated with these compounds are available for in silico work, but 
their physical availability is a more difficult problem.  There are ongoing attempts to 
build centralised libraries (see the examples below) containing all such compounds, 
but only about 40% are readily available.  The others are largely compounds that 
have entered Phase II trials, but not commercialisation; to contribute to the library, 
they would need to be synthesised (following receipt of appropriate permissions). 
The DrugBank initiative (Knox et al., 2011; Wishart et al., 2006) moves on another 
step by combining drug and target data; this is available in the public domain for 
in silico modelling (6811 compounds, linked to 4294 targets). 
The Johns Hopkins University Clinical Compound Library (JHCCL) 
The full JHCCL is the largest physical collection of approved compounds currently 
available for drug screening; to date, it consists of 3100 active ingredients found in 
known drugs (www.jhccsi.org/background.html).  Various versions exist; the one 
made available for Eve contained 1600 FDA and non-USA-approved components in 
7 plates, assembled in 384-well plate format carrying 5 mM stocks. 
It has been mooted that the library be expanded to include all therapeutic agents 
known to clinical medicine (~11,000), with a view to using them as a screening tool 
against all neglected diseases (Chong and Sullivan, 2007). 
The Prestwick Chemical Library 
The library contains 1200 small molecules approved for drug use, selected based on 
known bioavailability and safety in an effort to minimise the number of potential hits 
with properties too borderline for further development stages. 
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The Spectrum Collection 
This collection of 2000 compounds includes known drugs (50%), purified natural 
products (30%), and other bioactive compounds (20%).  The drugs are largely out of 
patent, and have well understood properties.  The natural products were chosen 
based on structural diversity but have largely unknown activity.  The remaining 
bioactive products have known activity (e.g. for herbicide/pesticide uses) but have no 
therapeutic approval for humans. 
The NCGC Pharmaceutical Collection (NPC) 
This collection has resulted from collaboration between several USA government 
agencies, and includes 2400 small molecules approved for drug use in the USA 
(FDA), European Union (EMA), Japan (NHI) and Canada (HC).  Further synthetic 
work is expected to build the library, and it is publically available for high-throughput 
experimentation (Huang et al., 2011). 
Chemical library/source Compounds Status 
Maybridge Hitfinder 14400 Available for Robot Eve 
Johns Hopkins Clinical 
Compounds (JHCCL) 
1187* Available for Robot Eve 
Full Maybridge library ~53000 Available for purchase 
Full JHCCL ~3100  
All approved drugs ~3500  
All drugs (minimum Phase II trials) ~11000  
All synthesised drug-like ~2×107  
All possible drug-like >1050  
* 1187 discrete compounds remained in the Aberystwyth copy of the JHCCL after 
removal of duplicates, problem wells, and compound wells incompatible with Eve‟s 
liquid handling systems. 
Table 2.2: Compound sources for use by Eve 
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2.11 Quantitative Structure Activity Relationships (QSAR)  
QSARs have been used for many years to predict activity levels in biological and 
chemical systems; they take a performance dataset relating to the known structural 
parameters of a chemical and/or reaction mechanism, and use this data to predict 
the activity of other compounds under similar conditions.  Larger and more complex 
groups of molecules and datasets can lead to highly fitted QSARs, which in turn 
require significant computing power to exploit.   
The state of the art was reviewed in (Dudek et al., 2006).  It is possible to build 2D 
QSARs based on several hundred attributes for a compound, describing topological, 
geometric, electrostatic and quantum-chemical properties across the range of 
possible fragments that might contribute to activity.  Application of such models 
across a large compound library suggests the need for large computing capacity, 
although the literature more regularly deals with small datasets in highly specialised 
applications.  Extending QSAR to 3D models involves a yet higher level of 
complexity, with a subsequent impact on the time taken to select candidate 
compounds.  Adoption of a Machine Learning approach (see section 2.11) might 
allow simpler activity/descriptor relationships to be built from a training set, although 
this might limit the search space of the model. 
Where more than one activity is being measured for an assay, advances in 
modelling and computation now allow separate models to be built and combined 
using multivariate QSARs (Arodz and Dudek, 2007).  The possibility of extending 
QSAR predictions across a range of parasite species has been suggested (Prado-
Prado et al., 2010).  Both of these approaches used artificial neural networks, but 
the latter concluded that this method offered little improvement in precision over 
linear methods e.g. linear discriminant analysis (LDA). 
The value of QSARs is reflected by the efforts shown in this research discipline 
(Tropsha, 2010).  It is emphasised that good practice be maintained around data 
management, and that models need to be validated externally to avoid oft levelled 
criticism; the problems faced by QSARs to label structural outliers were discussed, 




The tools used to build a dataset are not readily available to non-commercial 
organisations.  The pharmaceutical companies have proprietary methods, only 
glimpses of which are occasionally described in the public domain.  The original plan 
for the Robot Scientist Eve project was to collaborate with Pfizer for QSAR studies 
as well as Active Learning, but changes to the company‟s research and development 
outlook led to this option being withdrawn.   
Few QSAR techniques are available in Open Source form: 
The Bioclipse workbench includes a limited QSAR function (Spjuth et al., 2007 & 
2009), and has recently been upgraded to work with the statistical analysis software, 
R (Spjuth et al., 2013). 
An open source version of 3D QSAR, Open3DQSAR (Tosco and Balle, 2011), is 
aimed at ligand-based drug discovery, where structural/pharmacophore alignments 
are considered.  Limited studies have been published using this software in 
comparison with existing commercial versions e.g. CoMFA, CoMSIA (Ghasemi and 
Shiri, 2012). 
Several specialist software companies promote their tools as available to academics, 
but have limitations placed upon them, as might be expected of such collaborations.   
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2.12 Machine Learning and data mining  
When running an HTE screen, it is imperative that there are no computational delays 
to the compound selection process.  This is not a problem when simply mass 
screening a library, but is potentially a concern when a cherry-picking selection is 
required.  If the assay is able to be screened rapidly, this will provide a limit to the 
time available for the compound selection method.  The limits imposed by the yeast 
growth generated by Eve are not arduous in this respect, but later simulation work 
using alternative targets might be problematic if selection cycle times are long. 
The application of an array of Machine Learning techniques for drug development 
are discussed in (Barrett and Langdon, 2006) and (Dudek et al., 2006), and it is 
noted that these techniques offer a means of dealing with the huge amount of data 
relating to problem solving in this field: “Many drug discovery problems can be 
expressed as the problem of finding a computer program”.  One recurring concern in 
the literature is whether there had been sufficient industry take up of machine 
learning approaches, with the implication that pharmaceutical companies tending to 
stick conservatively to tried and trusted (albeit limiting) approaches.  
Reducing the complexity of a problem in Machine Learning should lead to more 
straightforward computations.  "A theory of the learnable" (Valiant, 1984) offers 
some insight into the importance of tightly specifying input information, to make 
computations feasible in a given time.  If too many variables and classifications are 
involved then reaching any single conclusion becomes increasingly complex (a 
polynomial number of steps). 
Activity prediction using QSAR can be conducted using supervised learning 
approaches, as the training set supplies output/activity levels for each item.  Both 
linear and non-linear methods have been applied to such data, and the task is to 
learn the mapping of the input data to the output.  Many elements of the input data 
also lend themselves to using unsupervised learning approaches through clustering 
strategies; the different methods of depicting structural similarities as shown in 
sections 2.7 and 2.8 can readily be exploited by such methods. 
Input and output data sets can also be grown to specifically assist the learner; this 
Active Learning (section 2.13) is a form of semi-supervised learning 
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2.12.1 Supervised learning 
Linear methods 
The properties of each compound can readily be evaluated using linear statistical 
methods to develop QSARs.  Linear models work well with small data sets of similar 
compounds, and are generally easy to interpret.  Multiple Linear Regression (MLR) 
builds a model for the single response variable (i.e. activity) based on a linear 
function of the explanatory variables (i.e. compound properties) chosen to minimise 
the squares of the difference between predicted and measured activity (McConway 
et al., 1999).  The technique is prone to over-fitting when explanatory variables are 
not truly independent, although it is possible to remove those with relatively low 
impact to provide simpler models.  Partial Least Squares (PLS) aims to improve on 
MLR by reducing the model to those explanatory variables that are independent.  
Linear Discriminant Analysis (LDA) aims to reduce dimensionality for classification 
rules by transforming the data set to separate the resultant classes more effectively 
(Alpaydin, 2004) with minimal effect on in-class variance. 
Non-linear methods 
k-Nearest Neighbour (kNN) 
The activities of k known neighbouring compounds are used to predict that of the 
unknown (Cover and Hart, 1967).  The effectiveness of this technique is potentially 
limited when nearby neighbours are sparse, and have reduced similarity across the 
locality; this is likely to be the case when the training set is small.  There are 
alternative approaches to use when low numbers of seed examples are available: 
(i) Provide a similarity boundary threshold at which the predictive capability is 
switched off, although this will result in some isolated unknown compounds 
remaining unlabelled. 





Activity predictions are based on a series of rules against which the properties of the 
compound are examined.  The rules are defined by multi-way cross validation of the 
training set, so that the full rule set provides the best fit to the observed activity 
levels.  Each rule/node asks which classification/leaf a single property will lead to, 
with two branches coming from each node.  The whole structure is a series of 
iterative nodes & branches, leading to a leaf at the end of each pathway. 
With large numbers of properties measured or calculated for each compound, it is 
ultimately possible to build a large number of rules, which in turn has the likely 
consequence of over-fitting.   The decision tree can subsequently be pruned by 
removing pathways or individual leaves to reduce the overall complexity of the rules, 
allowing general and readily interpretable sets. 
Application of decision tree QSAR models allows simple rules to be built 
(Suenderhauf et al., 2012; Lira et al., 2013) that can make accurate predictions 
within small to medium size data sets; they can suffer from limitations relating to 
over-fitting and lack of robustness (Hammann and Drewe, 2012), but appeal for 
their computational simplicity and interpretability if constructed carefully. 
Support Vector Machines (SVM) 
QSARs based on SVM methods aim to create a hyperplane that separates 
compounds according to their classification (Burbidge et al., 2001).  The training 
compounds at the boundary of the hyperplane define its location, and therefore 
become the support vectors; in practise, linear separation is unlikely to occur, and 
misclassified compounds will exist on either side of the hyperplane.  Because the 
SVM only uses information near or at the separation boundary, other simpler 
methods can remove compounds that will be distant from this region, thereby 
removing some of the computational complexity.  Once the location of the 
hyperplane is defined, predictions can be applied to unknown compounds. 
Increasing the dimensionality of the data by feature mapping techniques (Li et al., 
2009) can assist in realising the hyperplane if a simple low dimension approach 
gives insufficient discrimination.   
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2.12.2 Unsupervised learning 
For unsupervised learning (Ghahramani, 2004), there is no defined training set with 
predetermined inputs and output values against which the model will learn; instead it 
uses these data to recognise patterns that form beyond what might be expected from 
general noise.   
Clustering 
Clustering uses similarities in the input data to group items together.  Cluster size 
and usefulness will vary depending on the criteria by which they constructed; whilst 
knowledge of the value of these inputs might be useful, the ability of clustering to 
identify unexpected patterns is also of high importance. 
Many clustering algorithms have been suggested; two of the earliest approaches 
(k-means and hierarchical) have been used for many empirical studies, and provide 
a solid base upon which to build.  After splitting a data set into several discrete 
groups based on similarities in instances/data points, clustering can then be used as 
a starting point to apply supervised learning techniques (Alpaydin, 2004). 
k-means clustering 
The aim of k-means clustering is to find a pattern in the input data that gives 
k clusters whose components have minimised in-cluster variance (Hartigan & 
Wong, 1979); the clusters are then represented by their centre in subsequent 
analyses.  One widely used example for k-means clustering is its application to 
customer segmentation in commerce, where similar customers are grouped so that 
their business can be exploited in similar fashion.  
The size of the clusters is not controlled by this method, and it is possible to have a 
diverse range of cluster sizes; this can be useful, especially if there is interest in 
finding unrepresentative examples that might hold niche or rare information. 
Hierarchical clustering 
Simple strategies for hierarchical clustering are either divisive or agglomerative (Jain 
et al., 1999).  Divisive algorithms start with the full data set and divide it through a 
number of iterations until the desired level of detail has been reached.  The 
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alternative agglomerative approach starts with clusters of size n=1, which can then 
merge based on local similarities to form larger groups (e.g. nearest neighbour 
clustering).  Both methods typically use greedy selection, and both can be depicted 
in a tree-like structure. 
37 
 
2.13 Active Learning 
The sheer quantity of data capable of being generated using High Throughput 
Experimentation is typical of much empirical work in our technological age.  
However, this seemingly unending supply of data needs to be filtered and 
categorised in order for it to have relevance, and this can be achieved to a certain 
extent using algorithms based on experience.  Better still, rules derived from 
mathematical models and Machine Learning tools enable sense to be extracted, but 
there still remains the question of how to control the data generating process to 
make it more efficient. 
The role of Active Learning is to make improvements to the model using fewer 
resources than might be required with simple supervised or unsupervised learning 
approaches; the training set is grown by the learner itself as it learns, and the next 
sets of data to be gathered are chosen on the basis of how their knowledge might 
improve the model.  Active Learning can therefore be considered as a form of semi-
supervised learning. 
One aspect of the human learning process is the ability to adjust or evolve a query 
when additional experience is available.  For Machine Learning, it may be seen that 
query techniques can be measured for effectiveness; if these can subsequently be 
honed either by adjusting the rules upon which the query is based, or by directionally 
improving the data patterns upon which their selections rely, these active changes 
can lead to a more efficient selection process.   
If labelled examples are to be used to search the space in which the unlabelled 
examples exist, the queries should ideally be able to penetrate and explore all 
regions.  Greedily searching for items that are most similar to existing examples will 
lead to an initial gain, but this is likely to rapidly fail as no significant new information 
is available to improve the model.  Similarly, searching areas far away from known 
examples needs to be done in moderation.  In general, an Active Learning model 
needs to be able to balance the regions it searches, and retain the ability to both 
explore and exploit the unknown space. 
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A general repository of Active Learning techniques is (Settles, 2010); this online 
resource was being periodically revised after its initial appearance (2008), but does 
not seem to have been updated since 2010.   
2.13.1 Active Learning in drug discovery 
There seems to be little work reported on AL techniques in relation to drug discovery.  
It is considered likely that this is due to limited availability of assay data for 
development of AL algorithms, hence the potential advantages previously described 
for research using Robot Eve: the potential gains in efficiency of compound selection 
make this an area worthy of further investigation. 
Work reported in (Warmuth et al., 2003) aimed to find compounds in a large 
collection such that the fewest number of iterations of biochemical testing was 
conducted.  Selection of compounds was conducted by exploiting the maximum 
margin hyperplane generated by Support Vector Machines. 
The separating hyperplane allows different strategies to be used to choose the next 
compound for examination: 
(i) Random. 
(ii) The furthest on the positive side [exploitation strategy]. 
(iii) The closest to the previously known actives. 
(iv) Those nearest to the decision boundary [exploration strategy]. 
Strategy (i) does not use earlier information, and increases the number of hits 
linearly; (ii) selects those most likely to be active, which finds many compounds in 
few iterations at the expense of better modelling of the problem; (iv) allows better 
modelling of the SAR; (iii) only searches locally, based on current knowledge, and 
will not find actives that are remotely located. 
The Active Learning was carried out using descriptors generated by DuPont‟s 
in-house software (and using datasets supplied by DuPont Pharmaceuticals).  It was 
also shown empirically that the activity of an „active‟ compound is uncorrelated to its 
distance from the hyperplane.  Alternative Machine Learning techniques (Voted 
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Perceptron, Bayes Point Machine) were discussed in (Warmuth et al., 2001); it was 
stated that they gave similar performance on this data to the SVM approach. 
Hierarchical sampling for Active Learning (Dasgupta and Hsu, 2008) presents a 
potential technique for identifying the purity of data clusters during the learning 
process.  Extrapolating the techniques therein: 
By using a semi-supervised pre-clustering routine, and sampling within these 
clusters, it might be possible to identify spaces where the activity is unknown or 
uncertain in comparison to spaces where high certainty over activity or inactivity 
abounds.   
2.13.2 Active k-optimisation strategy 
One of the major goals for Eve‟s data analysis was to build algorithms to predict 
active compounds.  The array of information contained in assay data includes raw 
data for yeast target growth profiles, labelled classifications for activity, toxicity etc., 
and structural representations of the compounds. 
The prototype method for this work was to be based on the active k-optimisation 
strategy (De Grave et al., 2008a).  This strategy is introduced for machine learning 
as a way of finding and ranking the k best alternatives for evaluation, using Gaussian 
process to provide a mechanism for developing this model. 
The general idea is to develop a process to find more than one target (other than the 
optimal solution) to take into the next step of HTE.  The work is based on having a 
finite library of examples, of which the results from the known ones can be used to 
pick the best unknowns for evaluation. 
In this particular approach, the goal is to pick targets that have the best chance of 
success (the maximum predicted strategy) for comparison to several other existing 
approaches (King et al., 2004; Vandezande et al., 2005; Jones et al., 1998).  The 
lower confidence bound criterion (optimistic) (Cox and John, 1997), selecting the 
sample with the highest probability of improving the current solution (most probable 




Specific application of the active k-optimisation strategy to the drug screening 
process is provided in (De Grave et al., 2008); this describes the analysis of the 
NCI60 dataset (US National Cancer Institute, 60 anticancer drug screen).  The full 
techniques upon which this strategy is based are given in (Bishop et al., 2006). 
2.13.3. Transfer Learning 
It is expected that implementation of a Machine Learning process will be based on a 
set of data split into training and validation examples, together with an independent 
test set.  However, it is possible to provide additional strength to the training data by 
using knowledge gained from previous processes on different examples.   
The main questions are: what to transfer, how to transfer, and when to transfer.  The 
value of the transferable knowledge needs to be pre-determined, in order to avoid a 
negative transfer effect (Pan and Yang, 2010). 
In the context of a QSAR Active Learning algorithm, the knowledge transferred is 
embedded in a set of seed compounds previously found to be active against other 
targets.  There is no guarantee that similar activity will be found with the new target, 
so the simplest approach might be that an active compound set is retrained in the 
new experiment.  This is an application of inductive transfer learning, which in turn 
shows some similarities to multitask learning (Caruana, 1997). 
For Eve, knowledge of the phylogenetic similarity between target parasites 
(Tibayrenc et al., 1990) might be an additional tool to aid selection of training data 
for new experiments.  
2.13.4  Rare category/class detection 
Various models are employed to detect rare categories/events, in an effort to isolate 
useful anomalies.  It has been found that the most successful approaches include 
subjective classification by the user (i.e. a “hunch”!!); this was suggested alongside a 
novel approach (Pelleg and Moore, 2004) which used a known component applied 
to a data set whose contents are then ranked by a probability density function.  The 
untested examples with highest rankings (i.e. most anomalous) are classified and 
fed back into the next iteration.  The authors admit this is an intuitive/empirical 
approach that worked with their large database (> 106 records), without offering an 
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explanation; in my opinion, it is feasible that large outliers are more likely to be 
interesting as, if the data is in a Gaussian distribution, lower numbers of noisy points 
are expected at the extremities. 
The potential for identifying knowledge gaps (see 2.11.2) also lends itself to rare 
class detection and mining.  The methods identified in (Han et al., 2009) suggest 






Chapter 3  
Development of intelligent robotic systems for drug 
discovery 
 
Adventures with yeast, part 3 of 7:  Cwrw Cawrfil 
 
 
3.8 kg  Maris Otter pale malt 
1.0 kg  torrified wheat 
0.7 kg  white sugar 
100 grams East Kent Goldings hops 
100 grams Bobek (Styrian Goldings) hops 
1 packet Safbrew T58 wheat beer yeast 
1  Irish moss tablet 
 
 
Add the grains to the mash tun with 20 litres of water.  Steep at 70-75°C for two hours.  
Remove the grain sack and allow it to drain into the wort; sparge it with boiling water until 
the sugars have been depleted.  Remove 500 ml of wort and use it to make a yeast starter.  
Meanwhile, add the white sugar to the bulk wort, and bring to the boil; maintain the volume 
at approximately 25 litres.  Add 60 grams of each hop when the wort is at a rolling boil, and 
boil for 60 minutes; add 20 grams of each at 15 minutes from the end of the boil, and a 
further 20 grams of each at 5 minutes from the end, together with the Irish moss tablet. 
Cool the finished wort; decant it to a fermentation vessel and add the yeast starter.  Record 
the original gravity (~1058), and the final gravity (~1014 after 2 weeks).  Prime the finished 
brew with 100 grams of white sugar in 1 litre of boiled/cooled water prior to bottling. 
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3.1 Robot Scientist Eve project overview 
Robot Scientist Eve has been designed to screen compound libraries en masse 
against chosen targets, and to switch from this mass screening mode to a 
cherry-picking mode.  The latter allows Eve to examine activity in more detail across 
a wider range of compound concentrations. 
Eve‟s output has been used as a primary data source for this thesis.  The physical 
screening processes were being developed concurrently with this thesis‟ work on 
drug-like activity measurements.  Significant effort was put into building robust data 
sets that would underpin later work on drug discovery Active Learning approaches. 
This chapter covers the fundamental building blocks of the project, the 
transformation processes for the raw data provided by the screens, and example 
results from the screens conducted whilst Eve was based in Aberystwyth.   
The relative activity of compounds and negative controls was used to categorise 
potential hits, separating them from possible toxic compounds, inactive ones, and 
noise.  The use of two parasite target strains and one control strain (human) in each 
assay meant that the data analysis steps could also make use of intra-well strain 
performance.  
The main data corrections were based on negative controls, for which repeatability 
has been shown; it would have been advantageous to have more positive control 
data too, but the nature of such items (known protein-specific interactions) meant 
that this was near impossible to arrange.  Components from the data set were used 
to build a clear set of rules that displayed a good fit to the observations, and made 
sense in terms of the growth of the yeast. 
The confirmation screen data were also categorised successfully in terms of activity 
against the given target, with an indicator for possible toxicity.  The rules for the 
confirmation screens were based on a comparison of the shape of the 
concentration/activity curve of the parasite strain versus the human strain. 
Eve‟s compound libraries have been tested against several parasite strains, and 
many active compounds have been confirmed, including some from the library of 
44 
 
existing drug therapies (JHCCL); in vivo experiments were conducted on some of 
these compounds, and these results are included later in this chapter. 
An alternative approach to identifying potentially active compounds was provided by 
the School of Biological Sciences, University of Cambridge; its performance was 
compared to the methods mentioned above. 
3.1.1 Drug-like compound libraries 
Eve has been designed to grow multiple strains of modified yeast in the presence of 
drug-like compounds selected from chemical libraries; typically, two parasite strains 
were used to make up the assay for a single experiment, with a human strain as a 
control.  The relative growth rates of the yeast strains were then used to determine 
the activity of the compounds against the genetic modification.  The building blocks 
for these experiments were the chemical compound libraries (Table 3.1) and the 
yeast strains (Table 2.1): 
Chemical library/source Compounds Status 
Maybridge Hitfinder 14400 Available for Robot Eve 
Johns Hopkins Clinical Compound 
Library (JHCCL) 
1187* Available for Robot Eve 
Full Maybridge ~56000 Available for purchase 
Full JHCCL ~3100  
All approved drugs ~11000  
All synthesised drug-like ~2×107  
All possible drug-like >1050  
* After removal of replicates and compounds incompatible with Eve‟s liquid handling 
Table 3.1:  Compound libraries for Eve 
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3.1.2 Hardware and software 
Eve was designed as a fully integrated laboratory robotic system (Sparkes et al., 
2010); a variety of component instruments were included to enable future flexibility 
when developing alternative experiment regimes. 
The main components were: 
 a dry store for holding chemical compounds,  
 an incubator, 
 liquid handlers and multidrops for transferring materials between libraries 
and experiment plates, 
 shakers, 
 a capper-recapper, 
 plate readers for measuring growth across a wide range of the UV-visible 
spectrum, 
 imagers for recording cell growth and morphology. 
The robot control software has been written to execute mass and cherry-pick 
screens, and generate data sets based on the resultant yeast logistic growth curve.  
In addition, there was a requirement for data analysis and intelligent compound 










1 Labcyte Echo 550 acoustic liquid handler 
2 BMG Pherastar reader 
3 MDS ImageXpress Micro cellular imager 
4 BMG Polarstar reader 
5 Cytomat 2C435 incubator 
6 Cytomat 6003 dry store 
7 FluidX DC-96pro capper/recapper 
8 Variomag teleshake plate shakers and Metrologic Orbit 1D barcode readers 
9 Cytomat linear actuator track 
10 Robot plinth holding Mitsubishi robot arms; models RV-3SJB and RV-3SJ 
11 FluidX Xtr-96 tube rack 2D barcode scanner 
12 Agilent (Velocity 11) Bravo liquid handler 
13 Thermo Combi-nL multidrop 
14 Thermo Combi multidrops 
15 Consumables stacks for microplates, tube racks and tips 
 
Figure 3.2: Schematic layout for Eve (plan view) 
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3.1.3 Screening plates and growth curves 
General screens were made up of a number of 384 well plates, with each well 
containing three yeast strains for the chosen assay.  320 wells per plate were dosed 
with 50 nl of compound (10 M) dissolved in dimethylsulphoxide (DMSO), with 
64 wells used for controls; the plates contained up to 20 positive controls (5 separate 
compounds) and 44 negative controls (triple strain assay + DMSO), or contained 
64 negative controls. 
In vitro assays using HTS have typically used compound concentrations in the range 
of 1 to 50 M (Keser and Makara, 2006); the concentrations used by Eve were 
based on these practices: 
 10 M is a standardised concentration for screening purposes 
 The confirmation range (0.5 to 10 or 20 M) was kept broad but tended away 
from higher concentrations (unrepresentative of therapeutic doses). 
Originally, plates for cherry-pick and confirmation screens contained eight replicates 
of eight compounds, at 6 concentrations (0, 1, 2.5, 5, 10, 20), thereby also having 64 
negative controls by default.  Later confirmation screens contained four replicates of 
sixteen compounds, at 6 concentrations (0, 0.5, 1, 2.5, 5, 10 M); see section 3.2.5 
for more details. 
The plates were incubated for 40 hours, and growth was recorded every 90 minutes 
through measurement of fluorescence at the three strain emission wavelengths. 
Logistic growth curves were then derived, and parameters A to P (see Figure 3.3) 
calculated (King et al., 2009). 
The full list of assays is given in Appendix A.1; this lists the protein target and 





A startvalue I lagtime 
B startvaluetime J miylagtime: a biologist‟s 
popular estimation of the 
lagtime, as suggested by 
Professor Mike Young (MIY). 
C minvalue K startlinear 
D minvaluetime L endlinear 
E maxvalue M linearslope = (Q - R)/(L - K) 
F maxvaluetime N doubletime  = 1/M 
G endvalue O durlinear  = L - K 
H endvaluetime P snratio (signal/noise ratio) 
 
Figure 3.3:  Diagram of a typical logistic growth curve 
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3.2 Development of data analysis pipelines for active compound 
identification and confirmation 
Eve‟s data output for a mass screen contains the parameters listed in Figure 3.3 for 
each yeast strain, together with labels for sample identification purposes.  The first 
task was to identify which of these parameters could be used to identify activity of a 
compound against the chosen target.  The criteria eventually selected for routine 
analyses are listed in Appendix C.1.  There was also a strong requirement to show 
consistency between measurements in discrete screens.  The need for Eve to 
provide repeatable results, especially when operating in confirmation/cherry-picking 
mode, is of fundamental importance when running objective studies. 
The data set for the initial triple strain mass screen (MS_63_1_15_20110414203535; 
see section 3.3.1) was used to identify potential active compounds; the three yeast 
strains were HsDHFR, PvDHFR and PfRdhfr.  The data set was first checked for 
consistency through statistical analysis of the negative controls, and then 
abnormalities were identified versus these background controls.  Visual classification 
of these abnormal growth curves allowed rules to be built (decision tree analysis) 
that could identify activity through using a wider set of the growth curve parameters. 
3.2.1 Statistical analysis of negative control data 
The results from the negative control wells provide the baseline against which 
candidate wells were compared.  The negative controls (between 44 and 64 on each 
plate) only contained the three yeast strains in the growth media, together with 
DMSO (the solvent used for all candidate compounds).  In-plate and in-batch 
repeatability of negative control growth rates could be used to verify full data sets. 
With the exception of the „start‟ and „end‟ timings (Figure 3.3, B & H), it was expected 
that any of the logistic growth curve parameters might be affected by the presence of 
active compounds.  The negative control wells were available for a baseline 
comparison on a plate-by-plate basis.  
The doubling time (DT) parameter was chosen to determine: 
i. Repeatability in-plate using the negative controls. 
ii. Repeatability within a batch of plates using the negative and positive controls. 
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iii. Repeatability across a full screen of 45 plates using negative and positive 
controls. 
iv. Compounds that significantly affect growth in comparison to negative controls. 
The mean and variance of the DT results were calculated for the DHFR-TS3 assay 
negative controls with the assumption that they fit a normal distribution (under the 











Mean Variance Mean Variance Mean Variance 
1 2125 to 32 2.05 0.0046 3.64 0.0062 2.90 0.0037 415 
2 2133 to 40 2.04 0.0062 3.52 0.0042 2.86 0.0024 514 
3 2141 to 48 2.04 0.0077 3.15 0.0032 2.87 0.0035 514 
4 2149 to 56 2.76 0.0560 3.80 0.0181 3.65 0.0281 514 
5 2158 to 65 2.05 0.0055 3.39 0.0038 3.02 0.0036 440 
6 2170 to 74 2.09 0.0037 3.56 0.0035 2.91 0.0024 298 
All 2.19 0.0937 3.51 0.0531 3.05 0.0969 2695 
Not batch 4 2.05 0.0061 3.44 0.0358 2.91 0.0065 2181 




The results in Table 3.2 suggest that a problem arose when running batch 4.  The 










Mean Variance Mean Variance Mean Variance 
2125 2.06 0.0030 3.69 0.0052 2.89 0.0021 44 
2126 2.05 0.0042 3.67 0.0039 2.84 0.0023 44 
2127 2.04 0.0066 3.65 0.0060 2.89 0.0028 45 
2128 2.04 0.0049 3.64 0.0105 2.87 0.0039 45 
2129 2.03 0.0043 3.64 0.0040 2.90 0.0032 44 
2130 2.07 0.0062 3.66 0.0061 2.92 0.0038 65 
2131 2.04 0.0037 3.60 0.0041 2.95 0.0019 64 
2132 2.05 0.0036 3.62 0.0057 2.92 0.0029 64 
2149 2.79 0.0613 3.77 0.0133 3.67 0.0427 66 
2150 2.70 0.0371 3.76 0.0107 3.63 0.0222 63 
2151 2.74 0.0552 3.79 0.0119 3.66 0.0278 65 
2152 2.74 0.0638 3.77 0.0179 3.65 0.0265 64 
2153 2.75 0.0897 3.79 0.0290 3.66 0.0392 64 
2154 2.79 0.0458 3.82 0.0170 3.68 0.0193 64 
2155 2.80 0.0539 3.86 0.0230 3.70 0.0236 64 
2156 2.78 0.0385 3.85 0.0144 3.60 0.0193 64 
Table 3.3:  Descriptive statistics for negative control plates, batches 1 & 4 
 
Just prior to commencing analysis of the above, it was identified that the yeast 
strains for batch 4 had problems in the pre-inoculation phase due to incorrect make 
up of the growth media, before use by Eve.  The curves from batch 4 were not used 




A two sample t-test (unequal sample size & variance) using the mean and variance 
for batches 1 and 4 gave the following test statistics:  
 mcherry DT sapphire DT venus DT 
t statistic 65.3 22.4 94.5 
Degrees of freedom 616 851 672 
Table 3.4:  Population comparison, batches 1 and 4 
 
This analysis strongly indicates a difference between batches 1 and 4 (p<0.0001), in 
agreement with the observation concerning a problem with the growth media. 
The distribution of the negative controls DT for each strain in batch 1 was examined 
to make sure that they followed a normal distribution: 
     
 
Figure 3.4:  Population distribution for negative controls in batch 1 
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Triple Screen 3, batch 1, PfRDHFR
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3.2.2 Manual categorisation of triple strain screens 
The DT results for the compounds were screened against the distribution of negative 
controls, with any result more than 2 standard deviations above the mean being 
flagged as potentially active.  The aim of this step was to initially identify a batch of 
compounds with growth curves that differed from the norm, before conducting a 
deeper analysis of the reasons behind these differences; this process identified 
approximately 600 compounds.  It is expected that 2.28% of compounds would 
naturally meet this criteria if the negative control and compound populations are 
Gaussian and similar; this is equivalent to 328 of the 14400 Maybridge Hitfinder 
library compounds. 
Variation in DT was not expected to be the only measure of identifying activity, as it 
is possible for an assay to double at the same rate as a negative control but for a 
shorter period; it would therefore be limiting to select by this rule alone, as a 
compound so described would mistakenly not be identified as active. 
The potential actives were then examined visually in order to gain a better 
understanding of why they had been flagged as abnormal; they were then classified 
according to the shape of the curves for each strain: 
i. Some compounds autofluoresce at the same wavelength as the strains, 
thereby interfering with effective assessment; three curve shapes were 
identified having: 
a. High fluorescence throughout the run. 
b. High starting fluorescence, falling to meet the typical curve later in the 
experiment. 
c. Low starting fluorescence, but noticeably above the negative control; then 
generally staying above the typical curve. 
 
ii. Toxic compounds were classified as those with lower intensity curves for all 
three strains; these were of three types: 
a. Strains with typical growth curves, but at a lower intensity. 
b. Strains showing little or no growth. 
c. Strains with long lag times, only beginning to grow late in the experiment. 
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Active compounds were visually classified according to their effect on the strain: 
a. One or more strains with growth curves noticeably weaker (i.e. end-of-test 
growth <90% than the negative control), with one or more strains having 
normal growth curves. 
b. One or more strains with growth curves noticeably weaker, with one or 
more strains having stronger growth curves. 
 
iii. Other effects were sometimes seen, overlaying the regular growth curve: 
a. The curves are initially as normal, but the signal decayed later in the 
experiment to give a curve with a sharkfin appearance. 
b. Curves initially build as normal, but then continue to show a low growth 
rate when they should normally have reached a plateau. 
 Figure 3.5 represents the main classes of logistic growth curves produced by Robot 
Eve: 
 




Of the 600 compounds with an abnormal DT, 325 were categorised: 
 20 with strong and 9 with weak activity against HsDHFR 
 57 strongly and 64 weakly active against PvDHFR 
 9 active against PfRdhfr 
 83 toxic compounds (active against all three strains) 
 16 autofluorescent compounds 
 67 normal growth curves (inactive against all three strains) 
The active results for PfRdhfr were generally of lower quality/certainty than those for 
the Hs/PvDHFR curves.   
The above process for identifying candidate compounds was extremely labour 
intensive, but a necessary first step to produce learning/identification algorithms.  
This process also gave the author a better understanding of differences in growth 
patterns of yeast targets, and served as a visual check for Eve‟s behaviour. 
Normalisation of output data 
Prior to running machine learning routines, the well data for compounds needed to 
be normalised against the negative control data.  The recently gained experience of 
variants in the shape of the growth curves suggested that comparisons of the 
end-of-test fluorescence would be of primary significance, together with initial, 
minimum & maximum fluorescence, and lagtimes.  Fluorescence measurements 
were recalculated as ratios against the negative control, and lagtimes were treated 
as a difference to the negative control. 
Total growth ratios for each strain were calculated using the fluorescence data: 
    𝑠𝑡𝑟𝑎𝑖𝑛 𝑔𝑟𝑜𝑤𝑡𝑕 𝑟𝑎𝑡𝑖𝑜 =  
𝑒𝑛𝑑 𝑐𝑜𝑚𝑝𝑜𝑢𝑛𝑑 − 𝑠𝑡𝑎𝑟𝑡 𝑐𝑜𝑚𝑝𝑜𝑢𝑛𝑑
𝑒𝑛𝑑 𝑛𝑒𝑔 .𝑐𝑡𝑟𝑙 − 𝑠𝑡𝑎𝑟𝑡 𝑛𝑒𝑔 .𝑐𝑡𝑟𝑙
  (4) 
 =  
𝐺𝑐𝑜𝑚𝑝𝑜𝑢𝑛𝑑 − 𝐴𝑐𝑜𝑚𝑝𝑜𝑢𝑛𝑑





Start values were calculated as a proportion of the of the negative control growth: 
        𝑠𝑡𝑟𝑎𝑖𝑛 𝑠𝑡𝑎𝑟𝑡 𝑣𝑎𝑙𝑢𝑒 =  
𝑠𝑡𝑎𝑟𝑡 𝑛𝑒𝑔 .𝑐𝑡𝑟𝑙 − 𝑠𝑡𝑎𝑟𝑡 𝑐𝑜𝑚𝑝𝑜𝑢𝑛𝑑
𝑒𝑛𝑑 𝑛𝑒𝑔 .𝑐𝑡𝑟𝑙 − 𝑠𝑡𝑎𝑟𝑡 𝑛𝑒𝑔 .𝑐𝑡𝑟𝑙
  (5) 
 =  
𝐴𝑛𝑒𝑔 .𝑐𝑡𝑟𝑙 − 𝐴𝑐𝑜𝑚𝑝𝑜𝑢𝑛𝑑
𝐺𝑛𝑒𝑔 .𝑐𝑡𝑟𝑙 − 𝐴𝑛𝑒𝑔 .𝑐𝑡𝑟𝑙
 
 
Lagtimes and miylagtimes were calculated as a difference to the negative control: 
 𝑠𝑡𝑟𝑎𝑖𝑛 𝑚𝑖𝑦𝑙𝑎𝑔𝑡𝑖𝑚𝑒 = 𝑚𝑖𝑦𝑙𝑎𝑔𝑡𝑖𝑚𝑒𝑛𝑒𝑔 .𝑐𝑡𝑟𝑙 −  𝑚𝑖𝑦𝑙𝑎𝑔𝑡𝑖𝑚𝑒𝑐𝑜𝑚𝑝𝑜𝑢𝑛𝑑  (6) 
=  𝐽𝑛𝑒𝑔 .𝑐𝑡𝑟𝑙 −  𝐽𝑐𝑜𝑚𝑝𝑜𝑢𝑛𝑑  
   
Doubling times were recalculated as a direct ratio to the negative control: 
     𝑆𝑡𝑟𝑎𝑖𝑛 𝐷𝑇 =  
𝐷𝑇𝑐𝑜𝑚𝑝𝑜𝑢𝑛𝑑
𝐷𝑇𝑛𝑒𝑔 .𝑐𝑡𝑟𝑙
   (7) 
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3.2.3 Decision tree analysis of the first mass screen data set 
A total of 81 discrete attributes were available across all three strains; these were 
tested against the categorised growth curves for 325 compounds.  After systematic 
trial using Weka 3.6.2, C4.5 (J48) decision trees (Witten and Frank, 2005) on all 
attributes, four attributes for each strain gave rules that were readily interpretable: 
1. End-of-test growth ratio. 
2. Start value. 
3. Doubling time. 
4. miylagtime (point J on the logistic growth curve; miy are the initials of 
Professor Mike Young, IBERS, who has suggested this as the biologist‟s 
popular estimation of the lag phase (King et al., 2009)). 
The combined growth (sum of end-of-test growth for all three strains) was also used 
as an attribute in the final set of decision trees. 
Rules were built using Weka 3.6.2, C4.5 (J48) decision trees with 10-fold cross 
validation (those with the lowest average error on the validation set; 10 training 
activities: train on 9/10 of data and test 
1/10; superfluous attributes pruned):  
Category Rule General interpretation/ comments 
Fluoro 
sapphire_startvalue > -0.080 
[306 inactive instances] 
No fluorescence interference if initial 
value is less than 8% above that of the 
negative control. 
sapphire_startvalue  -0.080 
sapphire_ratio  0.85 
[11 active instances] 
sapphire_startvalue  -0.080 
sapphire_ratio > 0.85 
venus_startvalue -0.0007 
[2 inactive] 
sapphire_startvalue  -0.080 
sapphire_ratio > 0.85 
venus_startvalue >-0.0007 
[5 active/1 inactive] 








[57 active instances] 
 
mcherry_ratio > 0.91 
[2 inactive/1 active] 
Summed ratio for the three assays is 
very low, and Hs (mcherry) growth is 
reduced.   
total > 1.70 
venus_miylagtime -10.5 
1.20 mcherry_ratio > 1.58 
[17 active] 
 
1.20 mcherry_ratio < 1.58 
[3 inactive/1 active] 
A long lagtime is an indicator of activity. 
total > 1.70 
venus_miylagtime > -10.5 
venus_ratio 0.76 
0.71  sapphire_ratio  0.80 
[5 active/1 inactive] 
 
0.71 sapphire_ratio > 0.80 
[22 inactive] 
Multiple low individual strain ratios as 
indicators of activity. 
total > 1.70 
venus_miylagtime > -10.5 
venus_ratio > 0.76 
[214 inactive/2 active] 
Negative examples when one of the 
strains has growth within 24% of the 
negative control; this reduces the 
likelihood of overall toxicity. 





Category Rule General interpretation/ comments 
Hs & toxic 
mcherry_ratio  0.68 
[85 active/6 inactive] 
Low growth. 
mcherry_ratio > 0.68 
mcherry_miylagtime  -8.8 
[11 active] 
Long lagtime despite reasonable 
growth. 
0.68 < mcherry_ratio  0.79 
mcherry_miylagtime > -8.8 
[6 active/7 inactive] 
Borderline growth (< 80% of negative 
controls). 
mcherry ratio > 0.79 
[10 active/184 inactive] 
Negative examples when growth within 
21% of negative controls; still a few 
active curves at this level. 
Table 3.7: Decision tree rules HsDHFR-active compounds 
 
Category Rule General interpretation/ comments 
Pv & toxic 
sapphire_ratio 0.83 
[186 active/16 inactive] 
Low growth. 
sapphire_ratio > 0.83 
sapphire_miylagtime  -3.71 
sapphire_DT  1.25 
[2 inactive] 
Long lagtime but reasonable growth 
rate. 
sapphire_ratio > 0.83 
sapphire_miylagtime  -3.71 
sapphire_DT > 1.25 
[7 active/1 inactive] 
Long lagtime and slow growth rate. 
sapphire_ratio > 0.83 
sapphire_miylagtime > -3.71 
[86 inactive/11 active] 
Negative examples, but still a few 
active curves. 
Table 3.8: Decision tree rules PvDHFR-active compounds 
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After using Weka to provide classification rules, it became clear that the growth ratio, 
miylagtime, and doublingtime were of most relevance.  Further decision trees were 
built for HsDHFR and PvDHFR data using only pairs of these attributes: 








[186 active/16 inactive] 
Low growth 
sapphire_ratio > 0.83 
sapphire_miylagtime  -3.71 
[7 active/3 inactive] 
Long lagtime despite 
reasonable growth 
sapphire_ratio > 0.83 
sapphire_miylagtime > -3.71 
[86 inactive/11 active] 
Negative examples, but still 




ratio and DT 
sapphire_ratio 0.83 
[186 active/16 inactive] 
Low growth 
sapphire_ratio > 0.83 
sapphire_DT > 1.47 
[6 active/3 inactive] 
Slow doubling time (growth 
rate) 
sapphire_ratio > 0.83 
sapphire_DT  1.47 
[12 active/86 inactive] 
Negative examples, but still 
a few active curves. 
Table 3.9:  Rules using (1) growth ratio and miylagtime, and (2) growth ratio 



















[85 active/6 inactive] 
Low growth 
mcherry_ratio > 0.68 
mcherry_miylagtime  -8.8 
[11 active] 
Long lagtime despite 
reasonable growth 
mcherry_ratio > 0.83 
mcherry_miylagtime > -8.8 
[191 inactive/16 active] 
Negative examples, but still 









[85 active/6 inactive] 
Low growth 
0.68 > mcherry_ratio  0.72 
[3 inactive] 
 
0.68 > mcherry_ratio  0.72 
mcherry_DT  1.32 
[6 active] 
Slow doubling time (growth 
rate) 
mcherry_ratio > 0.79 
[21 active/186 inactive] 
Negative examples, but still 
a few active curves. 
Table 3.10:  Rules using (1) growth ratio and miylagtime and (2) growth ratio 
and doublingtime, for HsDHFR-active compounds 
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The rules obtained from the Weka decision tree analysis were still seen as specific to 
the individual TS3 strains and the Maybridge Hitfinder Library.  The rules for each of 
the filters were then generalised to give a set using startvalues, growth ratios, 
doubling times and lagtimes.  
Category Rule General interpretation/ comments 
Fluoro filter_startvalue  -0.08 
Compound is autofluorescent if the initial 
reading is >8% higher than the negative 
control. 
Active for filter 
filter_ratio  0.8 
Low growth at end of test, <80% of the 
negative control. 
filter_ratio > 0.8 
filter_DT > 1.5 
Reasonable growth, but doubling time is 
>50% higher than the negative control. 
filter_ratio > 0.8 
filter_miylagtime < -4 
Reasonable growth, but lagged by >4 
hours compared to negative control. 
Table 3.11:  Generalised categorisation rules for active compounds 
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3.2.4 Labelling the activity of compounds in a mass screen  
The rules for this process were found using J48 decision trees in Weka (Witten and 
Frank, 2005). 
Attributes required: 
F1 Fluorescence at start of test 
F2 Fluorescence at end of test 
MIY “Mike Young” lagtime 
DT Doubling time 
The attributes for the individual compound wells were evaluated against the 
respective mean of the negative controls (as calculated on a plate-by-plate basis).  
Compounds were filtered and labelled to describe their relative activity. 
Filters: 
A compound is labelled as autofluorescent if F1 is more than 8% through the range 
for the negative control: 
    
𝐹1𝑐𝑜𝑚𝑝𝑜𝑢𝑛𝑑 − 𝐹1𝑛𝑒𝑔 .𝑐𝑡𝑟𝑙
𝐹2𝑛𝑒𝑔 .𝑐𝑡𝑟𝑙  – 𝐹1𝑛𝑒𝑔 .𝑐𝑡𝑟𝑙
> 0.08     (8) 
A compound is labelled as a potential hit if the end-of-test fluorescence is less than 
80% of the negative control: 
    
𝐹2𝑐𝑜𝑚𝑝𝑜𝑢𝑛𝑑 − 𝐹1𝑐𝑜𝑚𝑝𝑜𝑢𝑛𝑑
𝐹2𝑛𝑒𝑔 .𝑐𝑡𝑟𝑙  – 𝐹1𝑛𝑒𝑔 .𝑐𝑡𝑟𝑙
> 0.80    (9) 
If the end-of-test fluorescence is more than 80% of the negative control, a compound 
may still be labelled as possibly active if: 
(a) the lagtime is more than 4 hours behind the negative control:  
   𝑀𝐼𝑌𝑐𝑜𝑚𝑝𝑜𝑢𝑛𝑑 −  𝑀𝐼𝑌𝑛𝑒𝑔 .𝑐𝑡𝑟𝑙 > 4           (10) 
or   (b) the doubling time is more than 50% above the negative control: 
     
𝐷𝑇𝑐𝑜𝑚𝑝𝑜𝑢𝑛𝑑
𝐷𝑇𝑛𝑒𝑔 .𝑐𝑡𝑟𝑙




The labelling process: 
1. Label and remove the autofluorescent compounds. 
2. If compounds are potential hits against all fluorophores (mcherry, sapphire, 
venus) label them as definitely toxic. 
3. Scoring a potential hit as 2, and a possibly active as 1, compounds not 
identified as definitely toxic are labelled as probably toxic if they score 5 or 
6 across the three channels. 
4. After removal of toxic compounds, active compounds can then be ranked 
either directly by using their end of test fluorescence ratio, or by taking the 
ratio of this value against the HsDHFR ratio. 
5. All other compounds are considered inactive. 
6. The compounds labelled in the toxicity categories are probably worth 
examining further, as the activity of the test strain might be sufficiently 
different to the Hs strain to warrant a deeper investigation.  Later confirmation 
work suggested that some toxic compounds might be of interest if examined 




3.2.5 Decision tree analysis for confirmation screens 
Analysing confirmation data 
Standard mass screens were run using a single well for each compound, dosed at 
10 M in the assay.  Confirmation screens were designed to identify whether 
compounds labelled as a potential hit in the standard screen are truly active; a range 
of concentrations was used for each compound, and replicates of each experiment 
were run.  The list of confirmation screens is given in Appendix A.6.  
Multiple replicates and concentrations allow an activity/concentration curve to be 
built for each compound/assay combination; these were inspected visually for 
evidence of preferential activity against the parasite strain rather than the human 
control.  The curves were examined to determine which compounds were clearly 
active using the confirmation screen data; these observations could then be used in 
combination with the discrete curve data for each well to produce further rules to 
classify their relative activity. 
Two main sets of experimental conditions have been used: earlier experiments used 
8 replicates across a concentration range of 1 to 20 M; this was later changed to 
4 replicates of concentration range 0.5 to 10 M.  The change in conditions allows 
more compounds to be run on each plate, with the added benefit of reducing the 
amount of chemical compound required for each confirmation curve; the reduction in 
concentration range was also designed to be more representative of a practical 
therapeutic dose.  Changing the conditions will have an effect on the concentration 
curve: a reduced number of replicates will mean more noise, and a reduced 
concentration range will lower the likelihood of a compound appearing active 
(although it may realise extended activity at lower concentrations).   
On considering these variations, it was decided to build a separate set of rules for 
each population.  The data from TS6 (CS_77_7_16_20110529120129) was used for 
the earlier approach, and the data from TS7 (CS_80_3_22_20110714113111) for the 
latter.  Subsequent results were then categorised according to the rules for an 
individual experiment, and these were analysed using Weka (J48 decision tree, 10 
fold cross validation) in combination with the visual results for each compound‟s 
concentration curve.  The concentration curves were categorised visually into active 
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versus the sapphire fluorophore, active versus the venus fluorophore, weak 
activity, toxic, and inactive.  It was possible to grade compounds with additional 
details, such as being active against two targets, or being a discrete hit at low 
concentration but toxic at high concentration. 
The following rules were observed when splitting visual observations into simpler 
parcels such as hit (active/weak), toxic, and inactive:  




v_hit  3 
[23 inactive/4 weak/2 active] 
v_hit  >  3  [23 active/11 inactive] 
For active compounds: 
 46/63 = 73% prediction success 
  2/25 = 8% false negatives  
If more than three of the 40 
individual venus curves are hits, 
then the compound is active 
against the venus target. 
TS6 
Sapphire hit 
s_hit    3  [4 inactive/1 active] 
3  <  s_hit    5  [2 weak] 
s_hit  >  5  [active 53/inactive 3] 
For active compounds: 
58/63 = 90% prediction success 
  1/54 = 2% false negatives 
If more than five of the 40 
individual sapphire curves are 
hits, then the compound is active 
against the sapphire target. 
TS6 
Toxic 
c_hit  4  [48 inactive/2 active] 
c_hit  >  4  [11 active/2 inactive] 
For active compounds: 
59/63 = 92% prediction success 
  2/11 = 18% false negatives 
If more than four of the 40 
individual cherry curves are hits, 
then the compound is active 
against the cherry target, and is 
classed as possibly toxic. 
Table 3.12:  Decision tree rules for TS6 confirmation results 
The data set for TS6 consisted of 63 compounds, which were initially chosen for the 
confirmation step due to potential activity versus the PvDHFR target (sapphire 
fluorophore).  The decision tree rules for the sapphire hits were therefore of most 
interest for this screen: they describe sapphire activity very well, with only one 
visually active classification not being selected out of 54 so classified.   
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The rules developed for the TS6 venus target were less clear, relating to the 
borderline nature of the confirmation curves.  A relatively high number of false 
positives were selected by the rules (visually classified as inactive); a visual 
re-examination of the curves suggested that activity versus the venus target may 
have been missed due to the relatively strong signal for the sapphire target in the 
same well.  This shows the strength of taking an objective machine learning 
approach for building rules for complex data analysis. 




v_hit  3  [17 inactive/2 active] 
v_hit  >  3  [26 active/8 inactive] 
For active compounds: 
43/53 = 81% prediction success 
  2/26 = 8% false negatives 
If more than three of the 20 
individual venus curves are hits, 
then the compound is active 
against the venus target. 
TS7 
Sapphire hit 
Insufficient hits for J48 decision 




c_hit  3  [39 inactive/1 active] 
c_hit  >  3  [9 active/4 inactive] 
For active compounds: 
48/53 = 91% prediction success 
  1/9   = 11% false negatives 
If more than three of the 20 
individual cherry curves are hits, 
then the compound is active 
against the cherry target, and is 
classed as possibly toxic. 
Table 3.13:  Decision tree rules for TS7 confirmation results 
The 53 compounds used to build the TS7 decision tree rules were predominantly 
selected for their potential activity versus PvRdhfr (venus flurophore).  In general, the 
strength of the confirmation curves was weaker than with the earlier TS6 set, hence 




3.2.6 Labelling activity of compounds in confirmation screens 
Applying the above rules, the simplest approach was to classify a compound as 
active and/or possibly toxic based on the cumulated screen rules score; under the 
mass screen rules an active compound is [score = 2] for a full hit, or [score = 1] for 
activity based on lagtime or doubletime.  Therefore, [score > 9] was taken as the limit 
above which a compound is defined active or toxic for TS6-type populations, and 
[score > 7] for TS7-type populations.  These limits were programmed in R, and this 
code was then extended to provide ranked lists of active compounds for each target 













1 – 20 m 
≤ 9 
≤ 9 No toxicity 
indicated 
Inactive 





> 9 Active 
4 replicates, 
0.5 – 10 m 
≤ 7 
≤ 7 No toxicity 
indicated 
Inactive 





> 7 Active 




3.2.7 Verification of labelling rules for confirmation screens 
Several confirmation screens were assessed both visually and by using the rules 
built with the data from TS6 (CS_77_7_xx) and TS7 (CS_80_3_xx), then generalised 
in Table 3.14.  The results in Table 3.15 show how many compounds were visually 
classified as active or inactive against the parasite targets, and whether there was an 
indication of general toxicity.  The columns showing the classification under the 
decision tree rules show the number of items classified and mis-classified against 
the „inactive‟ and „active‟ labels respectively. 
In general, the rules work well when comparing such classified activity against the 
visual results for each confirmation screen.  Some difference is seen concerning 
borderline toxicity; it is likely that this could be improved by adding an additional rule 
to the ranking mechanism for active compounds, thereby allowing strongly active 
compounds with borderline toxicity to be more visible.  It might also be possible to 




Visual Decision tree rules 
Comments 
Inactive Active Inactive Active 
TS3_63_2 
Sapphire 8 50 8/1 50/1 Rules pick up more borderline toxic 
compounds in TS3; this accounts for 
additional venus hits too. Main activity is 
reproduced very favourably. 
Venus 52 6 46/0 12/6 
Toxic 54 4 45/1 13/10 
TS4_64_4 
Sapphire 20 42 23/5 39/2 
Rules suggest more borderline active & 
toxic compounds. Good agreement with 
main activity. 
Venus 47 15 33/2 29/16 
Toxic 51 11 35/1 27/17 
TS5_71_2 
 
Cherry 24 36 18/2 42/8 
Rules suggest more borderline active & 
toxic compounds. Good agreement with 
main activity. 
Venus 22 38 15/2 45/9 
Toxic 37 23 33/4 27/8 
TS6_cherrypick 
Sapphire 15 33 20/6 28/1 
All four TS6 screens showed good general 
agreement between visual and rule-based 
analyses; the disagreements were with 
weak visual actives and with borderline 
toxic results using the rules. 
Venus 32 16 30/2 18/4 
Toxic 42 6 36/0 12/6 
TS6_77_3 
Sapphire 85 11 88/3 8/0 
Venus 91 5 90/1 6/2 
Toxic 91 5 89/1 7/3 
TS6_77_4 
Sapphire 80 22 90/10 12/0 
Venus 90 12 96/6 6/0 
Toxic 98 4 96/1 6/2 






Visual Decision tree rules 
Comments 
Inactive Active Inactive Active 
TS6_77_5 
Sapphire 72 14 84/12 2/0 
 Venus 81 5 82/2 4/1 
Toxic 80 6 81/2 5/1 
TS6_77_7 
Sapphire 5 58 6/2 57/1 
Rules pick up more borderline toxics, & 
sees other venus that might have been 
swamped by strong visual sap signal 
Venus 34 29 23/1 40/12 
Toxic 56 7 44/0 19/12 
TS7_80_4 
Sapphire 36 17 40/5 13/1 
Good agreement throughout.  Extra visual 
venus hits should really just be labelled as 
toxic. 
Venus 10 43 19/9 34/0 
Toxic 43 10 40/1 13/4 
PGK1_72_2 
Sapphire 23 36 20/2 39/5 
General agreement good.  Lots of well 
labelled toxics too. 
Venus 22 37 17/2 42/7 
Toxic 33 26 30/3 29/6 
PGK2_74_2 
Sapphire 37 25 45/11 17/3 
Good agreement.  Main disagreement 
around borderline/weak activity. 
Venus 30 33 35/8 27/2 
Toxic 50 13 53/5 9/1 
NMT1_78_2 
Sapphire 16 45 22/8 39/2 
Good agreement.  Main disagreement 
around weak activity. 
Venus 27 34 32/6 29/1 
Toxic 59 2 60/1 1/0 
NMT2_79_2 
Sapphire 36 25 43/9 18/2 
Good agreement.  Main disagreement 
around weak activity. 
Venus 19 42 24/7 37/2 
Toxic 47 14 50/3 11/0 
Table 3.15 (part 2):  Confirmation screen data – visual and rule-based activity classification 
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3.3 In vivo experiments with yeast-hosted targets 
Robot Scientist Eve ran mass screen experiments on triple strain sets between 
December 2010 and January 2012.  The results from these experiments provided 
leads for subsequent confirmation/cherry-pick screening, which duly ran between 
December 2010 and June 2012, at which point Eve was relocated to Manchester. 
3.3.1 Screens and cherrypicking 
Data from Eve 
Eve produces a comma-separated-variable data file (.csv) for each plate: 
384 wells per plate: each plate is 16 rows (labelled A to P) × 24 numbered columns. 
This typically represents 320 compounds and 64 control wells.  The control wells (up 
to 20 positive controls per plate; the remainder are negative controls) are typically 
located in the outer two columns for each plate (1, 2, 23 & 24) to help to counter 
edge-drying effects. 
A line of data is recorded for each well, with 25 parameters per well (29 for 
confirmation screens).  Assuming no empty wells have occurred (for which the data 
is removed at source), Eve therefore produces a 384×25 dataframe for each mass 
screen plate. 
Eve saves the .csv file in the format: 
 MS_77_1_22_20110316174043.csv 
 MS  =  mass screen (CS = cherry/confirmation screen) 
 77  =  code number for the assay in use 
1 =  code for the iteration number of this assay 
22 =  rolling number of experiments conducted on Eve to date 
20xx =  date/time stamp (2011, 16 March, 17:40:43) 




3.3.2 Mass screen results 
The decision tree rules derived for mass screens were subsequently applied for all 
such experiments run by Eve in Aberystwyth.  A total of 17 parasite targets 
(9×DHFR, 4×NMT and 4×PGK; see Appendix A.1 for details) have been evaluated 
during the course of 12 mass screens (Appendix A.2).  With the exception of TS6 
which was split over two screens, all mass screens contained all of the compounds 
available in the Maybridge Hitfinder Library and the JHCCL. 
The last two mass screens run in Aberystwyth (TS8 and TS9) both contained the 
SaDHFR target on the sapphire and venus fluorophores; for both screens, problems 
were experienced with fluorescence measurements.  An attempt was made to 
cherry-pick compounds using the data from TS9, but there was too much noise to 
provide usable confirmation results. 
Appendix A.3 shows the number of active compounds versus each target.  Each 
active compound is categorised as either a clean hit (i.e. no activity versus the two 
other targets in the screen), a co-hit with the other parasite target, or as possibly 
toxic (a hit, but also with a weak signal suggesting activity versus the Hs strain). 
Example – activity versus PvDHFR in TS6 
203 compounds were identified that had discrete activity versus PvDHFR in the TS6 
mass screen, with 81 that were jointly active versus PfDHFR and a further 19 
considered active but possibly toxic. 
The ideal behaviour for a strong candidate would be a large reduction in the growth 
of the target strain, with a corresponding overgrowth of the Hs strain.  This behaviour 
could be indicated by measuring the relative growth ratio at the mass screen stage, 
as shown in Table 3.16.  The decision tree scores in this table can be used to 
indicate whether activity is against a single target, or if there is potential for a multiple 
target effect or toxicity. 
For each mass screen, the candidates offering the best target activity potential were 
ranked for further evaluation in a confirmation screen (section 3.3.3).  This ranking 














Hs Pv Pf Total Hs Pv Pf Total 
978 3.17 0.12 0.15 3.44 0 2 2 4 0.04 0.04 
9082 0.96 0.16 0.77 1.89 1 2 2 5 0.08 0.16 
9499 1.28 0.26 0.89 2.43 0 2 0 2 0.11 0.21 
10838 0.94 0.20 0.77 1.90 1 2 2 5 0.10 0.21 
8766 1.21 0.27 0.80 2.29 0 2 0 2 0.12 0.22 
10371 1.20 0.29 0.66 2.15 1 2 2 5 0.13 0.24 
7091 1.76 0.44 0.68 2.87 1 2 2 5 0.15 0.25 
15497 1.89 0.51 0.49 2.89 1 2 2 5 0.18 0.27 
3466 1.29 0.37 0.72 2.38 0 2 2 4 0.15 0.28 
5829 1.27 0.36 0.90 2.54 0 2 0 2 0.14 0.29 
7352 0.40 0.12 2.19 2.71 2 2 1 5 0.04 0.29 
12803 1.95 0.58 0.74 3.26 0 2 2 4 0.18 0.30 
16914 1.63 0.53 2.29 4.44 2 2 1 5 0.12 0.32 
13015 1.99 0.64 2.11 4.74 0 2 1 3 0.14 0.32 
17167 1.12 0.36 0.70 2.18 1 2 2 5 0.17 0.33 
14244 0.80 0.26 2.74 3.81 1 2 1 4 0.07 0.33 
3978 0.96 0.32 2.02 3.30 2 2 1 5 0.10 0.33 
12054 1.27 0.44 0.95 2.67 0 2 0 2 0.17 0.35 
12913 1.38 0.48 3.74 5.61 1 2 1 4 0.09 0.35 
5833 1.82 0.64 1.21 3.67 0 2 1 3 0.17 0.35 





These 20 candidates all showed growth less than 35% that of the HsDHFR target 
during the course of the experiment, with most also displaying overgrowth of the 
latter.  Note:  Eve ID 978 is Pyrimethamine, the main positive control for the 
unmutated plasmodium species.   
The low growth for the Hs target for one candidate (Eve ID 7352) suggests that this 
is likely to have general toxicity, and two other candidates also had both the lagtime 
and doubling time indicators of weak toxicity, but reasonable Hs growth (Eve ID 3978 
& 16914). 
Mass screen negative control statistics 
The negative control statistics are displayed graphically in Appendix A.5.  The 
comments raised for TS3 (see section 3.2.1, where noisy data was identified due to 
incorrect make up of the growth media) can be related to the kick in the plot of 
standard deviation versus plate number.  There is a distinct rise in standard deviation 
(SD) for [sapphire=blue] and [venus=green].   
 
Figure 3.6: Standard deviation of TS3 negative controls, by plate 
This noise was high enough to cloud data interpretation for these plates; plates in 
other screens also showed high levels of noise, and in some cases a large 
proportion of the full screen was affected (e.g. TS8, TS9, PGK-2).  Unfortunately the 













support in Aberystwyth had reduced significantly by the time they were run.  The 
screens with high noise coincided with targets that returned lower proportions of hit 
compounds; if reasons for high noise could be isolated and countered, this might 
allow more screen data to be available, although it is highly likely that the affected 
screens would need to be re-run. 
78 
 
3.3.3 Confirmation screen results 
A full list of the confirmation screens is given in Appendix A.6. 
Appendix A.8 gives a full list of Maybridge Hitfinder compounds with activity against 
the relevant parasite strains during confirmation screens.  Appendix A.9 records 
equivalent activity lists for all active JHCCL compounds. 
The example compounds from Table 3.16 that potentially indicated activity versus 
the PvDHFR strain have been followed through the confirmation screen process: 
17 of the 20 strong PvDHFR candidates were run as part of one of the TS6 
confirmation screens (CS_77_7_16_...); the three compounds not in this screen 
were 12913, 17167 and 978.  In accordance with the confirmation screen rules, the 
compound activity scores and classifications are as follows:  
Eve ID 
Target score Active vs target 
Toxicity 
Hs Pv Pf Pv Pf 
9082 2 80 14 Yes Yes None indicated 
9499 8 80 10 Yes Yes None indicated 
10838 21 80 31 Yes Yes Possibly toxic 
8766 0 80 2 Yes  None indicated 
10371 0 80 76 Yes Yes None indicated 
7091 0 22 0 Yes  None indicated 
15497 8 20 21 Yes Yes None indicated 
3466 16 36 18 Yes Yes Possibly toxic 
5829 0 72 0 Yes  None indicated 
7352 10 13 8 Yes  Possibly toxic 
12803 16 36 42 Yes Yes Possibly toxic 
16914 33 38 26 Yes Yes Possibly toxic 
13015 9 28 8 Yes  None indicated 
14244 14 48 19 Yes Yes Possibly toxic 
3978 14 56 15 Yes Yes Possibly toxic 
12054 7 64 9 Yes  None indicated 
5833 30 36 21 Yes Yes Possibly toxic 
Table 3.17: Confirmation screen of 17 strong TS6 PvDHFR active candidates  
The confirmation curve for each of these compounds is given in Appendix A.7.   
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Example curves for stronger and weaker candidates, and for those exhibiting 
possible toxicity are shown in Figures 3.7 to 3.9; in these figures, HsDHFR is red, 
PvDHFR is blue, and PfDHFR is green.  
 
Figure 3.7: Confirmation curves for Eve ID 9082 
The confirmation curves for 9082 shows strong growth inhibition for the PvDHFR 
strain, with a weaker signal for PfDHFR. 
 
Figure 3.8: Confirmation curves for Eve ID 7091 
The PvDHFR concentration curves for 7091 shows weak growth inhibition, with little 




Figure 3.9: Confirmation curves for Eve ID 16914 
All three curves for 16914 are very noisy, which is a good indicator that the 
compound is generally toxic versus these targets. 
Confirmation screen negative control statistics 
The negative control statistics are displayed graphically in Appendix A.10.  A higher 
variability of in-plate standard deviation was seen than during the mass screens. 
As more progress is made with the development of Eve‟s data handling and analysis 
software, these negative control data can be used to define limits at which to reject 
results, or at least to label them as in need of further verification.  More repeat runs 
of mass and confirmation screens would be needed to construct such limits. 
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3.3.4 Testing an expansion seeded from confirmed hits 
After the first TS6 confirmation screen, it was noted that two adjacent compounds in 
the MaybridgeHF library (no.9081 & 9082) were active versus PvDHFR and had 
structural similarities.  A simple structural fingerprint search revealed other similar 
library compounds.   
  
Figure 3.10:  Core structural similarities for 9081 & 9082 
 
The levels of activity in the mass and confirmation screens (where tested) of the 
three additional compounds are given in the Table 3.18.  Only one of the five 
MaybridgeHF compounds was categorised as inactive after the mass screen. 
Subsequently, a search of the full Maybridge library (available as an online resource) 
was conducted, and 7 other candidates were found that had strong Tanimoto 
Similarity to 9081/HTS12148.  Six of these candidates were purchased for 
confirmation screen testing, and the other was not available; their confirmation 
growth curves are displayed in Table 3.19. 
Two candidates (18013 & 18015) were inactive in the confirmation screen; 
interestingly, they were smaller molecules with no large functional group attached to 
the thiol bridge, and could be described as small molecules for drug lead 
development in this context.  The other four compounds were active versus 
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Table 3.20: Activity of Maybridge full library compounds similar to 9081/9082 
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3.3.5 Confirmed activity for JHCCL compounds 
In addition to testing JHCCL drugs in confirmation screens (see Appendix A.9) 
against a single parasite-protein combination, the results were scrutinised to 
understand if any background effects might be suggesting false positives. 
It had been noted earlier that some MaybridgeHF compounds were repeatedly 
identified as active versus a particular fluorophore in otherwise unrelated screens; 
this suggested that fluorophore-specific effects should be evaluated once potential 
hits had been identified.   
The intrinsic value of finding a hit amongst the pre-approved JHCCL drugs is high.  
Many of these potential hit compounds were subsequently tested across a wide 
range of assays; this allowed discrimination of the compound activity versus 
unrelated proteins, thereby determining whether the effect might be protein-specific 
or an indicator of more generalised toxicity. 
A total of 13 JHCCL drugs were identified with activity versus at least one parasite 
target; Methotrexate was added to this list (another approved drug, present as a 
positive control).  The presence of each drug in multiple confirmation screens 
allowed statistical analysis of background effects to be considered.   
General performance versus either the fluorophore or the protein was evaluated 
using two-sample t tests and Wilcoxon Ranked Sign Tests using all the 
concentration curve data at 5 µM and 10 µM.  For identifying whether a compound 
was active versus a parasite-protein target independently from the fluorophore, the 
active data was compared to all data from inactive results.  Where more than one 
active target was identified, these results were separated from the inactive data, and 
tested for their own specific activity. 
As an example, TNP-470 was labelled as active versus PvDHFR in a confirmation 
screen, but not labelled as active versus any other targets tested (Hs/PfR/Tc& 
PfDHFR, Hs/Tb/Pv/Sm/TcNMT).  Testing the PvDHFR results versus all other 
(inactive) DHFR results showed the activity to be Pv-specific; similar statistical 
analysis of the results versus all TNP-470 experiments run against the sapphire 






Independence of confirmed activity 
Azaribine 904 
Active versus HsDHFR, TcDHFR & PfDHFR, 
independent of fluorophore.  [Note: all HsDHFR 
compared to all HsNMT] 
Triclosan 10450 
PvDHFR, TbNMT & SmDHFR activity is not 
independent of fluorophores. 
Bithionoloxide 1305 
TbNMT activity is independent of fluorophore.  
PvDHFR activity is not independent of fluorophore. 
Satraplatin 9003 
PvDHFR & TcNMT activity is independent of 
fluorophore. 
Apomorphine 715 PvDHFR activity is independent of fluorophore. 
Chloroquinaldol 2095 PvDHFR activity is not independent of fluorophore. 
Lamotrigine 5529 
PvDHFR activity is borderline independent of 
fluorophore. 
Closantel 2430 
PvNMT, TbNMT: insufficient data to test 
independence 
Dichlorophen 3038 TbNMT activity is independent of fluorophore. 
Methotrexate - TcDHFR activity is independent of fluorophore. 
Demacarium 
Bromide 
2831 SmNMT activity is independent of fluorophore. 
Meclocycline 6047 SmNMT activity is independent of fluorophore. 
Stanozolol 9409 HsDHFR: insufficient data to test for independence 
TNP-470 10251 PvDHFR activity is independent of fluorophore. 





Compound Enzyme Strain Fluorophore 
Versus inactive enzyme analogues Versus inactive fluorophore analogues 
10um 5um 10um 5um 
t-stat df WRST-p t-stat df WRST-p t-stat df WRST-p t-stat df WRST-p 
Azaribine 
DHFR Hs mCherry 
-4.97 78 1.13×10
-4
 -4.27 78 8.77×10
-4
 -5.40 42 2.57×10
-6
 -2.28 42 0.0486 
DHFR Hs Sapphire 
DHFR Tc Venus -13.5 62 2.87×10
-14
 -12.2 62 4.96×10
-12
 -11.4 38 4.60×10
-7
 -7.28 38 8.59×10
-8
 
DHFR Pf Venus -9.71 54 2.82×10
-9
 -9.78 54 1.69×10
-8
 -8.45 30 3.80×10
-7




DHFR Pv Sapphire -5.94 102 1.95×10
-7
 -8.08 102 2.57×10
-10
 0.513 38 0.859 -1.43 38 0.1489 
DHFR Pf Venus -1.28 94 0.0996 -2.96 94 5.91×10
-4
 -1.69 50 0.0526 -3.87 50 1.90×10
-4
 
NMT Tb Sapphire -2.90 26 3.71×10
-3
 -3.79 26 1.17×10
-3
 -0.339 18 3.71×10
-3
 -0.566 18 0.494 
NMT Sm Sapphire -2.23 26 2.89×10
-3
 -3.43 26 8.56×10
-6
 0.407 18 0.834 0.372 18 0.452 
Bithionoloxide 









2.26 50 0.833 50 
DHFR Pf Venus -1.17 90 0.174 -3.50 90 5.92×10
-4
 3.02 46 0.0130 4.09 42 3.76×10
-3
 
DHFR PfR mCherry 
-4.00 94 7.08×10
-3
 -2.52 94 0.153 
-2.17 58 0.0171 -1.12 58 0.0875 
DHFR PfR Venus 2.66 42 0.0171 0.627 46 0.573 
NMT Tb Sapphire -4.70 26 4.31×10
-5
 -4.08 26 2.98×10
-4
 -3.64 42 5.25×10
-5
 -4.06 42 6.61×10
-8
 
NMT Pv Venus -3.84 26 5.12×10
-4
 -2.76 26 0.0183 -1.21 38 0.0834 -2.28 38 0.0515 
Satraplatin 
DHFR 
Pv Sapphire -11.4 38 3.18×10
-11











DHFR -2.97 14 -3.19 14 
DHFR PfR Venus -4.40 30 3.18×10
-11
 -3.92 30 3.17×10
-4
 -2.62 18 2.16×10
-3
 -2.07 18 0.452 
NMT Tc Venus -3.30 22 1.88×10
-4
 -3.38 22 1.88×10
-4
 -5.53 14 1.10×10
-3
 -3.39 14 1.110×10
-3
 
Apomorphine DHFR Pv Sapphire -6.66 62 1.18×10
-5
 -5.78 62 1.17×10
-4
 -3.32 26 8.34×10
-3
 -3.12 26 9.71×10
-3
 
Chloroquinaldol DHFR Pv Sapphire -3.92 82 4.45×10
-6
 -3.83 82 2.06×10
-6
 0.487 34 0.934 -0.365 34 0.753 





Compound Enzyme Strain Fluorophore 
Versus inactive enzyme analogues Versus inactive fluorophore analogues 
10um 5um 10um 5um 
t-stat df WRST-p t-stat df WRST-p t-stat df WRST-p t-stat df WRST-p 
Lamotrigine DHFR Pv Sapphire -5.76 58 1.73×10
-4
 -4.72 58 7.20×10
-3
 -2.22 26 0.0120 -1.98 26 0.0387 
2,4,6-
tribromophenol 
DHFR Pv Sapphire -5.13 30 1.73×10
-4
 -5.45 30 7.20×10
-3
 2.21 14 0.0121 1.60 14 0.0387 
NMT Tb Sapphire -5.60 19 1.50×10
-3
 -4.23 19 1.88×10
-4
 -7.97 9 2.06×10
-3




NMT Pv Venus 
Insufficient data to test for cross-strain/fluorophore independence 
 
NMT Tb Sapphire 
Dichlorophen 
DHFR Tc Venus -0.971 58 0.254 -0.680 58 0.646 -2.01 26 0.0421 -1.27 26 0.291 
NMT Tb Sapphire -3.53 22 1.88×10
-4
 -4.68 22 1.88×10
-4
 -2.60 26 3.71×10
-4
 -4.30 26 6.84×10
-4
 
Methotrexate DHFR Tc Venus -3.23 235 0.0644 -3.07 238 0.0749 -3.57 92 0.0918 -3.46 92 0.0461 
Demacarium 
Bromide NMT Sm Sapphire -5.17 46 5.43×10
-6
 -6.57 46 3.23×10
-6
 -5.33 26 1.93×10
-5
 -6.05 26 1.93×10
-5
 
Meclocycline NMT Sm Sapphire -3.58 46 5.12×10
-4
 -3.52 46 6.69×10
-4
 -3.58 26 0.0134 -3.58 26 0.0134 
Stanozolol DHFR Hs mCherry Insufficient data to test for cross-strain/fluorophore independence 
 TNP-470 DHFR Pv Sapphire -4.84 94 9.05×10
-3
 -3.95 94 5.17×10
-3
 -3.21 38 8.70×10
-3
 -3.07 38 4.60×10
-4
 
Notes  t-stat:  Two-sample t test statistic 
df:  Degrees of freedom 
WRST-p: Wilcoxon Ranked Sign Test, p-value 
Red text: t statistic < -2.00 (p < 0.025)  





3.4 A comparison of rule development methods for Eve’s data 
3.4.1 Summary 
The predictions of Eve‟s decision tree-based rules have been compared to those 
made by an alternative method provided by the School of Biological Sciences, 
University of Cambridge.  Both approaches are designed to predict potential hit 
compounds following a mass screen, and to eliminate those compounds likely to be 
toxic or autofluorescent; analysis has shown that they have limited overlap.   
Eve‟s data analysis method demonstrates better discrimination between active and 
toxic compounds for individual screens, and also eliminates autofluorescent 
compounds that are otherwise missed.  By incorporating measurements of lagtime 
and doubling time, Eve‟s rules demonstrate a distinct advantage in their ability to 
identify compounds otherwise labelled as false negatives by the Cambridge method. 
The method provided by Cambridge uses data from across all screens during the 
selection process; this helps to eliminate compounds which are generally toxic or 
have repeatedly caused processing problems, and provides useful ideas for 
post-evaluation of data from multiple screens.  However, by only using end-of-test 
growth ratios, it misses information gleaned by Eve‟s rules that use growth rates and 
lagtimes, and consequently its ability to identify screen-specific activities is restricted. 
Ideally, a combined method could be constructed that incorporates the cross-screen 
data analysis of the Cambridge method with the additional information inputs used 
by the original decision tree rules.  This might itself be an Active Learning exercise 
for Eve to maintain. 
3.4.2 Introduction 
Two separate approaches have been used to define hits using Robot Eve‟s mass 
screen results, classifying each compound well in terms of relative activity and 
effects from noise.  The Cambridge method exploited the benefits of using all data 
across all available screens; this enabled it to build filters that highlighted compound 




In contrast, the rules originally derived for Eve were built using supervised decision 
tree learning based on visual interpretation of only the original triple strain mass 
screen (as described in section 3.2). 
Cambridge’s filters (based on analysis of end-of-test growth): 
 Toxic = {max growth < 0.70 for all three strains across all screens} 
 Autofluorescent = {mcherry, sapphire or venus > 1.2 in all screens} 
 Fluorophore specific = {growth < 0.60 for a specific fluorophore in all screens} 
 Problem well = {average value in all channels in a specific screen < 50% of 
average value in all other screens} 
 Hit = {parasite strain growth / human strain growth < 0.5} 
Eve’s filters (see section 3.2.4): 
 Autofluorescent = {initial fluorescence is more than 8% through the growth  
range for the negative control} 
 Potential hit = {growth < 80% of the negative control} 
 Possibly active = {growth > 80% of the negative control but  
(a) lagtime > 4 hours after the negative control or 
(b) doubling time > 50% above the negative control} 
Eve’s labelling process: 
1. Mark and remove the fluorescent compounds. 
2. If compounds are potential hits on all channels (mcherry, sapphire, venus), 
mark them as definitely toxic. 
3. Scoring a potential hit as 2, and a possibly active as 1, compounds not 
identified as definitely toxic are marked as probably toxic if they score 5 or 6 
across the three channels. 
4. After removal of toxic compounds, hit compounds can then be ranked either 
directly by using their end of test fluorescence ratio, or by adding a further 
step by taking the ratio of this value against the HsDHFR ratio.  Both 
approaches have been used for preliminary studies. 
5. All other compounds are considered inactive. 
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6. Note: the compounds marked up in the two categories of toxicity are probably 
worth examining further to see if the activity of the test strains is sufficiently 
different to the Hs strain to warrant a deeper investigation; earlier confirmation 
studies on PvDHFR hits suggested that some toxic compounds might be of 
interest if examined at lower concentration. 
3.4.3 Experimental and Results 
The new method was used by Cambridge to predict compounds that were active 
against PvDHFR or TbDHFR; the output contained several that had not previously 
been run through Eve‟s confirmation screen.  
 Cambridge predictions Not previously tested by 
Eve 
PvDHFR 67 12 (TS3 & TS6) 
TbDHFR 46 36 (TS4) 
Table 3.24:  New candidate compounds using Cambridge’s filters 
Additional confirmation screens were run to evaluate these compounds.  The five 
control compounds were also run in each screen; in the TS6 confirmation screen it 
was noted that the concentration curve for Pyrimethamine (the main PvDHFR 
positive control) was weaker than in previous studies, but was still clearly active. 
New activity predictions for TbDHFR 
All but two of the 46 compounds have now been tested in a confirmation screen. 
Predictions for each of the 44 compounds have also been made using Eve‟s original 
process; this splits compounds into various groups, including: toxic, sapphire-active 
(TbDHFR), probably toxic/sapphire hit, inactive, and autofluorescent. 













Toxic 18 6 1 11 
Active 11 2 4 5 
Active/probably toxic 4 2 1 1 
Inactive 4 3 1 - 
Autofluorescent 7 7 - - 
Table 3.25: TbDHFR predictions versus confirmation results 
 
New activity predictions for PvDHFR 
Of the 67 compounds new predictions, all but one compound has now been tested in 
a confirmation screen. Again, the original predictions for the mass screen were also 
compared against these confirmation results 
The subsequent confirmation curves are split into inactive, hit, and possibly toxic 
groups.  The final confirmation screen groupings are based on a compilation of the 













Toxic 24 3 3 18 
Active 30 - 25 5 
Active/probably toxic 6 2 1 3 
Inactive 5 2 1 2 




Toxic 15 3 - 12 
Active 32 1 23 8 
Active/probably toxic 12 1 4 7 
Inactive 6 2 3 1 
Autofluorescent 1 1 - - 
Table 3.26: PvDHFR predictions versus confirmation results 
 
Eve’s predictions for TS3 & TS6 
When applied to the PvDHFR results in TS3 and TS6, Eve predicts 316 (21 probably 
toxic) and 303 (19 probably toxic) compounds to be active, respectively.   
Confirmation screens were initially run on the top candidates from each of these lists.
94 
 
Eve’s top predictions for TS3 PvDHFR 
Two confirmation screens were run on TS3 Maybridge Hitfinder compounds; the 
predictions for these compounds were based on both parasite strains in the screen 
(Pv & PfRdhfr), and were compiled retrospectively for the compounds in the 
December 2010 screen as the rules had not been developed at this point.   Of the 85 
compounds tested in the confirmation screen, 67 were listed as possible hits from 







Toxic 8 - 1 7 
Active 19 1 16 2 
Active/probably toxic 2 - 1 1 
Inactive vs PvDHFR 3 3 - - 
Autofluorescent - - - - 
CS_ 63_2 
Toxic - - - - 
Active 48 2 36 10 
Active/probably toxic - - - - 
Inactive vs PvDHFR 4 4 - - 
Autofluorescent 1 - - 1 
Table 3.27: TS3 Mass screen PvDHFR predictions vs confirmation results 
34 of the 66 Cambridge predictions were included in the original TS3 confirmation 





Figure 3.11:   (a) Active TS3 compounds  (b) Confirmed TS3 hits 
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Eve’s top predictions for TS6 PvDHFR 
Similarly, two main confirmation screens (cherrypick & CS_77_7) were run on 
compounds selected visually after running the TS6 mass screen (Pv & PfDHFR).  
The results from these screens have been combined to give 75 selections, and Eve‟s 








Toxic 2 1 - 1 
Active 48 2 35 11 
Active/probably toxic 14 - 4 10 
Inactive vs PvDHFR 11 5 5 1 
Autofluorescent - - - - 
Table 3.28: TS6 Mass screen PvDHFR predictions vs confirmation results 
48 of the original 75 mass selections were predicted to be active using Eve‟s rules; 
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New 
     16     14 
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Eve’s top predictions for TS4 TbDHFR 







Predicted as active 53 14 13 26 
Table 3.29: TS4 Mass screen TbDHFR predictions vs confirmation results 
The new filters predicted 44 active compounds, of which 7 were confirmed; these 
included three compounds not identified by Eve‟s rules: 
9504:  Eve predicts this to be inactive. 
3951:  Eve predicts this as probably toxic/Tb-active. 
12803: Eve predicts this to be toxic. 






Figure 3.13:   (a) Active TS4 compounds  (b) Confirmed TS4 hits 
 
In general, the hits identified for the TbDHFR strain were of much lower strength 
than those for PvDHFR; this has probably contributed to the lower proportion of 
confirmed hits identified by either method. 
Bessie 
     33     11 
   Eve 
    42 
 
   Eve 
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Bessie 
     3      4 
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3.4.4 Precision-Recall graphs for PvDHFR predictions 
A comparison of how well the two approaches classify compounds can be made 
using Precision-Recall curves (Davis and Goadrich, 2006).  These are generated 
using quantification of true positives (TP), false positives (FP), true negatives (TN) 
and false negatives (FN). 
 Prediction 














+ TP FN 
- FP TN 
Figure 3.14:  Calculations for precision and recall parameters 
 
Across all three sets of predicted hits for PvDHFR (Cambridge‟s, Eve‟s for TS3 and 
TS6), some 128 different compounds have been identified; each of these 
compounds has been run in a confirmation screen.  These compounds were ranked 
based on the methods below, and these rankings were used to build P-R graphs: 
 When Cambridge‟s predicted hits were supplied they also included a ranking 
based on HsDHFR:PvDHFR end of test growth ratios.  The Cambridge 
method only originally predicted 66 active compounds; the remaining 52 were 
subsequently ranked based on the TS3/TS6 growth data. 
 Eve‟s predicted hits were ranked initially by whether they were identified as a 
discrete sapphire hit, and secondly by their end of test PvDHFR growth 





  Figure 3.15: Precision-Recall curves for PvDHFR predictions 
 
In addition to a comparison of Cambridge‟s method with Eve‟s, the mass screen 
predictions for TS3 and TS6 could also be cross-compared with the confirmed hits.  
TS3 screen data 
TS6 confirmed hits 
Prediction         Recall = 25/(25+10) =  0.71 
Precision = 25/(25+5) = 0.83 
 
F = 0.77 
+ - 
Actual 
+ 25 10 
- 5 8 
Table 3.30:  P-R result for TS3 mass screen data 
 
TS6 screen data 
TS3 confirmed hits 
Prediction         Recall = 31/(31+21) =  0.60 





+ 31 21 
- 9 6 




3.4.5 Interpretation of results 
Confirmed results 
A simple breakdown of the relative success rates for Cambridge‟s and Eve‟s filters 
can be made for PvDHFR: 
 30 of the 66 hits (45%) predicted by Cambridge‟s filters were confirmed. 
 52 of 67 (78%) were confirmed for Eve‟s filters for the TS3 mass screen. 
 35 of 48 (73%) were confirmed for Eve‟s filters for the TS6 mass screen. 
Note: evaluation of Eve‟s mass screen data gives much longer lists of potentially 
active compounds for PvDHFR than those run in the confirmation screens. 
The new prediction filters gave a lower proportion of novel confirmed hits; this effect 
was seen very strongly in TS3 (3 unique hits from 30 confirmed, versus 25/52 for 
Eve), and less so in TS6 (16/30 versus 21/35). 
Benefits and limitations of Cambridge’s filters 
The new method does not necessarily remove compounds active versus the Hs 
strain.  Empirical evidence suggests that potential hit compounds that are even only 
moderately active against Hs at 10 M have restricted discrimination through the 
concentration range used in the confirmation screen.  This is also evident in the P-R 
curves, where many of the compounds predicted to be most active were found to be 
toxic in confirmation screens. 
By only using end-of-test growth, the new method is also limited in its ability to 
identify autofluorescent compounds, and misses variations in growth and toxicity that 
the lagtime and doubling time can suggest. 
The idea of using multiple screens to identify generally toxic and problematic 
compounds is good, and has yet to be tried on a full scale in Eve‟s code; earlier work 
identified many such compounds, but it has yet to be shown whether it is suitable to 
remove them from evaluations as they may still offer useful information for future 
Active Learning processes. 
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The curves below show the possibilities for false negatives when filtering candidate 
compounds using only the end-of-test growth.  Depending upon which target curve is 
labelled as a false negative, the compound could be categorised as either inactive or 
as possibly toxic: 
False negative Hs      Possibly toxic candidate 
False negative parasite    Unidentified active candidate 




The two sets of filters used for selecting hits for Robot Eve use slightly different 
approaches.  The method provided by Cambridge is based solely on end-of-test 
growth of the parasite yeast strain and its relative performance versus the Hs control; 
the approach initially developed for Eve uses similar factors to those of this method, 
but also uses intermediate growth data in the form of lagtime and growth rate. 
In the work described here, Eve‟s decision tree rules clearly generate a higher 
proportion of confirmed hits than the alternative approach.  Whilst the new rule set is 
simpler and has been developed using cross-screen datasets, it appears to be 
limited in its ability to eliminate toxic and autofluorescent compounds, and does not 
select some of the strongly active compounds identified by Eve‟s code.   
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3.5 In vivo experiments with parasite targets 
3.5.1 Validation of confirmed hit compounds by demonstrating their action 
against Trypanosoma brucei in culture 
36 hits against yeast strains encoding T.brucei, T.cruzi or L.major targets were 
selected for validation by the Cambridge School of Biosciences using intact T.brucei 
parasites (Bilsland et al., 2013).  18 of the tested compounds were able to kill 
T.brucei Lister 427 bloodstream form parasites at 10 µM (after 48 hours) and 5 
additional compounds were responsible for a severely reduced parasite yield (Table 
3.32).  The drugs capable of killing the parasite at 10 µM were tested in titration 
experiments to determine the minimum concentration necessary to kill T.brucei Lister 
427 parasites.  All of the 10 µM hits were confirmed and 7 of the compounds showed 
some effect at 1 µM, 4 were effective at 100 nM and 2 were effective at 10 nM.   
When using two T.brucei strains for a quantitative study (Lister 427 - a monomorphic 
laboratory isolate, and EATRO 1125 - a pleomorphic isolate with limited passage 
history [i.e. being exposed to a relatively low number of subcultures of the strain in 
order to minimise variations]), it was observed that compounds ID_4584 and 






T. brucei target ID 
Lister 427 (growth score) 
Lister 427 
(% growth after 24/48 h), @ nM 
Eatro 1125 
(% growth after 24/48 h), @ 
nM 
µM nM 
1000 100 10 1000 100 10 
10 1 100 10 1 
DHFR, NMT 3259 L nt nt nt nt nt nt nt nt nt nt 
(TcDHFR) 3951 D D S L L 0/0 34/7 80/88 22/2 50/18 73/80 
DHFR 3978 D S L L L 40/0.2 79/57 101/64 nt nt nt 
DHFR 4584 D D S S L 0/0 5/0.2 36/46 0/0 0/0 14/0.7 
DHFR 5422 D L L L L nt nt nt nt nt nt 
DHFR 5833 D L L L L nt nt nt nt nt nt 
DHFR, PGK, NMT 6210 L nt nt nt nt nt nt nt nt nt nt 
DHFR 6480 D L L L L nt nt nt nt nt nt 
DHFR 6673 L nt nt nt nt nt nt nt nt nt nt 
DHFR 6777 D L L L L nt nt nt nt nt nt 
PGK 7107 L nt nt nt nt nt nt nt nt nt nt 
PGK, DHFR 8353 L nt nt nt nt nt nt nt nt nt nt 
(LmDHFR) 9034 L nt nt nt nt nt nt nt nt nt nt 
DHFR, PGK, NMT 9504 L nt nt nt nt nt nt nt nt nt nt 
NMT 9877 S nt nt nt nt nt nt nt nt nt nt 
DHFR 11133 D L L L L nt nt nt nt nt nt 
DHFR 11250 L nt nt nt nt nt nt nt nt nt nt 
(TcDHFR) 11783 D L L L L nt nt nt nt nt nt 
DHFR, PGK, NMT 12135 D L L L L nt nt nt nt nt nt 
(TcDHFR) 12803 D D L L L 20/26 89/88 111/88 nt nt nt 




T. brucei target ID 
Lister 427 (growth score) 
Lister 427 
(% growth after 24/48 h), nM 
Eatro 1125 
(% growth after 24/48 h), nM 
µM nM 
1000 100 10 1000 100 10 
10 1 100 10 1 
(TcDHFR, TcPGK) 12830 D L L L L nt nt nt nt nt nt 
DHFR 12913 S nt nt nt nt nt nt nt nt nt nt 
DHFR, PGK 13015 D L L L L nt nt nt nt nt nt 
DHFR, PGK, NMT 13085 S nt nt nt nt nt nt nt nt nt nt 
PGK 13309 S nt nt nt nt nt nt nt nt nt nt 
PGK 13528 L nt nt nt nt nt nt nt nt nt nt 
DHFR 13692 S nt nt nt nt nt nt nt nt nt nt 
DHFR 14129 D D D S L 0/0 0/0 20/68 0/0 0/0 0/0 
NMT 14238 D D L L L nt nt nt nt nt nt 
DHFR 14244 L nt nt nt nt nt nt nt nt nt nt 
DHFR 14608 L nt nt nt nt nt nt nt nt nt nt 
DHFR 14952 D L L L L nt nt nt nt nt nt 
DHFR 16236 D D S L L 0/0 32/0 97/83 43/65 65/88 76/113 
(TcDHFR) 16718 L nt nt nt nt nt nt nt nt nt nt 
DHFR 16724 L nt nt nt nt nt nt nt nt nt nt 
NMT 17196 D L L L L nt nt nt nt nt nt 
 
D = dead;  S = sick or slow growing;  L = live;  nt = not tested. Highlighted cells: orange = strong result, yellow = intermediate result. 
 
% 𝐺𝑟𝑜𝑤𝑡𝑕 𝑎𝑓𝑡𝑒𝑟 24/48 𝑕𝑜𝑢𝑟𝑠 = 100 ×
𝑐𝑒𝑙𝑙 𝑐𝑜𝑢𝑛𝑡 𝑤𝑖𝑡𝑕 𝑑𝑟𝑢𝑔
𝑐𝑒𝑙𝑙 𝑐𝑜𝑢𝑛𝑡 𝑛𝑜 𝑑𝑟𝑢𝑔 𝑐𝑜𝑛𝑡𝑟𝑜𝑙
 
 
Table 3.32 (part 2):  Hit validation in Trypanosoma brucei 
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3.5.2 Extracted Plasmodium sp. DHFR results (Mahidol, Thailand) 
Table 3.33 summarizes the inhibition by 3 selected JHCCL compounds of purified 
triple mutant PfDHFR (N51I + C59R + S108N) compared to DHFRs from P. vivax 
and human DHFR.   
Satraplatin was found not to inhibit the DHFRs from all 3 sources at concentration 
100 µM.  However, the delivery of this compound was delayed by several weeks, 
possibly being held by customs in Bangkok; transportation and storage of this 
compound should be done under refrigerated conditions, and it is possible that its 
activity will have degraded prior to conducting the work. 
Triclosan, was found to be able to inhibit PfDHFR, PvDHFR, and humanDHFR at 
similar concentration (with IC50 of 50 µM).   
TNP-470 was found to be able to inhibit only PvDHFR at IC50 0.16 µM, but not 
PfDHFR nor human DHFR.  Further investigations are required to test TNP-470 
against resistant PvDHFR. These studies could highlight the potential importance of 











(≥ 100 µM) 
No inhibition  
(≥ 100 µM) 
No inhibition  
(≥ 100 µM) 
Triclosan 
No inhibition 
(≥ 100 µM) 
25 µM 1.0 mM 
TNP-470 
No inhibition 
(≥ 165 µM) 
0.16 µM 
No inhibition 
(≥ 165 µM) 






Development of active learning algorithms for drug 
discovery 
 
Adventures with yeast, part 4 of 7:  Homegrown garlic & rosemary focaccia 
 
600 grams  white bread flour 
10 grams  sea salt 
10 grams  dried yeast 
80 ml   olive oil (plus a little extra) 
250 ml   warm water 
Several sprigs  rosemary 
8 cloves  garlic 
 
Make a dough from the first five ingredients; press it out in e.g. a lasagne tray (8”×10”) and 
leave to rise for one hour in a warm place.  Stud the dough deeply with garlic and rosemary.  
Drizzle with olive oil and broadcast a few flakes of sea salt.  Bake in a preheated oven at 
200°C for 30 minutes. 
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Several variations of Active Learning strategies were developed; these were all 
based on SMILES code fingerprints to describe the chemical compound structure.  
The seed activity inputs for the prototype active k-optimisation method were the 
numerical growth differences, with activity classifications being used for all other 
strategies.  The limited amount of cherry-pick/confirmation data meant that 
implementation of these strategies in simulations required that a suitable proxy be 
found for the multiple concentration measurements that would be made during 
confirmation HTE; log-weighted replicates of mass screen results were found to be 
suitable for this work.  
Several options for unsupervised clustering were examined; these ideas led to a 
study to find the likelihood of locating an active compound given the active seed 
input data.  Existing mass screen data was used to explore the thresholds at which 
the Tanimoto Similarity could give an indication of activity likelihood above the 
background signals, prior to running multiple simulations as described in Chapter 5. 
The strengths and weaknesses of clustering and transfer learning were also 
explored, and strategies were also developed based on their combination. 
Definitions were built to describe rare category compounds based on simple learning 
mechanisms.  Measurement of deficiency was adopted to describe the performance 




4.1 Cherry-picking using active k-optimisation 
4.1.1 Method 
The prototype Active Learning (AL) method for Robot Eve was provided by Kurt De 
Grave, based on his active k-optimisation strategy (De Grave et al., 2008a).  The 
inputs for this method are OpenBabel FP2 fingerprints (using the 0/7 configuration) 
(Babel; James et al., 1995) for compound SMILES codes (Weininger, 1988; 
Weininger et al., 1989) (training set and unknowns), and simple growth differences 
between target and human strains, i.e. 
(𝑠𝑡𝑟𝑎𝑖𝑛_𝑦𝑖𝑒𝑙𝑑_𝑟𝑎𝑡𝑖𝑜𝐻𝑠 −  𝑠𝑡𝑟𝑎𝑖𝑛_𝑦𝑖𝑒𝑙𝑑_𝑟𝑎𝑡𝑖𝑜𝑡𝑎𝑟𝑔𝑒𝑡 ) 
The method is designed to identify the next best set of compounds to test from a 
given library, whilst avoiding selection of a compound very similar to any in the 
training set.  The method selects compounds using four different search criteria, in 
order to provide a diverse approach to the exploration of the chemical space, with 
selection of the next candidates based on their ability to improve the overall model: 
 Compounds close to the decision boundary (the maximium predicted strategy) 
 Compounds that are expected to be maximal at the lower confidence 
boundary (the optimistic strategy) 
 Compounds estimated to provide the most probable improvement (MPI), as 
developed in (De Grave et al., 2008a) 
 Compounds selected using the efficient global optimisation algorithm, EGO 
(the maximum predicted improvement strategy) (Jones et al., 1998).  
By cycling through these strategies, exploration of the full chemical space of the 




4.1.2 Implementing experimental Active Learning loops 
The data analysis techniques and subsequent rules detailed in Chapter 3 were 
combined with the following, to enable an autonomous process: 
 a method to identify „hit‟ compounds (from data acquired either during the AL 
cherry-pick screens, or during a confirmation screen of potentially active 
compounds highlighted during a mass screen) 
 a method to combine the multiple confirmation/intelligent screen cherry-pick 
results with the simpler mass screen data, to build the information source for the 
AL feedback loop. 
 
Figure 4.1:  Hit compound identification process for Eve 
To implement the AL process for Eve, the method is primed by mass screening a 
section of the library as the training set; the robot runs in this mode until at least 
𝑥 parasite-active compounds have been identified, and the training set will now 
contain all the compounds on these analysed plates, whether active or otherwise.  
The AL algorithm is then run iteratively to select 𝑛 individual compounds to build a 
batch for the next round of testing.  Each group of selections is then tested by Eve in 
confirmation mode, and the compounds are classified by activity.  The SMILES 
codes and growth data are then fed back into the training set, and a fresh selection 
is made from the remaining unknown compounds.   In practice, 𝑥 = 25 was chosen 
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as the switching point in simulation work; other values of 𝑥 {50, 75, 100} were also 
examined using the TS6 PvDHFR/HsDHFR data sets (14099 compounds, 
303 PvDHFR total hits).   
At the time of the physical experimental AL runs (March/April 2011), Eve was 
capable of running 14 plates in a single batch, and each plate could hold 8 
compounds (8 replicates at 5 concentrations, plus positive and negative controls).  A 
choice was made to limit the batch size 𝑛 to 96 compounds spread over 12 plates. 
Eve ran two rounds of selections based on this approach.  The first round of 96 
compounds (CS_77_3_6_20110325115514.csv) was selected after a partial mass 
screen (4800 compounds, 69 hits).   
For the second round, it was also originally planned to test 96 compounds, but this 
became extended to 188 compounds (102 in CS_77_4_7_20110404123211.csv, 
86 compounds in CS_77_5_9_20110411115111.csv) to examine different methods 
of weighting the data from the first cherry-pick loop.  If the full data set from the 
cherry-picking loop were used, it was envisaged that this could create two problems: 
significant bias towards later selections, and a much larger data matrix with 
accompanying computational difficulties.  To examine different approaches to the 
problem of combining cherry-pick and mass screen data, seven versions of weighted 
cherry-pick data (𝑠𝑡𝑟𝑎𝑖𝑛_𝑦𝑖𝑒𝑙𝑑_𝑟𝑎𝑡𝑖𝑜𝐻𝑠 −  𝑠𝑡𝑟𝑎𝑖𝑛_𝑦𝑖𝑒𝑙𝑑_𝑟𝑎𝑡𝑖𝑜𝑡𝑎𝑟𝑔𝑒𝑡 )  were tested in the 
second loop: 
i. all replicates for each compound 
ii. all replicates multiplied by 10/𝑐𝑜𝑛𝑐 




iv. mean of replicates at each concentration for each compound 
v. mean of replicates multiplied by 10/𝑐𝑜𝑛𝑐 




vii. no additional data (i.e. the next best 96 compounds under loop1 conditions) 
The curves for the cherry-pick data were categorised visually, and evaluated against 




Loop Weighting options, loop 2 
1 2 i ii iii iv v vi vii 
Compounds 96 188 96 96 96 96 96 96 96 
Clean hit 3 9 7 6 8 6 7 9 1 
Hit/toxic - 3 3 3 3 3 3 3 2 
Weak activity 3 16 8 8 10 8 8 7 6 
Weak/toxic 1 - - - - - - - - 
Possibly toxic - 8 2 6 3 2 6 2 3 
No activity 87 160 76 73 72 77 72 75 84 
Table 4.1: Compound activity selected by different cherry-pick weightings 
Each weighting method, (i) to (vi), worked well, and far better than simply taking 
compounds 97-192 from the conditions under loop 1, method (vii).  It is suggested 
that option (vi) would provide an optimised method for combining the cherry-pick 
data with the mass screen data: the mean result for each concentration is used 
{5 data points c.f. 40 for options (i) to (iii)} and the behaviour across the 
concentration range is moderated by the application of a logarithmic weighting. 
4.1.3 Active Learning simulations 
Ideally this and other algorithms would have been tested physically across the full 
Maybridge Hitfinder library.  However, budget and time constraints required that 
testing could only be conducted in simulation form. 
To follow a similar route to the AL experiments above, the available inputs were: 
(i) End-of-test growth data for a group of seed compounds, unclassified. 
(ii) A group of “unknown” compounds. 
(iii) The SMILES codes for each group. 
(iv) Mass screen results and decision tree classifications for the “unknown” 
group, as a proxy for confirmation results (it was shown in Section 3.4 that 
the mass screen classification was a good indicator of ground truth for 
confirmation screen performance). 
The seed/loop1/loop2 results from weighting option (vi) were used to predict a third 
set of 96 compounds, which in turn were evaluated for activity by their mass screen 
performance.  Compound activity for all three loops was compared with other 
compound loop sets generated with different applications of proxy data.  Through 
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systematic trial it was discovered empirically that a five-fold application of   
(𝑠𝑡𝑟𝑎𝑖𝑛_𝑦𝑖𝑒𝑙𝑑_𝑟𝑎𝑡𝑖𝑜𝐻𝑠 −  𝑠𝑡𝑟𝑎𝑖𝑛_𝑦𝑖𝑒𝑙𝑑_𝑟𝑎𝑡𝑖𝑜𝑡𝑎𝑟𝑔𝑒𝑡 )  from the mass screen data set 
could be used to suitably represent the mean log weighted cherry-pick data from the 
AL loops.  This allowed simulations to be run using Eve‟s mass screen data, which in 
turn would allow examination of the overall performance of the active k-optimisation 
method.   
Loop Hits Weak activity 
Experiment Both Simulation Experiment Both Simulation 
1 5 5 5 3 3 5 
2 11 10 11 4 4 4 
3 4 2 8 0 0 3 
Table 4.2: Active compounds in each 96 compound AL loop 
Comparison of these in silico loops with the original experimental loops showed 
strong similarity in compound selection.  This weighting process has subsequently 




4.2 Greedy searching as a base case 
Whilst the active k-optimisation algorithm was designed to use raw data from the 
partial mass screen, it was also considered possible that selection strategies could 
be built based on classification data from the same seed compounds.  The quantity 
of input data would be much lower for such strategies due to relatively low numbers 
of active compounds; this should also allow less complex (and faster) predictions to 
be computed. 
The SimplyGreedy algorithm (Figure 4.2) 
SimplyGreedy is designed to simulate finding and testing of the next best 
𝑛 compounds, based on their similarity to existing hits.  Candidates are selected 
from the remaining unknowns, based solely on their proximity to compounds already 
flagged as active.  There are several limitations using this approach, as no 
consideration is given to either the magnitude of activity, or to the opportunity cost of 
finding additional compounds around clusters of known activity. 
SimplyGreedy has been constructed to give basic predictions of the next best 
compounds to run, for comparison with a linear, sequential evaluation of the 
compounds in the library.  The inputs are: 
(i) A group of seed compounds (classified into hit, probably toxic, toxic, 
autofluorescent, inactive as per previous decision tree rules). 
(ii) A group of “unknown” compounds. 
(iii) The SMILES codes for each group. 
(iv) Mass screen results and decision tree classifications for the “unknown” 
group, as a proxy for confirmation results. 
From the seed group of compounds, only those defined as hits and probably toxic 
are used, and the rest of the structures are ignored.  [Note: later, more complex 
algorithms also incorporated toxic as, if Hs/parasite growth ratio is high, these might 
yet point to similar structures that are less active versus Hs.] 
The SMILES codes for each active seed compound are used to calculate their 
Tanimoto Similarity (TS) versus the full list of unknown compounds.  The resultant 
matrix (i.e. 𝑛 active seeds versus the unknown compounds) is sorted so that only the 
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top TS is retained for each unknown; those compounds with the highest TS are 
selected from this matrix.  [Note: unlike the active k-optimisation strategy, this 
selection process doesn‟t take the magnitude of activity (𝑔𝑟𝑜𝑤𝑡𝑕𝐻𝑠 −  𝑔𝑟𝑜𝑤𝑡𝑕𝑝𝑎𝑟𝑎𝑠𝑖𝑡𝑒 ) 
into consideration; it is effectively a kNN selection process where k = 1 throughout.] 
These new selections are classified using the proxy data, and any hit compounds 
identified in this loop are compared to the remaining unknowns.  The resultant TSs 
are added to the truncated set from the previous loop, and again the compounds 
with highest TS are selected after the sorting process. 
Loops are run until all unknown compounds have been selected. 
Process: 
(i) get list of seed hit compounds, 
(ii) get list of compounds already tested, 
(iii) get full list of hit compounds (from the full mass screen data used to supply 
the proxy simulation data),  
(iv) get list of untested compounds, 
(v) build remaining unknown SMILES codes by removing (i) & (ii) from (iv), 
(vi) use each "hit" from (i) in turn against the remaining unknowns to 
select/remove the ones with the top 96 Tanimoto coefficients -- build a list 
of the selections, 
(vii) when the list is complete, e.g. 70 seed hits × 96 selections, sort all by TS 
and pick the top 96 discrete compounds, 
(viii) identify if any from (vii) are in (iii); if so then add to input used at (i) and run 
loop again from (v). If not then take next 96 from (vii) and so on until the 








function SIMPLYGREEDY returns list of compound sets to test next and the list 
of identified hit compound sets for each run of the test 
 
   inputs:   k, the number of compounds per simulation loop 
                  hit, a list of seed hit compounds 
                  unknown, a list of untested compounds 
                  fpt, a list of fingerprints (e.g. SMILES FPT2)  
                      for all library compounds 
                  sim, similarity measure (e.g. Tanimoto similarity) between two  
                      compounds based on corresponding fingerprints given in fpt.  
 
   list_next = Ø; list_found_hit = Ø 
   while unknown != Ø do: 
       next = set of k compounds in unknown with the highest sim with a 
compound in hit 
       add next to list_next 
       test compounds in next, store the hit compounds as found_hit  
       hit = hit + found_hit 
       unknown = unknown – next 
       add found_hit  to list_found_hit 
   return list_next, list_found_hit 
Figure 4.2: The SimplyGreedy algorithm 
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4.3 Alternative Active Learning strategies 
4.3.1 Clustering algorithms 
It is possible to build clusters of compounds using the SMILES codes and Tanimoto 
Similarity (TS) coefficients in many ways.  The following examples are illustrated in 
Figure 4.3, and their merits are summarised in Table 4.3. 
Example 1 
Build clusters containing compounds with 𝑇𝑆 > 𝑥 by starting with a single 
compound 𝑎, and adding to it all compounds with 𝑇𝑆 > 𝑥 to build a cluster 𝑐𝑎 .  The 
next cluster 𝑐𝑏   could be built using the compound least similar to  𝑎 , and the 
process repeated until all compounds are accounted for.   
Each cluster of 𝑛 compounds could be sampled representatively (e.g. by initially 
examining  𝑛
3
); if any active compounds are found then the priority of this cluster 
stays high, else the priority is reduced.  Compounds from the higher priority clusters 
are selected for the next round of testing, and these results are used to reprioritise 
the clusters (thereby allowing some of the lower priority clusters to be circulated back 
into the list for testing). 
𝑥 would need to be chosen to ensure there is a minimum size for 𝑛, else there might 
be a large number of orphan/small clusters. 
Process: 
(i) Pick a start compound 𝑎 and choose next 𝑛𝑎   compounds with 𝑇𝑆 > 𝑥 to 
make cluster 𝑐𝑎   
(ii) Make next cluster starting with 𝑏 (least similar to 𝑎); repeat for remaining 
compounds 
(iii) Test & classify ∛𝑛 compounds for each cluster 
(iv) Identify priority of clusters for further analyses 
(v) Goto (iii) 
The initial stage (building the clusters) would be an unsupervised learning process, 




If a value for 𝑥 is known which gives a minimum likely threshold for finding a similar 
hit (as an output of the work using the SimplyGreedy algorithm) then clusters could 
be built that might be richer in activity, using the known hits as the seed.  The 
non-clustered compounds are then arranged as per Example 1, and sampling of 
each cluster is conducted.  The partial mass screen data would be used to bootstrap 
the AL loops. 
Process: 
(i) Get hits from the partial mass screen data. 
(ii) Make clusters based on  𝑥𝑡𝑕𝑟𝑒𝑠𝑕𝑜𝑙𝑑 and each seed hit. 
(iii) Make additional clusters as per Example 1. 
(iv) Populate clusters with activity data from partial mass screen. 
(v) Explore unknowns as in Example 1. 
 
Example 3 
Force the clusters to contain 𝑛 compounds.  Run the experiment as in Example 1. 
If the initial run is of 1200 out of 14400 compounds, then: 
   𝑁.𝑛 = 14400  and  𝑁 𝑛
3 = 1200   ∴ 𝑛 ≈ 42    
(Douglas Adams would have been so proud/annoyed/non-plussed*) *delete as appropriate 
and 𝑁 = 343 𝑐𝑙𝑢𝑠𝑡𝑒𝑟𝑠 (i.e. not dissimilar to the 303 PvDHFR hits). 
 
Example 4 
Force the clusters to each contain 𝑛 compounds, and apply the seed data from a 




Example 1:   
Clusters of various sizes, with 𝑇𝑆 > 𝑥 
Seeded by representative sampling 
Continue by priority resampling those 
with likely activity (Bayesian approach) 
 
Example 2: 
Cluster size limited by 𝑇𝑆 >  𝑥𝑡𝑕𝑟𝑒𝑠𝑕𝑜𝑙𝑑   
Seeded by partial mass screen 




Clusters of fixed size 
Seeded by representative sampling 
Continue by priority resampling those 
with likely activity (Bayesian approach) 
 
Example 4: 
Clusters of fixed size 
Seeded by partial mass screen 
Priority given to relatively unexplored and 
active clusters. 




Example Perceived merits Perceived demerits 
1 Early coverage of all clusters. TS would need to be low   
defocused clusters. 
Possibly too greedy. 
2 Clusters based on activity 
threshold  focused. 
Many orphan clusters. 
3 Early coverage of all clusters. Variable TS. 
4  Variable TS. 
Table 4.3:  Merits of example clustering methods 
There might also be scope for switching between clustering strategies as a 
simulation progresses, and as more information becomes available.  There are also 
likely to be benefits to be had by reclustering mid-simulation, e.g. when a proportion 
of the full unknowns has been evaluated, or when the number of unknowns in a 
proportion of clusters drops below a threshold.  To fully evaluate potential options is 
beyond the scope of this project, but it should be possible to conduct useful thought 




4.3.2 Transfer Learning 
Cross-screen transfer 
If a compound has been identified as active versus one parasite/protein combination, 
there is a higher prior probability that it might be a hit versus a similar target, e.g. 
PfDHFR hits applied to PvDHFR targets (O’Neil et al., 2003).  Alternatively, its 
presence as a seed might suggest variants in the library that might be better suited 
to the new target.  This prior knowledge can be applied by initially running a batch of 
previously successful compounds, and then use their freshly tested activity levels to 
seed the rest of the AL process.   
Similarly, compounds that have previously been labelled as autofluorescent or 
confirmed as cytotoxic could be relegated in the AL process, or even omitted. 
This approach is applicable to any of the AL algorithms that are otherwise seeded 
using a partial mass screen.  In practise, the numerical data set used by the active 
k-optimisation would have required complex manipulation for each individual 
simulation, and would therefore have been difficult to pursue, notwithstanding failed 
attempts to re-run the original octave-based simulation code on the IBERS HPC.  
Algorithms based on classified compounds could be more readily tuned to adopt this 
transfer learning approach. 
If simulations indicate that this strategy is advantageous, it would be a fairly simple 
process to physically build and maintain a seed library based on all previously active 
compounds.  It might also be possible to tailor the seed to the parasite-protein 
combination based on measurements of previous AL successes. 
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Internal transfer/multi-objective learning 
After some initial proving studies using two strains, the experiments run by Eve all 
contained three strains.  However, the base and prototype AL strategies only use 
comparisons between the human strain and the target parasite: 
SimplyGreedy:   parasite-active, ¬Hs-active 
active k-optimisation: (𝑔𝑟𝑜𝑤𝑡𝑕𝐻𝑠 −  𝑔𝑟𝑜𝑤𝑡𝑕𝑝𝑎𝑟𝑎𝑠𝑖𝑡𝑒 ) 
Therefore, there remains scope to incorporate information from the third strain as 
there might be compounds active versus this strain that could be lead compounds for 
the target strain.  Similarly, it is conceivable that Hs-active compounds might also be 
considered as lead compounds for a protein target.   
Internal transfer 1:  parasite-active, 2nd-parasite-active, ¬Hs-active 
 Internal transfer 2:  parasite-active, 2nd-parasite-active, Hs-active 
This technique is not readily accommodated in the active k-optimisation strategy, but 
could be applied to a version based on SimplyGreedy. 
It was duly suggested that compounds classified as active versus any of the three 
strains during the course of a simulation could be used to provide multi-objective 
learning; it would be expected that this would be more advantageous for structurally 
similar targets (e.g. PfDHFR & PvDHFR), but the effects for less closely related 
targets were less obvious. 
Trans-protein versus trans-species 
When attempting cross-screen transfer learning, it is uncertain whether there would 
be any benefit from using trans-protein (same sp.) seeds e.g. PvNMT & PvPGK to 
predict PvDHFR.  It is assumed that trans-species learning would be more beneficial 
e.g. PfDHFR & TcDHFR to predict PvDHFR, especially if they were located close 
together in the phylogenetic tree.  The relative performance of each approach could 
be investigated by multiple simulation iterations using different seed groups. 
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4.3.3 Rare category detection 
One of the more thorny problems for AL is the identification of rare events (He and 
Carbonell, 2007).  In the case of finding active drug-like chemicals, it is arguably 
more valuable to identify rare classes of compounds than those that are similar to 
known or common scaffolds (Fischbach and Walsh, 2009; Butler & Buss, 2006).  
The use of a greedy, Bayesian algorithm will lead to the more unusual compounds 
remaining unidentified until late stages of the experiment (Figure 4.4); if an algorithm 
could be adjusted to allow their earlier detection, it might be feasible to curtail the 
experiment if sufficient coverage of the library was deemed to have occurred. 
 
 
Figure 4.4: Learning curves and rare events 
 
Hierarchical Trees 
The clustering algorithms described in 4.3.1 allow variations in: Tanimoto Similarity 
(TS) for the cluster, number of compounds in the cluster, and various cluster 
dispersions based on varying TS; these variants can be used to produce different 
hierarchical trees (Dasgupta and Hsu, 2008) which might assist with rare category 





Region of interesting hits?  i.e. Least 
similar to any seen previously [esp. if 
goood (Hs - parasite growth)] 
123 
 
Transfer & promotion of prior rare active compounds 
Where active compounds from previous experiments have been found to be from 
small clusters/low populations/rare events, it would be possible to use these 
compounds preferentially at the start of the next process.  It is likely that any hits 
from well populated active clusters will be found fairly quickly, so this approach might 
increase the chances of identifying otherwise rare compounds. 
Inactive seed compounds as indicators 
Any group of seed compounds, whether from an unselective approach such as a 
partial mass screen, or from a carefully chosen transfer learning set, will invariably 
contain a large proportion that are inactive against the targets in this new 
experiment.  In the same way that active compounds indicate the potential of similar 
molecules, so these inactive compounds can be used as priors to indicate potential 
inactivity for otherwise unknown molecules.  Although the changes to prior 
probabilities are small, similarity to a large number of known inactives might be a 
good indicator of likely inactivity in the unknown compound. 
Imparting this knowledge in a clustering algorithm will allow separation of unknown 
compounds into three phases: 
(i) Those with proximity to active compounds. 
(ii) Those with proximity to inactive compounds only. 
(iii) Those in their own chemical space. 
This approach would give two new ways of ordering the compounds for test.  The 
compounds in section (iii) are likely to contain a higher proportion of rare category 
compounds, and it would therefore be of benefit to examine these at an early stage.  
Also, the compounds identified as being similar to inactive compounds could be 




4.4 Activity prediction by chemical structure analysis 
4.4.1 Background 
There seems little information in the literature concerning a threshold where the 
TS/activity relationship tails off.  When the TS threshold question is discussed in 
(Keiser et al., 2007), it is concluded that there are no hard and fast rules, and the 
authors choose a threshold of 0.57 based on ligand group data in their work, and 
also suggest that TS in the range 0.2 - 0.3 shows insubstantial similarity between 
compounds (note: my work in this section suggests that this relationship tails off a 
slightly lower limit, closer to 𝑇𝑆 ≅ 0.45). 
4.4.2 Activity likelihood prediction 
There was a need to understand the likelihood that an active seed compound could 
predict another active compound, within defined similarity limits.   
The dataset for TS6 was used for this exercise, with initial questions concerning the 
likelihoods that: 
 Hit begats hit. 
 Toxic begats toxic. 
 Hs/cherry begats Hs/cherry. 
 Inactive begats inactive. 
The background level for the TS6 PvDHFR_sapphire data set was 306 active 
compounds in a library of 14099, i.e. 2.17% were deemed active. 
Three limits [𝑇𝑆 > (0.40,0.50,0.60)]were used to build clusters as suggested in 
section 4.3.1, Example 1.  The compounds identified as active in the mass screen 
were overlaid, and their distribution with respect to cluster size determined.  
The size and richness of the clusters were defined as follows: 
 Singleton: a single active compound; no other compounds within the TS limit. 
 Sparse doubleton: a cluster made up of a pair of compounds within the TS 
limit, with one active and the other inactive. 
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 Sparse large: one active compound amongst many inactive compounds within 
the TS limit. 
















sapphire 306 28 44 116 118 
cherry 72 1 10 46 15 
venus 138 8 14 78 38 
venus 
(188) 
venus 188 14 29 91 54 
sapphire 88 7 17 35 29 
cherry 79 4 10 46 19 
cherry 
(119) 
cherry 119 13 13 57 36 
sapphire 34 1 3 20 10 
venus 80 5 11 40 24 
toxic (94) toxic 94 9 14 32 39 
fluoro (56) fluoro 56 8 - 39 9 
Table 4.4: Activity/cluster relationships at 𝑻𝑺 > 0.50 
These data show that an active compound is more likely to predict another active 
against the same target rather than a different target, e.g. 
𝑝 𝑠𝑎𝑝𝑝𝑕𝑖𝑟𝑒_𝑎𝑐𝑡𝑖𝑣𝑒, 𝑟𝑖𝑐𝑕_𝑠𝑎𝑝𝑝𝑕𝑖𝑟𝑒_𝑐𝑙𝑢𝑠𝑡𝑒𝑟 ≅  
118
306
 = 0.386 
and that there are quite high proportions of active compounds that occupy a unique 
(or very sparse) chemical space: 




The proportion of compounds that occur as a single active in a large cluster (𝑛 > 2) 
make up the remainder:  




The data also show that an active seed compound from any target is better than a 
random seed (𝑝 = 0.0217), e.g. 
𝑝 𝑠𝑎𝑝𝑝𝑕𝑖𝑟𝑒_𝑎𝑐𝑡𝑖𝑣𝑒, 𝑟𝑖𝑐𝑕_𝑐𝑕𝑒𝑟𝑟𝑦_𝑐𝑙𝑢𝑠𝑡𝑒𝑟 ≅  
15
72
 = 0.208 
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𝑝 𝑠𝑎𝑝𝑝𝑕𝑖𝑟𝑒_𝑎𝑐𝑡𝑖𝑣𝑒, 𝑟𝑖𝑐𝑕_𝑠𝑎𝑝𝑝𝑕𝑖𝑟𝑒_𝑐𝑙𝑢𝑠𝑡𝑒𝑟 ≅  
118
306
 = 0.386 
𝑝 𝑠𝑎𝑝𝑝𝑕𝑖𝑟𝑒_𝑎𝑐𝑡𝑖𝑣𝑒, 𝑟𝑖𝑐𝑕_𝑐𝑕𝑒𝑟𝑟𝑦_𝑐𝑙𝑢𝑠𝑡𝑒𝑟 ≅  
15
72
 = 0.208 
𝑝 𝑠𝑎𝑝𝑝𝑕𝑖𝑟𝑒_𝑎𝑐𝑡𝑖𝑣𝑒, 𝑟𝑖𝑐𝑕_𝑣𝑒𝑛𝑢𝑠_𝑐𝑙𝑢𝑠𝑡𝑒𝑟 ≅  
38
138
 = 0.275 
 
 
𝑝 𝑣𝑒𝑛𝑢𝑠_𝑎𝑐𝑡𝑖𝑣𝑒, 𝑟𝑖𝑐𝑕_𝑣𝑒𝑛𝑢𝑠_𝑐𝑙𝑢𝑠𝑡𝑒𝑟 ≅  
54
188
 = 0.287 
𝑝 𝑣𝑒𝑛𝑢𝑠_𝑎𝑐𝑡𝑖𝑣𝑒, 𝑟𝑖𝑐𝑕_𝑠𝑎𝑝𝑝𝑕𝑖𝑟𝑒_𝑐𝑙𝑢𝑠𝑡𝑒𝑟 ≅  
29
88
 = 0.329 
𝑝 𝑣𝑒𝑛𝑢𝑠_𝑎𝑐𝑡𝑖𝑣𝑒, 𝑟𝑖𝑐𝑕_𝑐𝑕𝑒𝑟𝑟𝑦_𝑐𝑙𝑢𝑠𝑡𝑒𝑟 ≅  
19
79
 = 0.231 
 
 
𝑝 𝑐𝑕𝑒𝑟𝑟𝑦_𝑎𝑐𝑡𝑖𝑣𝑒, 𝑟𝑖𝑐𝑕_𝑐𝑕𝑒𝑟𝑟𝑦_𝑐𝑙𝑢𝑠𝑡𝑒𝑟 ≅  
36
119
 = 0.303 
𝑝 𝑐𝑕𝑒𝑟𝑟𝑦_𝑎𝑐𝑡𝑖𝑣𝑒, 𝑟𝑖𝑐𝑕_𝑠𝑎𝑝𝑝𝑕𝑖𝑟𝑒_𝑐𝑙𝑢𝑠𝑡𝑒𝑟 ≅  
10
34
 = 0.294 
𝑝 𝑐𝑕𝑒𝑟𝑟𝑦_𝑎𝑐𝑡𝑖𝑣𝑒, 𝑟𝑖𝑐𝑕_𝑣𝑒𝑛𝑢𝑠_𝑐𝑙𝑢𝑠𝑡𝑒𝑟 ≅  
24
80
 = 0.300 
 
 
𝑝 𝑡𝑜𝑥𝑖𝑐, 𝑟𝑖𝑐𝑕_𝑡𝑜𝑥𝑖𝑐_𝑐𝑙𝑢𝑠𝑡𝑒𝑟 ≅  
39
94
 = 0.425 
 
Figure 4.5: Demonstration of success rates for predicting activity in clusters 




















sapphire 306  4*  7* 93 202 
cherry 136 0 1 90 45 
venus 197 2 3 88 104 
venus 
(188) 
venus 188 2 5 73 108 
sapphire 122 2 2 52 66 
cherry 112 0 1 56 55 
cherry 
(119) 
cherry 119 3 3 46 67 
sapphire 59 0 0 31 28 
venus 89 0 1 31 57 
toxic (94) toxic 94 0 1 30 63 
fluoro (56) fluoro 56 0 0 36 20 
*Active compounds in unique/very sparse chemical space: 3.6% for PvDHFR_sap  
















sapphire 306  141*   63* 64 38 
cherry 42 14 12 13 3 
venus 106 48 21 24 13 
venus 
(188) 
venus 188 84 44 31 29 
sapphire 84 37 23 14 10 
cherry 69 29 21 14 5 
cherry 
(119) 
cherry 119 53 26 26 14 
sapphire 25 6 7 9 3 
venus 74 31 18 17 8 
toxic (94) toxic 94 36 29 21 8 
fluoro (56) fluoro 56 20 16 18 2 
*Active compounds in unique/very sparse chemical space: 66.7% for PvDHFR_sap 






𝑇𝑆 > 0.40 𝑇𝑆 > 0.50 𝑇𝑆 > 0.60 
𝑝(𝑠𝑎𝑝𝑝𝑕𝑖𝑟𝑒_𝑎𝑐𝑡𝑖𝑣𝑒, 𝑟𝑖𝑐𝑕_𝑠𝑎𝑝𝑝𝑕𝑖𝑟𝑒_𝑐𝑙𝑢𝑠𝑡𝑒𝑟) 0.660 0.386 0.124 
𝑝(𝑠𝑎𝑝𝑝𝑕𝑖𝑟𝑒_𝑎𝑐𝑡𝑖𝑣𝑒, 𝑟𝑖𝑐𝑕_𝑐𝑕𝑒𝑟𝑟𝑦_𝑐𝑙𝑢𝑠𝑡𝑒𝑟) 0.331 0.208 0.071 
𝑝(𝑠𝑎𝑝𝑝𝑕𝑖𝑟𝑒_𝑎𝑐𝑡𝑖𝑣𝑒, 𝑟𝑖𝑐𝑕_𝑣𝑒𝑛𝑢𝑠_𝑐𝑙𝑢𝑠𝑡𝑒𝑟) 0.528 0.275 0.123 
𝑝(𝑠𝑖𝑛𝑔𝑙𝑒𝑡𝑜𝑛 ˅ 𝑠𝑝𝑎𝑟𝑠𝑒 𝑑𝑜𝑢𝑏𝑙𝑒𝑡𝑜𝑛)𝑠𝑎𝑝𝑝 𝑕𝑖𝑟𝑒  0.036 0.235 0.667 
    
𝑝(𝑣𝑒𝑛𝑢𝑠_𝑎𝑐𝑡𝑖𝑣𝑒, 𝑟𝑖𝑐𝑕_𝑣𝑒𝑛𝑢𝑠_𝑐𝑙𝑢𝑠𝑡𝑒𝑟) 0.574 0.287 0.154 
𝑝(𝑣𝑒𝑛𝑢𝑠_𝑎𝑐𝑡𝑖𝑣𝑒, 𝑟𝑖𝑐𝑕_𝑠𝑎𝑝𝑝𝑕𝑖𝑟𝑒_𝑐𝑙𝑢𝑠𝑡𝑒𝑟) 0.541 0.329 0.119 
𝑝(𝑣𝑒𝑛𝑢𝑠_𝑎𝑐𝑡𝑖𝑣𝑒, 𝑟𝑖𝑐𝑕_𝑐𝑕𝑒𝑟𝑟𝑦_𝑐𝑙𝑢𝑠𝑡𝑒𝑟) 0.491 0.241 0.072 
    
𝑝(𝑐𝑕𝑒𝑟𝑟𝑦_𝑎𝑐𝑡𝑖𝑣𝑒, 𝑟𝑖𝑐𝑕_𝑐𝑕𝑒𝑟𝑟𝑦_𝑐𝑙𝑢𝑠𝑡𝑒𝑟) 0.563 0.303 0.118 
𝑝(𝑐𝑕𝑒𝑟𝑟𝑦_𝑎𝑐𝑡𝑖𝑣𝑒, 𝑟𝑖𝑐𝑕_𝑠𝑎𝑝𝑝𝑕𝑖𝑟𝑒_𝑐𝑙𝑢𝑠𝑡𝑒𝑟) 0.475 0.294 0.120 
𝑝(𝑐𝑕𝑒𝑟𝑟𝑦_𝑎𝑐𝑡𝑖𝑣𝑒, 𝑟𝑖𝑐𝑕_𝑣𝑒𝑛𝑢𝑠_𝑐𝑙𝑢𝑠𝑡𝑒𝑟) 0.640 0.300 0.108 
    
𝑝(𝑡𝑜𝑥𝑖𝑐, 𝑟𝑖𝑐𝑕_𝑡𝑜𝑥𝑖𝑐_𝑐𝑙𝑢𝑠𝑡𝑒𝑟) 0.670 0.415 0.085 
Table 4.7: Activity predictions at different TS limits 
  
𝑇𝑆 > 0.40 𝑇𝑆 > 0.50 𝑇𝑆 > 0.60 
Clusters(all) 2690 5681 9437 
𝑛 = 1 741 2604 6523 
𝑛 = 2 480 1305 1927 
𝑛 > 2 1469 1772 987 
Compounds(all) 14105 14105 14105 
𝑛 = 1 741* 2604* 6523* 
𝑛 = 2 960* 2610* 3854* 
𝑛 > 2 12404 8891 3728 
Table 4.8: Cluster sizes at different TS limits 
Overall, these data show there is no advantage in isolating singletons & doubletons 
to search for rare compounds, as the hit rate is not better than the background level:  
7+4
741+960
=   0.006 𝑓𝑜𝑟 𝑇𝑆 > 0.40:   0.014 𝑓𝑜𝑟 𝑇𝑆 > 0.50;   0.0198 𝑓𝑜𝑟 𝑇𝑆 > 0.60 
Therefore, this tactic would only be suitable for a library where the singletons and 
doubletons represented a low proportion; at such a point a case could be made to 
rapidly explore these compounds in pursuit of rare category detection. 
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4.4.3 Rich and inactive cluster analysis 
Rich, active clusters 
The active compounds that occur in the rich clusters can be used to determine the 
threshold at which TS infers likely activity.  Using the total number of compounds in 









> 0.60 38 1058 3.59 3.59 
0.50 – 0.60 +80 1494 5.35 4.62 
0.40 – 0.50 +84 4076 2.06 3.05 
≤ 0.40 +101 other(7477) 1.35 2.17 
Table 4.9: Analysis of rich clusters 
Having 𝑇𝑆 > 0.50  between compounds gives a good rate of identifying another 
active compound.  Dropping the level to 𝑇𝑆 > 0.40  allows a larger number of active 
compounds to be found, whilst having a section success rate similar to the 
background rate and maintain a good running success rate. 
Inactive clusters 
By extension, the inactive seed compounds that occur in a given cluster might be 
useful as an indicator for possible inactivity of similar candidate compounds.  For 
larger cluster sizes, an increasing number of prior inactive compounds might 
reinforce the notion that all similar compounds are inactive, allowing such a grouping 
to be relegated to a later point in the experiment. 
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4.5 Active Learning algorithms 
4.5.1 General 
For each simulation, the relevant full mass screen dataset was mined to provide 
input data for the simulations.  After the initial data analysis step, all results were 
recorded in the file “full_activity_results_output.csv”.  All active compounds were 
identified and stored in separate .csv files (e.g. “full_toxic_compounds.csv”, 
“full_sapphire_hits.csv”). 
In addition to the prototype active k-optimisation and baseline SimplyGreedy 
methods, the ideas in section 4.3 based on TS clustering were resolved into three 
further processes; these used the evidence for TS threshold-activity relationships 
recorded in section 4.4 to limit the diversity of seeded clusters. These ideas were 
aimed at promoting rare category detection, and to determine any beneficial effects 
of in-screen (endogenous) and cross-screen (exogenous) transfer learning. 
It was noted that using TS to create unseeded clusters (as an unsupervised learning 
approach) would result in potentially more diverse/dilute clusters when operating at 
similar TS thresholds to the above processes.  When active compounds are 
identified in such clusters, to guarantee that their proximity to other compounds in 
the cluster is within the threshold-activity boundary, this limit would now be  𝑇𝑆 . 
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4.5.2 Active k-optimisation 
Process: 
(i) Select a subset of a full mass screen as a proxy for a partial mass screen. 
Store this as the seed list of compounds already examined. 
(ii) Identify active seed compounds. 
(iii) Build a list of remaining unknown compound SMILES codes by removing 
the seed compounds from the full mass screen list. 
(iv) Generate OpenBabel FP2 fingerprints for seed and unknown compounds. 
(v) Build an indexed matrix for the activity of the seed compounds, based on: 
(𝑠𝑡𝑟𝑎𝑖𝑛_𝑦𝑖𝑒𝑙𝑑_𝑟𝑎𝑡𝑖𝑜𝐻𝑠 −  𝑠𝑡𝑟𝑎𝑖𝑛_𝑦𝑖𝑒𝑙𝑑_𝑟𝑎𝑡𝑖𝑜𝑡𝑎𝑟𝑔𝑒𝑡 ). 
(vi) Select next best compounds for examination based on strategy. 
(vii) Evaluate; add results to seed compounds and loop back to (ii). 
 
 
4.5.3 SimplyGreedy (see Figure 4.2) 
Process: 
(i) Select a subset of a full mass screen as a proxy for a partial mass screen. 
Store this as the seed list of compounds already examined.  
(ii) Build a list of active seeds from this subset (e.g. “sapphire_hits.csv”). 
(iii) Build a list of remaining unknown compound SMILES codes by removing 
the seed compounds from the full mass screen list. 
(iv) Generate FP2 fingerprints for seed and unknown compounds. 
(v) Use each active seed in turn to find the compounds with the highest TS; 
select the top 96 compounds for each seed. 
(vi) When the list is complete, e.g. 70 seeds × 96 selections, sort by TS and 
select the top 96 discrete compounds. 
(vii) Identify if any of these 96 are in the original active compound list.  If so, 
add to seed list and loop back to (iv); if not, return to step (v) and select 
the next best 96 compounds. 
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Options for exploring effect of SimplyGreedy inputs 
The SimplyGreedy code allows several variations to be examined: 
(a) The number of seed hits can be varied by simulating different partial mass 
screens. 
(b) The active seed input can be changed to include compounds active versus 
other targets, or “probably toxic” and interesting “toxic” compounds, which 
in turn will create an internal transfer learning algorithm. 
(c) The SMILES/Tanimoto fingerprint type can be changed; this is set at chain 
length depth search of 7 by default. 
(d) The fingerprint type can be changed from “standard” to “extended”; this will 
then take ring structures into account. 
(e) AL curves could be built based on seed hits only; this would help to 
quantify the benefits of AL. 
Note:  The changes/variants of the fingerprint are not possible when using 
OpenBabel, which was a restriction on the coded active k-optimisation simulations.  
Therefore, no direct comparison could be made with this prototype method. 
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4.5.4 Pre-clustering to induce promotion of rare categories (Figure 4.6) 
This algorithm is designed to run in three phases: initially find all compounds that are 
chemically similar to active seed compounds, then to identify and explore all 
remaining compounds not tagged as similar to inactive compounds, and finally to 
evaluate those similar to the inactives.  As with all the algorithms (with the exception 
of active k-optimisation) the seed compounds and internal transfer learning can be 
set to include all streams of activity across the Hs & parasite strains. 
In practise, three levels of  𝑇𝑆 > 𝑥  were tested: 𝑥 = {0.40, 0.45, 0.50} 
(i) Select a subset of a full mass screen as a proxy for a partial mass screen. Store 
this as the list of compounds already examined. 
(ii) Build a list of active seeds from this subset. 
(iii) Build a list of remaining unknown compound SMILES codes by removing the 
seed compounds from the full mass screen list. 
(iv) Generate FP2 fingerprints for seed and unknown compounds. 
(v) Use each active seed in turn to find the compounds with 𝑇𝑆 > 𝑥 .  Build these 
into a candidate list. 
(vi) Select and evaluate the top 96 discrete compounds; categorise them in terms of 
activity, toxicity or inactivity. 
(vii) Add active compounds to seed list and loop back to (iv) until < 96 compounds 
are identified with 𝑇𝑆 > 𝑥.  Switch to evaluate Rare Category molecules. 
(viii) Cluster the remaining unknown compounds with respect to the inactive 
compounds at 𝑇𝑆 > 𝑥.  Split into two sets: 𝑢𝑛𝑘𝑛𝑜𝑤𝑛𝑖𝑛𝑎𝑐𝑡𝑖𝑣𝑒  and   
𝑢𝑛𝑘𝑛𝑜𝑤𝑛𝑢𝑛𝑘𝑛𝑜𝑤𝑛 .  Rank the 𝑢𝑛𝑘𝑛𝑜𝑤𝑛𝑖𝑛𝑎𝑐𝑡𝑖𝑣𝑒  set in terms of the number of 
inactive compounds to which they have similarity. 
(ix) Evaluate the 𝑢𝑛𝑘𝑛𝑜𝑤𝑛𝑢𝑛𝑘𝑛𝑜𝑤𝑛   compounds using the SimplyGreedy algorithm. 
(x) Evaluate the 𝑢𝑛𝑘𝑛𝑜𝑤𝑛𝑖𝑛𝑎𝑐𝑡𝑖𝑣𝑒   compounds in ranked order (fewest similar 







function PRECLUSTERING returns lists of compound set to test next over three 
phases, and the list of hit compound sets identified in each test loop. 
 
   inputs:    k, the number of compounds per test loop 
                   hit, a list of seed hit compounds 
                   not_hit, a list of compounds tested as non-hit 
                   unknown, a list of untested compounds 
                   fpt, a list of fingerprints for all library compounds 
                   sim, similarity measure between two compounds using fpt 
                   threshold, similarity threshold 
 
   list_next = Ø; list_found_hit = Ø; inPhase1 =True; 
   while unknown != Ø do:  
      if inPhase1                                                                           # PHASE 1 
           pool = set of compounds from unknown whose values of sim with a  
                      compound in hit > threshold 
           if length(pool) >= k  
                next = set of k compounds from pool with the highest sim values with a 
                           compound in hit  
                 test compounds in next, store the hit compounds as found_hit and  
                        non-active compounds as found_nothit  
                 update hit, not_hit, unknown, list_next, list_found_hit accordingly 
           else     
                store all compounds to set unknown3 if their values of sim with a  
                   compound in not_hit > threshold; otherwise store them to set unknown2 
                inPhase1 = False # phase switch  
 
      if (not inPhase1  and unknown_phase2 != Ø)                      # Phase 2 
            call function SIMPLYGREEDY(input: unknown=unknown2)  
            update list_next and list_found_hit, non_hit accordingly  
 
      if (not inPhase1  and unknown3 != Ø)                                  # Phase 3 
                    for each compound in unknown3, calculate sim value with every compound  
                in non_hit; store the number of sim values > threshold to nothit_counts 
            next = k compounds in unknown3 with the lowest nothit_counts 
            test compounds in next, store the hit compounds as found_hit and  
                 non-active compounds as found_nothit  
            update hit, not_hit, unknown, list_next, list_found_hit accordingly 
    
   return list_next, list_found_hit               




4.5.5 Transfer Learning from other parasites (Figure 4.7) 
Rather than running a partial mass screen to provide active seeds, this algorithm 
selects a tranche from previously completed screens to use as the seed.   
(i) Identify previously evaluated parasite/strain combinations to be used as a 
transfer learning seed.   
(ii) Build a seed subset based on the full list of target-active compounds. 
(iii) Evaluate this seed subset as a proxy for a partial mass screen.  Store this as 
the list of compounds already examined. 
(iv) Continue from step (ii) of SimplyGreedy. 
function TRANSFERLEARNING returns lists of compound sets to test next, and the list 
of hit compounds identified for each test. 
 
  inputs:   transfer, a list of seed hit compounds tested with a different strain 
                 k, the number of compounds per loop 
                 hit, a list of seed hit compounds in the transfer screen 
                 unknown, a list of untested compounds, initially the full library 
                 fpt, a list of fingerprints for all library compounds 
                 sim, similarity measured between two compounds using fpt 
 
       list_next = Ø; list_found_hit = Ø 
       test each compound in transfer, store the set of hit compounds to transfer in  
               found_hit 
       hit = hit + found_hit 
       unknown = unknown - transfer 
       if unknown != Ø  
               call SIMPLYGREEDY (k, hit, unknown) and update list_next, list_found_hit 
       return list_next, list_found_hit 




4.5.6 Transfer Learning with Preclustering (Figure 4.8) 
The ideas for preclustering and transfer learning are brought together in the 
expectation that the benefits accrued by each method will be cumulative and build a 
more efficient selection process. 
(i) Identify previously evaluated parasite/strain combinations to be used as a 
transfer learning seed.   
(ii) Build a seed subset based on the full list of target-active compounds. 
(iii) Evaluate this seed subset as a proxy for a partial mass screen.  Store this as 
the list of compounds already examined. 
(iv) Continue from step (ii) of Preclustering. 
function TRANSFERLEARNING WITH PRECLUSTERING returns lists of 
compounds to test next, and the lists of hit compound sets for each test loop 
 
  inputs:    transfer, a list of seed hit compounds versus a different strain 
                  k, the number of compounds per loop 
                  hit, a list of seed hit compounds in the transfer screen 
                  not_hit, a list of compounds tested as not-hit 
                  unknown, a list of untested compounds, initially the full library 
                  fpt, a list of fingerprints for all library compounds 
                  sim, similarity measure between two compounds 
 
       list_next = Ø; list_found_hit = Ø 
       test each compound in transfer, store the set of hit compounds in  
              transfer to found_hit, and non-hit compounds to found_nothit 
       hit = hit + found_hit;  
       not_hit = not_hit + found_nothit; 
       unknown = unknown - transfer 
       if unknown != Ø  
               call PRECLUSTERING (k, hit,not_hit, unknown) and update list_next,  
                      list_found_hit 
       return list_next, list_found_hit 
 




4.6 Simulations, methods and evaluation techniques  
4.6.1 Datasets for simulations 
All simulation datasets used in the learning algorithms were derived from the original 
mass screen experiments.  The decision tree activity results were taken as absolute, 
and acted as a proxy for confirmation results.  
The learning algorithms based on a simulated partial mass screen used the raw data 
from a series of mass screen plates as the seed group; these were selected to 
provide the required minimum number of active seeds (typically 𝑛 ≥ 25).  Several 
simulations were run for each target, with a different batch of seed compounds 
selected from the mass screen in each case. 
The other learning algorithms used a seed compound list defined by previous screen 
results as a transfer learning (TL) process.  In these instances the number of active 
seeds was therefore not predetermined, and depended on the response of the new 
parasite target to compounds with high potential.  Only one simulation could be run 
for each transfer seed/target combination. 
The partial mass screen data sets used in the active k-optimisation and 
SimplyGreedy/preclustering simulations were slightly different: the RCDK SMILES 
fingerprint tool (Guha, 2007) for R didn‟t support work with chiral centres, so all such 
molecules had to be screened out at the start of the simulation process.  This did not 
affect the active k-optimisation simulations (where the SMILES strings were parsed 
by OpenBabel) but meant that 164 compounds could not be evaluated in the 
SimplyGreedy & preclustering simulations; none of these were identified as hits in 
any mass screen, so the effect on the simulation results is expected to be negligible. 
The seed data for active k-optimisation was used in the form:  
(𝑠𝑡𝑟𝑎𝑖𝑛_𝑦𝑖𝑒𝑙𝑑_𝑟𝑎𝑡𝑖𝑜𝐻𝑠 −  𝑠𝑡𝑟𝑎𝑖𝑛_𝑦𝑖𝑒𝑙𝑑_𝑟𝑎𝑡𝑖𝑜𝑡𝑎𝑟𝑔𝑒𝑡 ) 
This dataset expanded with each additional evaluated compound.   
The seed data for all other simulations was applied as a list of active compounds, 
and this set was incremented each time a new active compound was discovered.
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4.6.2 Deficiency measurement of general/rare category curves 
The effectiveness of the AL algorithm can be measured by comparing the yield curve 
with a baseline curve to give a deficiency measurement (Baram et al., 2004).  For 
the AL simulations, the baseline curve is defined by the linear rate at which active 
compounds would be found if no learning was occurring.  It is also feasible to 
compare any pair of AL curves by similar measurements. 
 
 
𝐴𝑟𝑒𝑎 𝐴 =  























Rare category detection 
It is reasonable to assume that a greedy selection mechanism based on TS will 
make it difficult to find active compounds that have low similarity to other active 
seeds.  If these orphan compounds are in sparsely populated regions of the 
chemical space then it is highly likely that they will not be detected until the late 
stages of a simple search e.g. SimplyGreedy.  If the last 5%/10% of active 
compounds found by SimplyGreedy are taken as a baseline for rare category 
detection, deficiency measurements can be made by comparing their occurrence in 
other AL simulations based on the same seed/unknown datasets.  
 
Figure 4.10:  Definition of rare category compounds in SimplyGreedy 
 
 







Simulations of Active Learning for drug discovery 
 
 
Adventures with yeast, part 5 of 7:  Aberystwyth sourdough bread* 
 
~1.5 kg mixture of white and wholegrain (e.g. rye) bread flours 
~1.5 kg water 
10 grams sea salt 
 
Day 1: Mix 100 grams of flour with 100 grams of water in a large pyrex bowl.  Take the 
mixture on an open air walk along Aberystwyth prom, then cover it with clingfilm and leave it 
in a warm place for 24 hours. 
Day2: Mix in 100 grams of flour, and sufficient water to keep the mixture sloppy.  Cover 
tightly and store at room temperature. 
Day 3 to day 7:  Each day, discard half the mixture, then mix in a further 100 grams of flour 
and water.  Cover tightly and store at room temperature. 
The starter can then be maintained, with samples extracted from it for making bread: 
Add 150 grams of starter to 250 grams of flour and 250 ml of water.  Cover and leave 
overnight.  The following day, add 300 grams of flour and 10 grams of salt, and mix into a 
stiff dough.  Knead the dough and then leave it to rise for a couple of hours (a more sedate 
process than ordinary bread making).  Knock it down, knead again, then allow to prove for 
another couple of hours in a proving basket.   
Bake at 230°C for 40 to 45 minutes. 
 
* In deference to San Francisco sourdough, that other west coast staple. 
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This chapter describes how five discrete Active Learning strategies were applied to 
the mass screen data to simulate high throughput experimentation for drug 
discovery.   
As seen in section 4.1.2, only limited cherry-picking work could be conducted due to 
resource restraints; the active k-optimisation algorithm was evaluated physically, but 
only for the very early phase of the cherry-picking screen for PvDHFR. 
The proxy confirmation screen data derived in section 4.1.3 was subsequently used 
to portray potential activity, and allowed the alternative Active Learning algorithms to 
be examined and compared in silico.  The proxy confirmation data for all targets was 
used individually in active k-optimisation, SimplyGreedy and preclustering 
simulations, and data from combinations of targets were used to examine the 
transfer learning ideas.  
The settings for the simulations were chosen to examine a wide range of the 
features of these algorithms, whilst endeavouring to keep a consistent approach.  In 
general, the seed group of compounds were maintained across those algorithms 
without a transfer learning element; full details of the set up are embedded in each of 
the algorithm analysis sections.  
Using the deficiency measurement described in section 4.6.2, this chapter examines 
the absolute and relative ability of both the prototype AL algorithm and those 
developed in Chapter 4 to select active compounds.  The SimplyGreedy approach is 
compared to the linear results expected of random screening, and the other 
algorithms are then compared to each of these as baselines.  The ability of each 
algorithm to search the chemical space and identify rare category compounds (as 
defined in their selection by SimplyGreedy) is similarly evaluated. 
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5.1 General examples of learning curves (TcDHFR simulations) 
General curve descriptions 
Normalised hit cumulative frequency curves (in red, below) display the algorithm‟s 
identification rate for active compounds compared to the expected stochastic 
discovery rate (in black); these are used for deficiency calculations.  The variant for 
the performance of preclustering algorithms (right hand graph) also include two 
vertical lines which identify where the algorithm switches between strategies. 
     
Figure 5.1: Examples of normalised hit cumulative frequency curves 
 
Normalised actives cumulative frequency curves (Figure 5.2) are an extension of the 
above; compound activity versus the chosen target (red), the second parasite target 
(green), human strain (blue), and likely general toxicity (orange) are depicted. 
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Figure 5.2: Examples of normalised actives cumulative frequency curves 
 
Deficiency curves for rare category compounds 
These display the rate at which the algorithm under test (the black curve in this 
example) identifies rare compounds.  In the example below, the rare compounds are 
defined as the last 5% of active compounds found by the SimplyGreedy stategy (red 
curve).  Again, deficiency measurements are calculated by comparing these curves. 
 




The Active Learning curves and deficiency curves were built using the full Maybridge 
Hitfinder library; all simulations are displayed in Appendix B.  The following examples 
use the data for TcDHFR as the target and PfRdhfr as the second parasite; they 
show typical curve characteristics, and the features related to the algorithm under 
test are also described: 
Active k-optimisation, active learning curves 
Red:      active vs target 
Blue:      active vs Hs 
Green:   active vs other parasite 
Orange: toxic 
  
Figure 5.4: Examples of Active k-optimisation learning curves 
  





Figure 5.6:  Rare category deficiency curves, last 5% & 10% actives: 
active k-optimisation (black) versus SimplyGreedy (red) 
In general, active k-optimisation and SimplyGreedy AL curves are fairly similar when 
using common seed compound sets.  The benefit of the former‟s strategy for 
exploration of the chemical space becomes apparent when the rare category 
compounds are identified and examined: these are typically found at a steady rate 












Preclustering, 𝑇𝑆 > 0.40 
Red:      active vs target 
Blue:      active vs Hs 
Green:   active vs other parasite 
Orange: toxic 
  
Figure 5.7: Examples of Preclustering learning curves, TS > 0.40 
 
Preclustering, 𝑇𝑆 > 0.45 
  





Preclustering, 𝑇𝑆 > 0.50 
  
Figure 5.9: Examples of Preclustering learning curves, TS > 0.50 
 
Rare category deficiency curves, last 5% & 10% 
Blue:     𝑇𝑆 > 0.40 
Purple:  𝑇𝑆 > 0.45 
Green:  𝑇𝑆 > 0.50 
Black:   active k-optimisation   
Red:     SimplyGreedy 
  
Figure 5.10:  Rare category deficiency curves, last 5% & 10% actives: 
active k-optimisation (black) versus SimplyGreedy (red) versus preclustering 




For the preclustering algorithm, the effect of different limits for 𝑇𝑆 > 𝑥 can readily be 
seen in the three phases of candidate compounds: 
 Phase 1: testing those unknowns that are similar to seed active compounds. 
 Phase 2: greedy selection from unknowns which are not similar to inactive 
compounds.  
 Phase 3: the remaining unknowns are ranked in ascending order of number of 
similar inactive compounds.   
High limits for 𝑇𝑆 result in a short initial phase, with a commensurately long second 
phase.  As the threshold for 𝑇𝑆 falls, the first two phases expand and contract 
accordingly. 
The exploration of Phase 3 could be extended to incorporate selections based on 
similarity to active seeds.  The existing method for this tail section doesn‟t seem to 
offer much performance benefit over a random selection strategy.  This suggestion 





Figure 5.11: Examples of TranferLearning learning curves 
 
Rare category deficiency curves, last 5% & 10%. TL versus SimplyGreedy (red) 
   
Figure 5.12:  Rare category deficiency curves, last 5% & 10% actives: 
TransferLearning (black) versus SimplyGreedy (red)  
 
The preceding TL cumulative frequency curves show the strong boost provided by 
the exogenous active seeds at the start of the simulation.  The right-hand curve 
shows how the selection progresses if the initial active and inactive seed results are 
stripped from the dataset.  In the endogenous learning curves, the proportion of 
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active:inactive will typically be the same as the background level for the full library, 
whereas the proportion of active seeds in transfer learning regimes could be much 
higher if there is strong similarity between targets. 
Similarly, rare category detection is given an early boost by having some compounds 
from the rare chemical space in the seed group.  The greedy selection method used 
by the TL algorithm means that the remaining proportion of rare category 
compounds are not likely to be found until the late stages of the simulation. 
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Transfer Learning with preclustering 
  
Figure 5.13: Examples of TransferLearning with preclustering learning curves 
  
Figure 5.14:  Rare category deficiency curves, last 5% & 10% actives: 
TransferLearning with preclustering (black) versus SimplyGreedy (red)  
Combining the Transfer Learning and preclustering ideas, another boost is seen for 
the detection of rare category compounds.  The early, initial seed rarities are 
augmented by those in the inactive-dissimilar compounds in Phase 2. 
This combination gives the strongest overall performance of all the algorithms tested 




5.2 Results for endogenous simulations 
Each AL algorithm was evaluated extensively using multiple parasite-protein 
datasets.  The algorithms that operated on a single assay were tested using several 
different sets of plates to provide the seed data.  The algorithms that included 
transfer learning elements (see section 5.3) were evaluated by building learning 
curves for each parasite-protein target when seeded using different sets of known 
parasite-active compounds.  
Parasite 
Protein -  
screen no. 





Preclustering, 𝑇𝑆 > 𝑥 
𝑥 = 0.40 𝑥 = 0.45 𝑥 = 0.50 
Pv 
DHFR-TS3 
3 3 3 3 3 
PfR 3 3 1 1 1 
Tb 
DHFR-TS4 
3 3 - - - 
Sm 3 3 - - - 
PfR 
DHFR-TS5 
3 3 2 2 2 
Tc 3 3 1 1 1 
Pv 
DHFR-TS6 
11 11 10 10 10 
Pf 3 3 3 3 3 
Lm 
DHFR-TS7 
3 3 - - - 
PvR 3 3 2 2 2 
Tb 
NMT-1 
3 3 1 1 1 
Pv 3 3 2 2 2 
Sm 
NMT-2 
- - - - - 
Tc 8 9 4 4 4 
Sm 
PGK-1 
2 2 - - - 
Tc 3 3 1 1 1 
Tb 
PGK-2 
2 2 - - - 
Pv 3 3 - - - 
Table 5.1: Experiments using endogenous single mass screen datasets 
 
At least three iterations of each algorithm were attempted for all parasite-protein 
combinations; more were started for PvDHFR-TS3 (11) and TcNMT (9).  Not all 
active k-optimisation and SimplyGreedy simulations ran to completion, due to the 
level of active compounds being too low to support continuation.  
All learning curves are reported in Appendix B, together with deficiency 
measurements for all experiments.  The tables in this section contain the mean of 
the deficiencies for all parasite-protein combinations, including those for the rare 
category compounds.  Experiment means marked * are based on less than three 
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curves.  Two parasite-protein combinations (PvDHFR & TcNMT) were run over a 
larger number of iterations to examine the repeatability of the simulations.  
Figures 5.15 to 5.17 compare the performance of SimplyGreedy, active 
k-optimisation and preclustering algorithms, by using boxplots built from full data sets 
(i.e. where an individual seed/unknown data set has been used in a simulation for 
each strategy).  Whilst this approach will not use all of the available experiments in 









Preclustering, 𝑇𝑆 > 𝑥 
𝑥 = 0.40 𝑥 = 0.45 𝑥 = 0.50 
Pv 
DHFR-TS3 
0.64 0.67 0.72 0.76 0.74 
PfR 0.91 0.88  0.91*  0.94*  0.88* 
Tb 
DHFR-TS4 
0.69 0.63 - - - 
Sm 0.84 0.79 - - - 
PfR 
DHFR-TS5 
1.01 0.88  0.84*  0.84*  0.87* 
Tc 0.73 0.72  0.78*  0.76*  0.77* 
Pv, mean 
DHFR-TS6 
0.62 0.67 0.78 0.79 0.77 
Pv, SD   0.012   0.016   0.042   0.025   0.039 
Pf 0.83 0.74 0.77 0.80 0.76 
Lm 
DHFR-TS7 
0.83 0.66 - - - 
PvR 0.83 0.70  0.76*  0.78*  0.77* 
Tb 
NMT-1 
0.72 0.78  0.92*  0.86*  0.84* 
Pv 0.83 0.79  0.82*  0.80*  0.77* 
Sm 
NMT-2 
- - - - - 
Tc, mean 0.80 0.80 0.91 0.87 0.83 
Tc, SD   0.018   0.015   0.023   0.018   0.041 
Sm 
PGK-1 
 0.71*  0.62* - - - 
Tc 0.93 0.86 - - - 
Tb 
PGK-2 
 0.79*  0.53* - - - 
Pv 0.95 0.82 - - - 







Protein -  
screen no. 
Completed simulation iterations 
Active k- 
opti’mstn 
Preclustering, 𝑇𝑆 > 𝑥 
𝑥 = 0.40 𝑥 = 0.45 𝑥 = 0.50 
Pv 
DHFR-TS3 
0.51 0.40 0.41 0.59 
PfR 0.40  0.52*  0.44*  0.51* 
Tb 
DHFR-TS4 
0.41 - - - 
Sm 0.37 - - - 
PfR 
DHFR-TS5 
0.55 0.40 0.44 0.58 
Tc 0.44  0.42*  0.52*  0.62* 
Pv, mean 
DHFR-TS6 
0.45 0.50 0.50 0.65 
Pv, SD     
Pf 0.42 0.37 0.42 0.54 
Lm 
DHFR-TS7 
0.62 - - - 
PvR 0.57  0.38*  0.46*  0.63* 
Tb 
NMT-1 
0.43  0.44*  0.56*  0.68* 
Pv 0.42  0.37*  0.38*  0.50* 
Sm 
NMT-2 
- - - - 
Tc, mean 0.40 0.45 0.52 0.69 
Tc, SD   0.052   0.057   0.056   0.051 
Sm** 
PGK-1 
- - - - 
Tc 0.39  0.47*  0.51*  0.69* 
Tb 
PGK-2 
- - - - 
Pv 0.71 - - - 





Completed simulation iterations 
Active k- 
opti’mstn 
Preclustering, 𝑇𝑆 > 𝑥 
𝑥 = 0.40 𝑥 = 0.45 𝑥 = 0.50 
Pv 
DHFR-TS3 
0.47 0.42 0.42 0.58 
PfR 0.48  0.49*  0.42*  0.50* 
Tb 
DHFR-TS4 
0.23 - - - 
Sm 0.47 - - - 
PfR 
DHFR-TS5 
0.50 0.45 0.44 0.57 
Tc 0.48  0.47*  0.54*  0.64* 
Pv, mean 
DHFR-TS6 
0.40 0.52 0.52 0.65 
Pv, SD   0.047   0.038   0.053   0.062 
Pf 0.44 0.44 0.46 0.57 
Lm 
DHFR-TS7 
0.54 - - - 
PvR 0.52  0.49*  0.51*  0.66* 
Tb 
NMT-1 
0.38  0.51*  0.58*  0.71* 
Pv 0.42  0.45*  0.42*  0.50* 
Sm 
NMT-2 
- - - - 
Tc, mean 0.38 0.46 0.50 0.67 
Tc, SD   0.030   0.036   0.046   0.076 
Sm 
PGK-1 
- - - - 
Tc 0.45  0.48*  0.53*  0.71* 
Tb 
PGK-2 
- - - - 
Pv 0.70 - - - 






Figure 5.15: Boxplots for collated deficiency measurements: mean and rare 
category compounds (5% & 10%).  A comparison of the SimplyGreedy, active 
k-optimisation and preclustering algorithms, using simulation data where all 
strategies were tested.  
 
























Figure 5.16: Boxplots for deficiency measurements in 10 PvDHFR TS6 
simulations: mean and rare category compounds (5% & 10%).  A comparison 
of the SimplyGreedy, active k-optimisation and preclustering algorithms, using 
simulation data where all strategies were tested. 
























Figure 5.17: Boxplots for deficiency measurements in 4 TcNMT simulations: 
mean and rare category compounds (5% & 10%).  A comparison of the 
SimplyGreedy, active k-optimisation and preclustering algorithms, using 
simulation data where all strategies were tested. 





















5.3 Results for Transfer Learning simulations 
5.3.1 Transfer Learning 
In its simplest form, the Transfer Learning simulation could only be run once for each 
set of seed compounds.  However, each target could be seeded with one of several 
sets of transfer seeds, so multiple applications and resultant cross-strain evaluations 
were possible. 
The initial work (see Tables 5.5 to 5.7) concentrated on identifying the beneficial 
effect of using lists of active compounds from previous screens; these simulations 
were built using a greedy search after taking the initial seed compounds (the TL 
training set) as a proxy partial mass screen.  For each parasite-protein combination, 
a simulation was also run using a HsDHFR dataset; it was expected that this might 
identify interference due to general toxicity against the target (possibly a significant 




DHFR seeds NMT seeds 
Hs Pf Pv(TS6) Tb Tc Pv Tb Tc 
Pv 
DHFR-TS3 
0.68 0.59 0.29 0.58 0.51 0.60 0.50 0.59 
PfR 0.35 0.65 0.71 0.88 0.66 0.74 0.74 0.75 
Tb DHFR-TS4 0.57 0.66 0.43  0.45 0.60 0.51 0.57 
Tc DHFR-TS5 0.55 0.43 0.47 0.66   0.54 0.50 
Pv 
DHFR-TS6 
0.66 0.49  0.59 0.55 0.58 0.51 0.59 
Pf 0.54  0.45  0.43 0.55 0.57 0.54 
PvR DHFR-TS7 0.63 0.52 0.42 0.65 0.50 0.57 0.52 0.56 
Tb NMT-1 0.74 0.66 0.59 0.72 0.66 0.58  0.67 
Pv NMT-1 0.74 0.62 0.63 0.77 0.65  0.53 0.50 
Tc NMT-2 0.56 0.62 0.61 0.76 0.60 0.49 0.65  
Mean deficiency, all 
targets 
0.60 0.58 0.51 0.70 0.56 0.59 0.56 0.59 
Mean of deficiencies: 0.59 
*Mean of core PfDHFR/PvDHFR seed deficiencies: 0.60  
Note *: the experiments in the nine cells highlighted in green were run in all TL 
simulations, and could therefore be used as a core comparison between the simple 
and TL+preclustering methods. Results in bold text indicate those which were 
significantly better than when compounds active versus HsDHFR were used as the 
TL seed.  








DHFR seeds NMT seeds 
Hs Pf Pv(TS6) Tb Tc Pv Tb Tc 
Pv 
DHFR-TS3 
0.98 1.06 0.67 1.07 0.76 0.99 0.68 0.91 
PfR 0.36 0.90 0.89 1.15 0.97 0.98 1.04 0.89 
Tb DHFR-TS4 0.83 1.23 1.22  0.83 1.23 0.80 0.83 
Tc DHFR-TS5 1.02 0.64 0.52 1.15   0.76 0.90 
Pv 
DHFR-TS6 
1.06 0.75  1.07 0.75 0.83 0.90 0.91 
Pf 0.88  0.36  0.61 0.74 0.74 0.62 
PvR DHFR-TS7 0.95 0.79 0.61 0.89 0.61 0.70 0.69 1.05 
Tb NMT-1 1.12 1.04 0.95 1.12 0.88 0.67  1.11 
Pv NMT-1 1.05 1.14 0.94 1.15 1.05  0.85 0.95 
Tc NMT-2 0.76 1.08 0.97 0.98 1.08 0.54 0.97  
Mean deficiency, all 
targets 
0.90 0.96 0.79 1.07 0.84 0.84 0.83 0.91 
Mean of deficiencies: 0.89 
Mean of core PfDHFR/PvDHFR seed deficiencies: 0.97 





DHFR seeds NMT seeds 
Hs Pf Pv(TS6) Tb Tc Pv Tb Tc 
Pv 
DHFR-TS3 
1.01 1.02 0.56 1.00 0.84 1.02 0.76 0.92 
PfR 0.34 0.92 0.93 1.11 0.96 1.02 1.01 0.96 
Tb DHFR-TS4 1.01 1.30 1.28  0.45 1.03 1.00 1.02 
Tc DHFR-TS5 0.83 0.58 0.67 1.15   0.80 0.76 
Pv 
DHFR-TS6 
1.06 0.90  0.89 0.90 0.84 0.87 0.87 
Pf 0.86  0.57  0.70 0.67 0.72 0.72 
PvR DHFR-TS7 0.93 0.71 0.69 0.97 0.72 0.72 0.61 0.95 
Tb NMT-1 1.12 0.92 0.84 1.01 0.88 0.80  0.96 
Pv NMT-1 1.05 1.09 1.03 1.15 0.94  0.83 0.83 
Tc NMT-2 0.73 0.90 0.78 1.03 0.73 0.57 0.93  
Mean deficiency, all 
targets 
0.89 0.93 0.82 1.04 0.79 0.83 0.84 0.89 
Mean of deficiencies: 0.88 
Mean of core PfDHFR/PvDHFR seed deficiencies: 0.92 




5.3.2 Transfer Learning with preclustering 
Layering the preclustering and TL algorithms allowed a further round of simulations 
to be conducted.  In addition, the preclustering Tanimoto Similarity threshold could 
be adjusted to observe any effects on how the unknown compounds were 
categorised versus the active and inactive seeds. 
Two rounds of experiments were conducted.  The parameters were chosen based 
on observations from the earlier preclustering work (section 5.2).  The first round 
used a similarity threshold of 𝑇𝑆 > 0.60 to identify the initial candidate list, followed 
by a threshold of 𝑇𝑆 > 0.40 for the body of the experiments.  This was designed to 
restrict the number of seed compounds, just in case this group became too large 
with a subsequent detrimental effect on inactive-dissimilar unknown compounds. 
The second round used 𝑇𝑆 > 0.40 as the threshold throughout the experiments; this 
brought the experiments closer to those reported in section 5.2.  These experiments 
were only run using PvDHFR or PfDHFR as the transfer seeds.  A summary of the 
deficiency measurements for this work is given in Table 5.8, together with the simple 
TL results and the ranges of results from earlier endogenous work. 
Row ID Description Mean, all Mean, core 
a 
Transfer Learning 
Main AL curve 0.59 0.60 
b Rare category, 5%  0.89 0.97 
c Rare category, 10% 0.88 0.92 
d TL + precluster, version 1 
(0.6 then 0.4) 
Main AL curve 0.70 0.73 
e Rare category, 5%  0.54 0.55 
f Rare category, 10% 0.52 0.53 
g 
TL + precluster, version 2  
(all 0.4) 
Main AL curve 0.65 0.69 
h Rare category, 5%  0.52 0.58 
i Rare category, 10% 0.51 0.55 
 SimplyGreedy (range for 
equivalent simulations) 
Main AL curve 0.63 - 0.88 
 
Preclustering (range) 
Main AL curve 0.72 - 0.92 
Rare category, 5%  0.37 - 0.69 




Main AL curve 0.62 - 0.91 
Rare category, 5%  0.40 - 0.57 
Rare category, 10% 0.40 - 0.52 
Table 5.8:  Mean deficiencies for TL simulations 
161 
 
The main curve deficiencies for the two TS threshold variants were not significantly 
different from each other, and were in line with the better results from endogenous 
simulations using SimplyGreedy and active k-optimisation.  Both TL+precluster 
variants were were appreciably better at rare category detection than the simple TL 
method, and were both in line with typical results from active k-optimisation (note: a 
direct comparison could not be made between endogenous and exogenous results 
as, by definition, the simulation used different seed/unknown compounds sets).   
The differences in deficiency between simple TL and TL+preclustering given in 
Table 5.9 confirm the improvement in rare category detection with the latter method, 
albeit with a slight reduction in overall selection efficiency.  
Description 
Calculation 
(from row data 





Version 1 versus  
simple TL 
Main AL curve a – d -0.11  -0.13  
Rare category, 5% b – e 0.40 0.42 
Rare category, 10% c – f 0.38 0.39 
Version 2 versus 
simple TL 
Main AL curve a – g -0.11  -0.10  
Rare category, 5% b – h 0.37 0.39 
Rare category, 10% c – i 0.34 0.37 
Table 5.9: Deficiency differences, TL simulations 
The full result tables for this work are given in Appendix B.5.  These tables are split 
into two variants, and an overall evaluation of the algorithm‟s performance versus 
simple Transfer Learning:  
 Tables B.5 (1 to 3) report results where preclustering Phase 1 was conducted 
using a threshold of  𝑇𝑆 > 0.60  with Phase 2 using a threshold of  𝑇𝑆 > 0.40.  
This was designed to build on the potentially strong seed dataset; this should 
have the effect of creating a longer initial phase than the simple preclustering 
routines in section 5.2.  It was also expected to limit the number of unknown 
compounds that were labelled as similar to inactive seeds. 
 Tables B.5 (4 to 6) were built used a preclustering routine where all phases 
used the threshold  𝑇𝑆 > 0.40.  Simulations were only run using two of the 
exogenous seed datasets; this was to examine whether the conditions applied 
to the immediately preceding experiments were too conservative. 
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 Combining the TL and preclustering mechanisms was expected to deliver 
better overall performance for AL than the baseline SimplyGreedy selections.  
It was also expected to boost identification of rare category compounds at an 
earlier stage in the process.  The difference in deficiencies for the main 
TL/preclustering learning curves compared to using TL only are shown in 




 5.4 Relative speed and complexity of algorithms 
The time taken for the selection process for each loop of active k-optimisation was 
dominated by generation and evaluation of the seed matrix.  After each loop, multiple 
data points for each newly analysed compound were added to the seed in 
preparation for calculating the next set of unknowns to be tested.   
In contrast to the selection processes based on categorised seed compounds (i.e. all 
processes other than active k-optimisation) the confirmation results were used to 
merely make a single categorisation of each compound.  In all phases of these 
processes, once potential candidates had been ranked in terms of their similarity to 
the initial seed compounds, any subsequent re-ranking was based entirely on 
analysis of any freshly identified active compounds.  Both of these simplifications led 
to a much shortened selection process.  
During early work with active k-optimisation, benchmarking between my PC and the 
Leuven computing facility was conducted.  Partial simulations of 30 loops length 
were conducted and timed, and the results are given in Table 5.10. 




Initial 85‟24 82‟12 82‟44 
2nd 27,01 24‟02 24‟12 
3rd 28‟15 24‟55 25‟05 
4th 29‟03 25‟51 26‟00 
5th 30‟00 26‟46 26‟57 
28th 54‟36 48‟19 48‟26 
29th 55‟44 49‟10 49‟20 
30th 56‟53 50‟07 50‟09 
Table 5.10: Timing comparisons for active k-optimisation simulations 
Full simulations of >100 loops were found to take in excess of 1 week to complete; 
this is in contrast to the selection processes based on simpler categorised seed 
compounds where, for example, a 148 loop transfer learning with preclustering 
simulation took 12½ hours to complete (this will have been close to the longest 
duration of any of the non- active k-optimisation simulations). 
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The large difference between these approaches isn‟t necessarily a barrier to using 
the more complex method, as more computing power could be used to accomplish 
the required tasks in an appropriate time.  However, when using much larger 
chemical libraries it is clear that selection times will be stretched further, and if 
simpler algorithms also give suitable outputs then they will be seen as more 
competitive.  It is also evident that the matrix computations required by the active 
k-optimisation algorithm are memory intensive: another potential limitation. 
Another factor to consider would be the time taken to physically conduct each 
experiment loop.  Eve‟s assay is comparatively long at 40 hours, but it is known that 
pharmaceutical companies strive for short duration assays where possible, and for 
an Active Learning approach to be useful it would need to generate selections that 





Comparisons across all endogenous algorithm variants (Tables 5.2 to 5.4, 
Figures 5.15 to 5.17) 
By taking the mean of all comparable deficiencies for the endogenous algorithms, it 
was possible to compare their performance when selecting both active compounds 
and rare category compounds.  The full AL curves for SimplyGreedy and active 
k-optimisation had marginally better deficiency results than when preclustering. 
In contrast, the SimplyGreedy algorithm is (by definition) a poor selector of rare 
category compounds, and comparison made at the 5% and 10% levels shows that 
the active k-optimisation performs well in this respect, due to its chemical space 
exploration strategy.  The three variants of the preclustering algorithm (𝑇𝑆 >
[0.40,0.45,0.50]) are also strong performers, but reduce in effectiveness with 
increasing  𝑇𝑆 limits; it has already been suggested that this relates to the increasing 
number (with an increasing TS limit) of unlabelled unknowns for evaluation in 
Phase 2 of this algorithm. 
Comparisons between exogenous algorithms (Tables 5.8 & 5.9) 
When an exogenous set of parasite-active compounds is applied as a TL seed, a 
strong improvement is seen in the rate of selection of active candidates when 
compared to all the endogenous AL curves.  Identification of rare category 
compounds shows a marginal improvement over SimplyGreedy. 
Using preclustering together with TL reduces the overall effectiveness slightly, but 
provides a large boost to rare category detection.  The combination of the different 
attributes of these methods results in a performance trade off from both sides, but 
the overall effect is very encouraging.  Slightly different strategies for Phase 1 of this 
process were compared; there seemed to be a marginal improvement when 
preclustering at 𝑇𝑆 > 0.40 was compared to 𝑇𝑆 > 0.60, but this effect was much 
lower than seen in the endogenous preclustering scoping work. 
It should be noted that the above comments relate to the generalised TL processes.  
Depending on the choice of exogenous seed, much larger gains in active compound 
and rare category compound deficiencies were observed (e.g. PvDHFR as a seed 
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for TcDHFR).  This suggests that much better gains can be made by tailoring the 
seed group, depending on knowledge or prediction of cross-strain target similarity.  
When comparing the best of the TL/preclustering simulations with those of the active 
k-optimisation process, it is clear that the gains offered by the former are potentially 
much larger. 
Strain-by-strain analysis of Transfer Learning versus endogenous Active 
Learning algorithms (Tables 5.5 to 5.7) 
The simple TL simulations used several active seed data sets from the DHFR and 
NMT mass screens, including those of HsDHFR.  The TL results from the HsDHFR 
seed could therefore be used as a baseline for identifying any benefits from using a 
parasite seed group.  An improvement in the learning curve deficiency in comparison 
to the curve from the HsDHFR seed can therefore be interpreted as a positive effect 
directly relating to the seed parasite-protein strain.  Any parasite seed benefits may 
relate to similarities in the protein structure of the seed and target, and this may 
especially be evident in detection of the rare category compounds. 
In general, there were strong transfer effects from Pv and Pf seeds to assays 
containing other plasmodium strains in comparison to the Hs baseline; the only 
exception to this was with PfRdhfr (which again shows how difficult this target is). 
 TcDHFR-active seeds showed a positive effect when used against assays 
containing Pv, Pf and PvRdhfr strains. 
 The TcDHFR target benefits from having Pv or PfDHFR hits in the seeds. 
 TbNMT-active seeds had a positive effect on identifying compounds active 
against PvDHFR and PvRdhfr, and also improved rare category selection for 
these targets. 
These transfer simulations provide only a snapshot for each seed/target combination 
but they have begun to suggest patterns in seed/target strain similarity that could be 
exploited.  Further experimental work would need to be undertaken to show the 
statistical significance of these effects. 
Fuller analyses of the effects of active seeds applied to individual target strains are 




The five AL strategies displayed a variety of features: 
Active k-optimisation (described in section 4.5.2) 
This algorithm has strong overall performance when selecting generally active 
compounds.  The strategy of sampling unexamined areas of the chemical space 
allows rare category compounds to be found at a steady pace. 
The main drawback of this strategy was its need to recompute ever larger matrix 
products at each cycle; growth measurements relative to the human orthologue are 
central to identifying the next best compounds to test, and needed to be continually 
re-evaluated.  This feature was designed out of the algorithms subsequently 
developed that used simpler activity classification; however, it should not be 
considered a major practical problem as good performance will generally be more 
important than physical computational requirements (which can generally be solved 
by investment in more processing power). 
SimplyGreedy (described in section 4.5.3) 
Constructed as a baseline learning strategy using simple, greedy searching based 
on similarity to existing active classified compounds, this strategy gave good 
performance for general active compound selection.  The process of only identifying 
active compounds which are similar to previously active compounds defines the 
algorithm as having minimal ability to identify rare compounds; this allows it to be 
used as a benchmark for rare category detection in other methods. 
Preclustering (described in section 4.5.4) 
These strategies demonstrated the power of classification of multiple negative/ 
inactive instances; in addition to using active results, they also use the likelihood that 
unknown compounds that are structurally similar to inactive seeds will also be 
inactive, thereby allowing them to be relegated to a later stage in the screening 
process.  This promotes compounds with no significant similarity to those already 
examined, and potentially enables the earlier examination of rare active compounds. 
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The ability to find generally active compounds was slightly weaker when straight 
preclustering approaches were used, compared to the above strategies. 
Transfer Learning (described in section 4.5.5) 
This approach showed a significant improvement in detecting generally active 
compounds, owing to the higher prior likelihood of the initial seed group containing a 
large number of strong candidates.  In some cases this will also relate to similarities 
between the parasite-protein structures of the target and from the transferred entity 
(e.g. PfDHFR and PvDHFR). 
Rare category detection was improved when compared to SimplyGreedy. 
Transfer Learning with Preclustering (described in section 4.5.6) 
Combining the benefits of the preclustering and transfer learning algorithms gave 
very good results for the rate of selection of generally active compounds and for rare 
category detection; in keeping with the other classification-based methods, it also 
had the additional benefit of requiring a lower computing capacity than the prototype 
active k-optimisation method.  If this method were to be developed further, it would 
be expected that modifications could be made to the final phase to improve detection 
rates for active compounds. 
General comments 
Further modifications could be made to the seed and unknown compound data sets 
to routinely relegate problematic compounds (i.e. toxic, autofluorescent) as 
knowledge is built up screen by screen. 
The ideas upon which the preclustering/rare category detection are based could also 
be used in combination with either active k-optimisation or SimplyGreedy, especially 
if an artificial endpoint were desired.  The operator would simply need to 
predetermine the point at which to run a routine based on proximity of prior inactive 







Development of an econometric model of drug discovery 
 
 
Adventures with yeast, part 6 of 7:  The perfect Marmite sammich 
 
2 slices Khorasan bread 
1 knob  good quality butter 
1 measure Marmite 
1 bottle Cwrw Cawrfil 
 
Butter each slice of bread in a liberal fashion.  Smear a sufficiency of Marmite onto one slice, 
and layer the sandwich. 
Decant the Cwrw Cawrfil into a globed beer glass, taking care to leave the lees. 




An econometric model was developed to determine the utility of Eve for drug 
discovery; it identifies when conditions exist for efficiency gains, and when economic 
advantages might be found for active compound selection when compared to a 
linear screen.  Assays that provide large numbers of potentially active compounds 
(e.g. PvDHFR) show the potential for efficiency gains when using AL selection 
strategies, whereas for targets that are difficult to hit (e.g. PfRdhfr, LmDHFR, 
SmDHFR), the econometric model shows that the AL strategies struggle to show any 
economic benefit. 
The expected general advantages using the prototype active k-optimisation strategy 
and SimplyGreedy were readily shown; the additional advantages provided by 
transfer learning methods were also clearly seen in comparison to strategies based 
on internally-provided seed data. 
The limitations of the model have been examined and discussed in terms of any 
assumptions made and limitations due to minimal information on the cost-benefit of 
the drug discovery phase in the public domain. 
The potential beneficial effect of stronger rare compound detection, as offered by the 
preclustering strategies, could not be quantified.  In order to accomplish this, a 
suitable range would need to be placed on the value of rare scaffolds compared to 
the active compounds that are similar to earlier seeds.  Earlier detection of rare 
category compounds might allow screens to be terminated earlier, containing 
econometrically optimised information; if the value of rare compounds was known 




There is little information in the public domain about the true cost of drug discovery 
and development.  There are no published details that can be considered a gold 
standard (Morgan et al., 2011), with a large range covering estimates ($92m - 
$883.6m) based on 13 publications up to 2009.  The available data is broken into 
discovery and development steps, and tends to show an approximate 1:2 split in 
costs across these tasks. 
A breakdown of the discovery and development steps (Paul et al., 2010) provides 
the most recent cost estimates and attrition rates of candidate compounds, based on 
data provided by Eli Lilley & co.  The target-to-hit and hit-to-lead discovery steps 
account for 9% of the discovery/development process. 
Robot Eve‟s existing operational configuration is designed to fit into the target-to-hit 
region of the drug discovery process.  The multi-target assays are expected to 
provide information on pathway-specific activity, with additional comparison against 
the equivalent human strain.  The active k-optimisation strategy is designed to select 
suitable candidates and to explore based on these Hs-parasite growth differences.  
In the longer term, across several screens, these data could also be used to build up 
candidate-specific knowledge that highlights repeat offenders in terms of cytotoxicity 
and autofluorescence; this would assist cherry-pick screening by relegating these as 
unlikely candidates. 
When considering libraries of existing drug therapies such as the JHCCL, the cost 
emphasis will be skewed by the additional knowledge available.  It is envisaged that 
repositioning an existing therapy might be significantly less expensive (Boguski et 
al., 2009); arguably, a lead compound could progress far more rapidly to a Phase II 
trial (drug effectiveness) thanks to previous pre-clinical and Phase I (safety) studies 
once in vivo performance has been established.  However, some structures might 
not respond well enough and only be considered lead compounds that require 
additional development, thereby reverting to the „lead optimisation‟ step. 
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6.2 Econometric modelling for Eve 
An econometric model for the differential advantage of using intelligent screening is 
displayed below; it was developed to determine the utility of Eve for drug discovery, 
i.e. the range of conditions for which using a Robot Scientist to guide candidate 
compound selection is economically advantageous compared with performing a 
standard whole-library screen.  In all types of screen there are costs associated with 
physically using up the contents of the compound library, as well as utility, time and 
labour costs; in mass screens the cost of loss of compound is significantly lower than 
in more complex confirmation screens. 
∆ 𝑈𝑡𝑖𝑙𝑖𝑡𝑦 𝑜𝑓 𝐸𝑣𝑒 =     𝑇𝑚 + 𝐶𝑚  𝑁𝑚1 +  (𝑇𝑐 + 𝐶𝑐 − 𝑈𝑕) 
𝑁𝑥
1 +  (𝑇𝑚 − 𝑇𝑐 + 𝐶𝑚 − 𝐶𝑐)  
𝑁𝑒
1   (12) 
Nm - Number of compounds not assayed by Eve 
Tm - Cost of the time to screen a compound using the mass 
   screening assay, $ 
Cm - Cost of the loss of a compound in the mass screening assay, $ 
Nx - Number of hits missed by Eve 
Tc  -  Cost of the time to screen a compound using a cherry-picking 
 (confirmation or intelligent) assay, $ 
Cc - Cost of the loss of a compound in a cherry-picking assay, $ 
Uh - Utility of a hit, $ 
Ne - Number of compounds assayed by Eve 
 
The net utility is made up of three cost components; the cost of: 
(i) not screening Nm compounds which, based on the QSAR learning, are less 
likely to be hits [i.e. a cost saving]; 
(ii) not finding any hits (Nx) that might be present in this unscreened set 
(Uh >> Tc + Cc ) [an indeterminate, negative, opportunity cost]; 
(iii) cherry-picking Ne compounds, (Tc + Cc )>(Tm + Cm ) [physical negative cost]. 
173 
 
6.3 Application of the model to Active Learning curve simulations 
6.3.1 Model rearrangement 
Rearranging the utility equation assists with simplifying the calculations when using it 
to evaluate the AL simulation loops:  
 
 ∆ 𝑈𝑡𝑖𝑙𝑖𝑡𝑦 𝑜𝑓 𝐸𝑣𝑒 =     𝑇𝑚 + 𝐶𝑚  𝑁𝑚 +𝑁𝑒1 −   𝑇𝑐 + 𝐶𝑐  
𝑁𝑒−𝑁𝑥
1 − (𝑁𝑥 × 𝑈𝑕)      (13) 
 
The first term is now effectively the full cost of performing a standard library screen.  
For Eve and the Maybridge HitFinder library, upfront and ongoing library and 
consumables costs for a library screen are fixed. 
The second term is the operational cost associated with cherry-picking Ne 
compounds but not the Nx undiscovered hits when the Active Learning algorithm is 
selecting candidate compounds based upon the QSAR learning. 
The third term is the economic value of a hit compound against the parasite (Uh), 
and the number of such hits (Nx) yet to be found by the Active Learning; again, this 
opportunity cost is recalculated in the simulations for each loop in the screen.   
6.3.2 Econometric modelling using simulation data 
The active k-optimisation AL algorithm was applied to the seed input data and the 
unknown compound SMILES codes; simulated learning curves were produced for 
each parasite strain using the proxy confirmation data (see section 5.1).  The 
progression of these learning curves was then compared to the base case of a linear 
progression throughout the screen in accordance to the utility equation (Equation 
12).  For each 96 compound loop, the number of proxy confirmed hits and 
compounds screened to date (Ne ) were applied to the utility equation, together with 
the fixed utility and cost terms.  An example of the resultant 2D plot for the PvDHFR 





 Compounds Screen hits 
Full screen 14386 316 
Seed     958   25 
Unknowns 13428 291 
No. of 
loops 
No. of screen hits in simulation loops 
n=0 n=10 n=20 n=30 n=40 n=50 n=60 
n+1 8 53 106 133 162 190 204 
n+2 12 60 109 137 163 192 206 
n+3 17 67 111 141 167 194 208 
n+4 23 73 112 142 169 196 210 
n+5 29 79 116 144 174 198 214 
n+6 30 86 117 146 179 199 216 
n+7 36 90 118 148 182 200 217 
n+8 39 95 123 152 184 201 218 
n+9 44 98 125 154 186 202 221 
n+10 47 104 127 157 189 203 223 
No. of 
loops 
No. of screen hits in simulation loops 
n=70 n=80 n=90 n=100 n=110 n=120 n=130 
n+1 226 244 260 279 291   
n+2 228 247 263 280    
n+3 229 250 264 281    
n+4 231 251 268 283    
n+5 233 252 271 284    
n+6 235 253 273 285    
n+7 238 254 274 286    
n+8 240 255 275 288    
n+9 242 256 277 289    
n+10 243 259 278 290    
Table 6.1:  Simulation data for the TS3 PvDHFR target - number of hit 
compounds found with progression of the loop count. 
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Note: the utility increase example displayed below is the percentage increase over 
the equivalent stage in the base case linear screen; this is true for all the utility 
curves shown in this document.  Overall utility will become negative once the screen 
has progressed beyond the point at which the benefits from AL are outweighed by its 
additional costs. 
 
Figure 6.1: Hits found in TS3 PvDHFR simulation (red) versus base case 
(black), and the resultant econometric utility % increase (blue), based on data 
in Table 6.1 
(Tm = 800 per cycle, Cm = 0.4 per compound,Tc = 1000 per cycle, 
Cc = 3 per compound, Uh = 2000) 
 
The cost of a cycle of AL includes both the time and cost of the computing power, 
and the cost of testing a 96-compound batch in the cherry-picking assay.   Based on 
the active k-optimisation simulated cherry-picking cycles, these terms were also 
calculated for examples of each parasite target (Figure 6.2). 
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Figure 6.2: Simulations of intelligent screening for each DHFR target using the 
active k-optimisation strategy. 
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A utility landscape was also constructed for the TS3 PvDHFR parasite data across a 
range of ML efficiencies and drug economic values (Figure 6.3); the value of a hit 
compound for this study ranged from £2K to £15K, based on a broad estimate of the 
number of hits required to give sufficient drug-like lead compounds to commence 
lead optimisation studies.  Variation in the time-cost ratio comparing mass to 
intelligent screening (Tc/Tm) was studied, and utility versus cost of compound loss 
during cherry-picking (Uh/Cc) was also evaluated. 
Efficiency benefits are more readily found when the time-cost ratio tends towards 
unity, and when the utility of a hit increases compared to the cost of loss of library 
compounds.  These observations would be expected of an AL strategy capable of 
improving the selection process for drug-like candidates. 
 
Figure 6.3: Utility landscape for TS3 PvDHFR, Time-ratio = Tc/Tm , and 
Cost-ratio = Uh/Cc 
Figure 6.4 displays the effect of the econometric model when applied to example 
SimplyGreedy simulations.  Figure 6.5 depicts a similar set of examples from the 
Transfer Learning/ Preclustering (TS > 0.40) simulations based on the compounds 
previously identified as active versus PfDHFR in TS6. 
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Figure 6.4: Intelligent screening simulations, DHFR targets, SimplyGreedy 
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TS5 PfR  Tc 
 
TS6 Pv  Pf  
TS7 Lm  PvR 
 
Figure 6.5: Intelligent screening simulations, DHFR targets, Transfer Learning from 




Figure 6.6: Intelligent screening simulations, TcDHFR targets: Hits identified 
by Transfer Learning from PfDHFR with preclustering at TS > 0.40 (red) versus 
random selection (black).  Relative econometric performance (utility increase) 
of active k-optimisation (grey) and transfer learning/preclustering (blue) 
 
Figure 6.6 overlays the econometric curves for TcDHFR from Figures 6.2 (grey) and 
6.5 (blue), showing the strong performance offered by the combination of Transfer 
Learning and Preclustering (TLP) by its effect on overall utility.  The initial boost to 
utility enables the curve to remain above the active k-optimisation curve throughout 
the experiment.  It should be noted that the TLP approach will also have provided 




6.4 Modifications to the econometric model 
One aspect that has not been considered in the econometric model is whether the 
utility of a hit (Uh) has a variable value.  It has been argued in section 5.5 that rare 
category active compounds are likely to be of significant interest, as their structures 
are dissimilar to other active compounds.  The ability to promote and find these 
candidate compounds is considered a potentially important feature of an AL 
algorithm for Robot Eve.  The ability of the active k-optimisation strategy to search 
for diverse compounds meant that it performed reasonably well by finding rare 
category compounds linearly throughout the simulation.  Introduction of the transfer 
learning with pre-clustering strategy gave a strong improvement on detection of 
these rare category compounds. 
 
6.5 Discussion 
6.5.1 The econometric model helps to describe the efficiency gains when using 
Active Learning.  Although the applied financial variables are not directly taken from 
the pharmaceutical development process, they are considered to be fair guesses 
and Figure 6.3 displays the effect of a spread of these values.  In Figure 6.3, utility is 
improved as the time cost of intelligent screening approaches that of standard mass 
screening, and is also improved with increasing value/utility of hit versus the cost of 
loss of compound (raw material replenishment). 
6.5.2 As expected, there is little difference in the econometric performance of the 
prototype active k-optimisation strategy and SimplyGreedy.  The curves for those 
targets with a strong set of active compounds are broadly similar using either 
strategy, as indicated by the earlier deficiency measurements.  
The poor quality of the curves for PfR, Sm & LmDHFR suggest that these parasite 
proteins are difficult targets to fit into an econometric model.  This reinforces the 
opinion that these are difficult drugable targets, as identified by the low number of 




6.5.3 The positive effect of transfer learning on econometric performance is clear.  
The econometric model has only been applied to a few of the transfer learning 
curves, but the expected advantages are easily highlighted.  Figure 6.6 shows an 
example of the large boost to econometric performance when comparing the overlaid 
transfer learning curve (blue) and the prototype curve (grey) for TcDHFR.  Similar 
strong effects would also be seen with the other targets. 
6.5.4 There remains the question of when to terminate the screen.  The simulations 
and econometric model suggest that there are advantages in running a partial 
screen if there are capacity limitations on the equipment.  The ability of any Active 
Learning regime to highlight active rare category compounds would provide 
additional impetus to curtail the screen after their identification, if these are of high 
value as expected.   
Rare category compounds were defined by having no near active or inactive 
neighbours in the Maybridge Hitfinder library; this might be impractical in a large 
commercial library, so it is suggested that a threshold quantity of near inactive 
neighbours could be established.  It is also suggested that the current tail set of 
compounds with near inactive neighbours might provide more valuable information if 
the set were graded for examination based on a rising proportion of near inactive 
neighbours. 
6.5.5 The model has certain limitations, as there is little information in the public 
domain that describes some of the values applied to its parameters.  Assumptions 
have been made for the utility of active candidates in the drug discovery phase, and 
only costs associated with the experiments in Aberystwyth could be used.  The 
model can readily be used for comparing economic merits of different simple AL 
approaches reported herein, but might struggle if used to provide an absolute 






Conclusions and further work 
 
Adventures with yeast, part 7 of 7:  Gwynant Cochnant 
 
 
4.0 kg  Maris Otter pale malt 
0.2 kg  crystal malt 
0.1 kg  dark crystal malt 
0.05 kg            light chocolate malt 
50 grams Challenger hops 
50 grams Mount Hood hops 
1 packet SafaleS-04 beer yeast 
1  Irish moss tablet 
 
 
Add the grains to the mash tun with 20 litres of water.  Steep at 70-75°C for two hours.  
Remove the grain sack and allow it to drain into the wort; sparge it with boiling water until 
the sugars have been depleted.  Remove 500 ml of wort and use it to make a yeast starter.  
Bring the bulk wort to the boil; maintain the volume at approximately 25 litres.  Add the 
Challenger hops when the wort is at a rolling boil, and boil for 60 minutes; add 25 grams of 
Mount Hood hops at 30 minutes from the end of the boil, and a further 25 grams at 15 
minutes from the end, together with the Irish moss tablet. 
Cool the finished wort; decant it to a fermentation vessel and add the yeast starter.  Record 
the original gravity (~1040), and the final gravity (~1010 after 10 days).  Prime the finished 
brew with 100 grams of white sugar in 1 litre of boiled/cooled water prior to bottling or 
casking. 
This recipe is a “work in progress” for the purpose of revitalising Bragdy Gwynant, the 
world’s smallest commercial brewery (according to Guinness World Records). 
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The scope of this thesis was very broad, encompassing the need to understand and 
develop several computational methods that explored aspects of drug discovery and 
design, biochemical pathways, and general data analysis.  Whilst much of the early 
focus was on the empirical aspects of the Robot Scientist programme, analysis of 
Eve‟s output was a necessary hurdle to overcome before embarking on the 
development of Active Learning processes.  The resultant data sets have allowed an 
independent analysis of the similarities between active, drug-like compounds.   
The simple input/output data structures required by the AL methods developed 
herein would readily lend themselves to other drug discovery processes.  Similarly, 
the use of inactive labels, as shown in the preclustering strategy, could be adopted  
for the exploration of other problems where the detection of rare categories is 
important e.g. detection of financial fraud or network security breaches. 
 
7.1 Primary achievements 
7.1.1 A robust data analysis process has been built for Robot Scientist Eve 
The method developed to analyse mass screen data for Eve incorporates several 
descriptors from across the full growth curve of the substrate, and has shown itself to 
be robust after application across many mass screens.  It has shown evidence of 
better sensitivity versus an alternative method based on measurements of final 
growth alone, which was retrospectively compiled after completion of several 
screens.  Now that a larger body of experience and confirmation data has been 
acquired, it would be feasible to tune the mass screen analysis to reduce noise 
caused by repeat instances of autofluorescent and cytotoxic compounds, although 
these are very few in number relative to the bodies of the libraries in use.  Similarly, 
a better background signal might now be possible to build, by using a moving 
average for individual compounds in additional to the in-plate negative controls. 
Similarly, the processes for analysing confirmation data worked well, with the 
decision tree rules providing a satisfactory indicator of borderline activity.  It might be 
useful to enhance these rules with an additional indicator to give the magnitude of 
activity, although this is already provided in a semi-quantitative fashion using a 
scoring process.  
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7.1.2 The ability of Eve to consistently find active compounds, and perform 
quantitative studies of selected compounds, was demonstrated 
Eve‟s library screening studies have identified a large number of molecules in the 
Maybridge Hitfinder collection that have confirmed activity versus the parasite 
strains.  These instances are recorded in Appendix A.8. 
There are also several compounds with confirmed activity originating from the Johns 
Hopkins Clinical Compound Library; these instances are recorded in Appendix A.9.   
7.1.3 A prototype Active Learning system was implemented 
The prototype active k-optimisation algorithm was applied to Eve‟s mass screen data 
for end-of-test growth to provide an Active Learning regime.  When combined with 
the above data analysis process, Eve was able to operate a closed loop drug 
discovery process. 
Due to cost and time constraints only three rounds of AL were applied; the output 
from these was used to identify a means whereby mass screen data might act as a 
proxy for confirmation screen data, thereby allowing an AL cherry-picking simulator 
to be constructed.   
7.1.4 Alternative Active Learning processes were developed 
The active k-optimisation strategy was benchmarked against a greedy learning 
algorithm based on Tanimoto Similarity between candidates and active compounds; 
this SimplyGreedy algorithm was based on classification rules rather than quantified 
activity, and was further developed using transfer learning techniques to give a 
simple yet effective mechanism to identify active candidates.   
7.1.5 Strategies for detecting rare category compounds were developed 
The SimplyGreedy algorithm and its off-shoots were combined with clustering 
techniques to explore the compound library.  This led to the identification of similarity 
thresholds below which active compounds are unlikely to be found efficiently, and 
enabled algorithms to be built which switched to searching unexplored spaces in the 
library.  The resultant rare category detection algorithms allowed Eve to promote 
active compounds that would otherwise have been difficult to find until later stages.  
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By allowing an experiment to terminate earlier, these compounds are inevitably now 
found at the expense of less „rare‟ compounds, but compensate by providing diverse 
chemical structure scaffolds. 
7.1.6 Generalised applicability of Eve’s Active Learning strategies  
The Active Learning strategies based on classification of drug-like activity have been 
developed successfully.  The simple input data structure means that these strategies 
should be readily adaptable to other drug discovery regimes, and will also have 
applicability for dealing with other problems where rare category detection is 
required. 
The inputs mainly used in this thesis (i.e. FPT2 fingerprints, Tanimoto Similarity, and 
activity classification data) are fairly simple information sets but, for drug discovery 
work, these Active Learning strategies could easily adopt other methods of showing 
potential biochemical similarity between candidate compounds.  The main aspect 
that would need to be considered for using other information sources would be the 
similarity thresholds at which the activity measurement system can give a rich vein of 
candidate compounds. 
 
7.2 Secondary Achievements 
As might be expected of any major research and development programme, several 
discoveries have been made that were outside the original scope of the project:  
7.2.1 The benefits of discrete, classification-based inputs over the 
continuous variables for end-of-test growth quantification were shown 
The active k-optimisation strategy provided a strong selection process, with good 
overall identification of active compounds together with an effective means of 
searching for rare category compounds throughout experiments.  However, this 
algorithm required much more computational capacity than the simpler, 
classification-based algorithms developed from the initial SimplyGreedy strawman, 
which in turn were eventually constructed to provide both strong overall performance 
and very strong rare category detection.  The latter methods will have benefitted 
from using transfer learning, and it would have been of interest to apply a similar 
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approach as part of the seed for active k-optimisation had there been appropriate 
facilities for such work. 
7.2.2 Benefits were shown when classifying activity using several attributes 
of the yeast growth curve, in comparison with end-of-test quantification rules 
When the initial data analysis rules (set up using multiple attributes of the yeast 
growth curve) were compared with simple growth-based rules, they showed strong 
performance in identifying a wider range of active candidates.  These rules 
performed better owing to their ability to identify candidates that might otherwise 
have been miss-labelled as false negatives; simple end-of-test growth rules were 
found to misread candidates with slower growth rates or inhibited lag phases. 
7.2.3 A possible mode of parasite growth inhibition was shown for some 
JHCCL candidates 
Two of the JHCCL candidate compounds with confirmed screen activity have 
previously been suggested as having anti-malarial activity, and specific protein 
targets have been suggested in the literature.  Follow-on in vivo evaluation of these 
compounds has suggested potential alternative sites for their anti-parasitic 
behaviour.   
It is possible that Triclosan (SM-JH-10450) has been identified as an anti-folate for 
Plasmodium sp.; earlier indications of its anti-parasitic behaviour (Surolia and 
Surolia, 2001) suggested its activity was through inhibition of FabI, its bacterial 
target (McMurry et al., 1998), although it was later convincingly shown that FPfFabI 
is not the main target of the anti-Plasmodium activity of triclosan (Yu et al., 2008). 
The anti-cancer angiogenesis inhibitor Tnp-470 has previously been reported to 
possess activity in vitro against P. falciparum - with the target believed to be 
methionine aminopeptidase 2 (Arico-Muendel et al., 2009).  Eve found weak activity 
against P. falciparum DHFR but much stronger activity against P. vivax DHFR; this 





7.2.4 A family of Maybridge compounds having activity versus the PvDHFR 
target was investigated 
Twelve candidates (5 from the Maybridge Hitfinder library, 7 from the full Maybridge 
collection) that had strong similarity to a small group of active seed compounds were 
identified for confirmation testing (see section 3.3.4).  Seven were found to be active 
versus the PvDHFR target, with two inactive and three untested.  The inactive 
compounds were smaller molecules with no large functional groups attached, and 
could be described as small molecules for drug lead development in this context. 
This family might be a useful starting point for a lead compound versus PvDHFR. 
7.2.5 The economic benefits of Active Learning were shown 
An economic model was developed to show the economic benefits of AL in the drug 
discovery process.  Comparison between the prototype active k-optimisation strategy 
and a simple, linear candidate selection process showed the advantage of informed 
selection, and that significant efficiency gains are possible. 
The same set of conditions was used to test a simple, greedy AL algorithm, together 
with a number of alternative selection mechanisms for candidate compounds.  The 
overall shape and measured deficiencies for the other non-transfer AL algorithms 
suggest that similar econometric performance would be found.  An exception to 
these observations might be found for the transfer learning algorithms, where the 
learning curve is strongly boosted by many early active examples. 
It has been mooted that the intrinsic value offered by finding rare category 
compounds would boost the overall econometric value of a screen; the ability to find 
such items at an earlier stage might allow the search to be truncated, with the screen 
value deemed as maximised.  The combined transfer learning/preclustering strategy 
was very successful in promoting compounds that were otherwise difficult to find; in 
most cases >90% of the rare category compounds were detected by the end of the 
second phase of this strategy, and would therefore have much higher partial 




7.3 Further Work 
Eve‟s ML rules could be extended to include some of the ideas used in Cambridge‟s 
proposed data analysis systems, e.g. finding and removing superactive (toxic and 
autofluorescent) compounds, removing consistently problem wells, relegating 
promiscuous active compounds.  
If experience across more screens were available it might be possible to build rules 
to test whether the selection strategy is working effectively.  Empirical evidence 
suggests that some targets are difficult to hit, and there might need to be a larger 
body of active compounds needed to assist with predictions.  In such cases, a switch 
to an alternative selection strategy might be beneficial, or even a switch back to 
mass screening mode to acquire a broader data set. 
It is suggested that SMILES FP2 fingerprints based on fragments of 7 atoms 
(Daylight 0/7 configuration) are less productive in QSAR studies than larger 
fragments (up to 10 atoms in length, Daylight 3/10 configuration) (McGaughey et al., 
2007).  The rcdk toolkit allows for changes in chain length, and such effects could be 
investigated prior to completing a publication based on the AL studies. 
Finding the dividing line between potentially active compounds and toxic ones is an 
interesting subject for Eve, and one that probably requires different approaches for 
the Maybridge Hitfinder and JHCCL libraries.  There were occasions where JHCCL 
compounds were considered borderline toxic when using the methods set up with 
Maybridge data, but could well be useful for further evaluation.   
If a lead originates from the approved drugs in the JHCCL, how much more valuable 
is it than a compound from a standard library such as the Maybridge collection?  
Could different, less strict toxicity criteria be constructed for approved drugs in Eve‟s 
decision tree rules, compared to those with less readily-available information? 
An enhancement of the Robot Eve programme would be to expand the libraries to 
include a larger set of existing drug therapies.  Similarly, other libraries outside of 
normal pharmaceutical collections (e.g. the SIDR Natural Products Collection 
(Harvey et al., 2010)) might lend themselves to exploitation by Eve‟s processes and 
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A.1 Assay strains 
Screen Target 
Strain/Fluorophore 
mcherry sapphire venus 
TS3 DHFR Hs Pv PfR 
TS4 DHFR Hs Tb Sm 
TS5 DHFR PfR Hs Tc 
TS6 DHFR Hs Pv Pf 
TS7 DHFR Hs Lm PvR 
TS8 DHFR Hs Sa Sa 
TS9 DHFR Hs Sa Sa 
PGK1 PGK Hs Sm Tc 
PGK2 PGK Hs Tb Pv 
NMT1 NMT Hs Tb Pv 







A.2 List of mass screens  
Assay 
 
File ID Compounds 
Maybridge JHCCL 
TS3 MS_63_1_15_20110414203535.csv 14386+17 1249 
TS4 MS_64_1_16_20110414205040.csv 14386+17 1245 
TS5 MS_71_1_17_20110414210718.csv 14380+17 1249 
TS6 
MS_77_1_22_20110316174043.csv 14099 - 
MS_TS6_JHCCL.csv - 1248 
TS7 MS_80_1_25_20110630113217.csv 14376+17 1252 
TS8 MS_83_1_26_20111028130222.csv 14224+17 284 
TS9 MS_85_1_28_20120116103737.csv 13925+17 297 
PGK1 MS_72_1_18_20110414212243.csv 14347+17 1249 
PGK2 MS_74_1_20_20110414213751.csv 14272+17 1249 
NMT1 MS_78_1_23_20110414215320.csv 14376+17 1250 






A.3 Mass screens, Maybridge Hitfinder activity 
Assay Target Strain Compounds 








173 198 13 384 
Pv 236 59 21 316 




193 78 8 279 
Tb 34 30 11 75 




130 41 8 179 
Hs 6 19 12 37 




46 62 11 119 
Pv 203 81 19 303 




195 51 20 266 
Lm 8 31 16 55 




    
Sa     




    
Sa     




171 174 4 349 
Sm 12 16 9 37 




57 38 9 104 
Tb 13 17 7 37 




18 24 14 56 
Tb 200 98 13 311 






173 74 7 254 
Sm 29 36 5 10 






A.4 Mass screens, JHCCL activity 
Assay Target Strain Compounds 








- 1 1 2 
Pv 7 3 1 8 




5 - - 5 
Tb 2 1 1 4 




1 - 1 2 
Hs - 2 3 5 




49 12 3 64 
Pv 7 7 1 15 




2 6 2 10 
Lm 2 7 1 10 




    
Sa     




    
Sa     




60 10 5 75 
Sm 1 1 4 6 




118 7 5 130 
Tb 2 2 3 7 




4 3 2 9 
Tb 4 8 - 12 






71 29 1 101 
Sm 4 6 1 11 
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A.6: List of confirmation screens  
Confirmation screens were generally run using 8 replicates at five 
concentrations (1, 2.5, 5, 10, 20 m), or 4 replicates at a lower range of five 
concentrations (0.5, 1, 2.5, 5, 10 m). 






1 - 20 
27* - 
8 
2, 10, 50 3 
CS_63_2_10_20110421150005.csv 1 - 20 53 5 8 
CS_63_3_32_20111209133124.csv 0.5 - 10 15* 4 4 
CS_63_7_45_20120417093418.csv 0.5 - 10 2**+5 14 4 
CS_63_12_61_20120531103405.csv 0.5 - 10 29** 2 4 
TS4 
CS_64_4_13_20110521153113.csv 1 - 20 54 8 8 
CS_64_5_23_20111028073121.csv 0.5 - 10 36* - 4 
CS_64_6_31_20111209113125.csv 0.5 - 10 1* 3 4 
TS5 
CS_71_2_14_20110528141537.csv 1 - 20 53*** 5 8 
CS_71_3_30_20111208133125.csv 0.5 - 10 10* 3 4 
CS_71_5_40_20120205070253.csv 0.5 - 10 0*** 7 4 
CS_71_6_46_20120417093526.csv 0.5 - 10 5**+5 15 4 
TS6 
TS6cherrypick.csv 1 - 20 12**+17 16 8 
CS_77_3_6_20110325115514.csv 1 - 20 96 - 8 
CS_77_4_7_20110404123211.csv 1 - 20 102 - 8 
CS_77_5_9_20110411115111.csv 1 - 20 86 - 8 
CS_77_7_16_20110529120129.csv 1 - 20 63 - 8 
CS_77_8_24_20111028120222.csv 0.5 - 10 20* - 4 
CS_77_10_37_20111212093549.csv 0.5 - 10 17** - 4 
CS_77_11_41_20120205063144.csv 0.5 - 10 0*** 7 4 
CS_77_14_51_20120427104149.csv 0.5 - 10 4**+6 15 4 
CS_77_15_62_20120607090640.csv 0.5 - 10 29** 2 4 
TS7 
CS_80_3_22_20110714113111.csv 0.5 - 10 37***+4 10 4 
CS_80_4_29_20111208110223.csv 0.5 - 10 10* 3 4 
CS_80_6_58_20120531103231.csv 0.5 - 10 30**+6 8 4 
TS9 
CS_85_2_38_20120127090445.csv 0.5 - 10 43*+1 3 4 
CS_85_3_63_20120615100158.csv 0.5 - 10 7*+1 3 4 
PGK1 
CS_72_2_17_20110603120112.csv 0.5 - 10 44 15 8 
CS_72_4_35_20111210133124.csv 0.5 - 10 21* 2 4 
PGK2 
CS_74_2_18_20110605120113.csv 0.5 - 10 50 12 4 
CS_74_4_36_20111212100237.csv 0.5 - 10 21* 1 4 
NMT1 
CS_78_2_19_20110609210111.csv 0.5 - 10 38+5 18 4 
CS_78_4_33_20111210110222.csv 0.5 - 10 9* 2 4 
CS_78_6_54_20120427104757.csv 0.5 - 10 4**+6 15 4 
NMT2 
CS_79_2_20_20110611133112.csv 0.5 - 10 38+1 22 4 
CS_79_6_53_20120427104440.csv 0.5 - 10 4**+6 15 4 
 
    * plus five positive controls 
    ** plus three positive controls 




A.7 Confirmation curve examples 
These curves are for 17 of the 20 strong PvDHFR candidates in Section 4.3.2.  
They are from TS6 CS_77_7_. 
red=HsDHFR, blue=PvDHFR, green=PfDHFR. 
   
   
   










A.8 Confirmation: active Maybridge compounds 
TS3 DHFR assay 
 Eve ID Maybridge ID HsDHFR PvDHFR PfRdhfr Pv active PfR active Toxic 
TS3_Dec2010 510  0 74 0 Yes  No 
TS3_Dec2010 516  0 44 0 Yes  No 
TS3_Dec2010 978  0 80 0 Yes  No 
TS3_63_7 978  1 40 0 Yes  No 
TS3_63_12 978  0 40 0 Yes  No 
TS3_63_2 3143 hfAW 00846 32 68 22 Yes Yes Possibly 
TS3_63_2 3390 hfBTB 01480 0 52 0 Yes  No 
TS3_Dec2010 3466 hfBTB 02152 16 30 8 Yes  Possibly 
TS3_63_2 3474 hfBTB 02216 15 54 8 Yes  Possibly 
TS3_63_2 3548 hfBTB 02678 0 37 0 Yes  No 
TS3_Dec2010 3892 hfBTB 05160 41 43 40 Yes Yes Possibly 
TS3_63_2 3947 hfBTB 05522 16 78 6 Yes  Possibly 
TS3_Dec2010 3951 hfBTB 05541 34 61 51 Yes Yes Possibly 
TS3_Dec2010 3978 hfBTB 05727 0 32 0 Yes  No 
TS3_63_2 4305 hfBTB 08264 0 60 0 Yes  No 
TS3_Dec2010 4848 hfBTB 13456 6 16 12 Yes Yes No 
TS3_63_2 5678 hfCD 06694 13 16 7 Yes  Possibly 
TS3_63_2 5809 hfCD 08381 18 42 54 Yes Yes Possibly 
TS3_63_2 5822 hfCD 08497 0 60 0 Yes  No 
TS3_Dec2010 5829 hfCD 08585 0 66 0 Yes  No 
TS3_63_2 5868 hfCD 08965 0 56 0 Yes  No 
TS3_63_2 6178 hfCD 11546 0 24 0 Yes  No 
TS3_63_2 6254 hfDFP 00054 15 15 8 Yes  Possibly 
TS3_Dec2010 6310 hfDP 00458 22 16 36 Yes Yes Possibly 
TS3_63_2 7652 hfHTS 03328 0 56 0 Yes  No 
TS3_63_2 8366 hfHTS 07614 0 72 0 Yes  No 
TS3_Dec2010 8751 hfHTS 09910 0 56 0 Yes  No 
TS3_63_2 9048 hfHTS 11969 0 42 0 Yes  No 
TS3_Dec2010 9081 hfHTS 12148 0 80 0 Yes  No 
TS3_Dec2010 9082 hfHTS 12152 7 80 4 Yes  No 
TS3_63_2 9186 hfHTS 12551 0 80 0 Yes  No 
TS3_Dec2010 9444 hfJFD 00261 7 76 1 Yes  No 
TS3_Dec2010 9499 hfJFD 00787 13 78 6 Yes  Possibly 
TS3_63_3 9504 hfJFD 00823 6 6 30  Yes No 
TS3_63_2 9525 hfJFD 00979 0 74 0 Yes  No 
TS3_63_2 9557 hfJFD 01295 16 38 16 Yes Yes Possibly 
TS3_63_2 9843 hfJFD 03375 0 74 0 Yes  No 
TS3_Dec2010 10371 hfKM 03205 26 78 66 Yes Yes Possibly 
TS3_63_2 10693 hfKM 05465 0 32 0 Yes  No 





 Eve ID Maybridge ID HsDHFR PvDHFR PfRdhfr Pv active PfR active Toxic 
TS3_63_2 11635 hfMWP 00601 0 50 0 Yes  No 
TS3_Dec2010 11636 hfMWP 00602 0 22 0 Yes  No 
TS3_63_2 11706 hfMWP 01127 0 78 0 Yes  No 
TS3_Dec2010 11783 hfNRB 00102 16 32 16 Yes Yes Possibly 
TS3_63_2 12037 hfNRB 03604 0 26 0 Yes  No 
TS3_Dec2010 12054 hfNRB 03723 0 30 0 Yes  No 
TS3_63_2 12100 hfNRB 04269 0 42 0 Yes  No 
TS3_63_2 12255 hfPD 00426 0 0 10  Yes No 
TS3_63_2 12376 hfPHG 00991 0 44 0 Yes  No 
TS3_63_2 12588 hfRDR 02635 0 66 0 Yes  No 
TS3_63_2 12830 hfRF 02175 24 70 16 Yes Yes Possibly 
TS3_Dec2010 13162 hfRH 00731 32 10 16 Yes Yes Possibly 
TS3_63_2 14021 hfRJF 00951 0 80 0 Yes  No 
TS3_63_2 14144 hfS 01961 0 52 0 Yes  No 
TS3_63_2 14182 hfS 03874 0 66 0 Yes  No 
TS3_63_2 14246 hfS 05379 0 54 0 Yes  No 
TS3_Dec2010 14352 hfS 10015 28 8 28  Yes Possibly 
TS3_63_2 14447 hfS 12623 24 56 20 Yes Yes Possibly 
TS3_63_2 14453 hfS 12745 0 38 32 Yes Yes No 
TS3_63_2 14576 hfS 14685 7 46 8 Yes  No 
TS3_63_2 15107 hfSEW 01466 0 54 0 Yes  No 
TS3_63_2 15210 hfSEW 02156 0 54 10 Yes Yes No 
TS3_Dec2010 15254 hfSEW 02484 24 40 24 Yes Yes Possibly 
TS3_63_2 15667 hfSEW 05115 0 54 0 Yes  No 
TS3_Dec2010 16020 hfSP 00278 0 80 0 Yes  No 
TS3_63_12 16169 hfSP 01458 8 9 8 Yes Yes Possibly 
TS3_Dec2010 16213 hfSPB 00471 28 32 29 Yes Yes Possibly 
TS3_63_2 16219 hfSPB 00514 0 74 0 Yes  No 
TS3_63_2 16490 hfSPB 02620 30 80 20 Yes Yes Possibly 
TS3_63_2 16499 hfSPB 02669 0 54 0 Yes  No 
TS3_63_2 16536 hfSPB 02854 0 64 0 Yes  No 
TS3_Dec2010 16718 hfSPB 04137 26 32 26 Yes Yes Possibly 
TS3_63_2 16756 hfSPB 04438 16 24 11 Yes Yes Possibly 
TS3_Dec2010 16830 hfSPB 05131 14 66 9 Yes  Possibly 
TS3_Dec2010 17006 hfSPB 06520 24 80 23 Yes Yes Possibly 
TS3_63_2 17125 hfSPB 07412 0 30 0 Yes  No 
TS3_63_2 17131 hfSPB 07441 0 40 0 Yes  No 
TS3_63_2 17132 hfSPB 07445 0 66 0 Yes  No 
TS3_Dec2010 17226 hfSPB 08252 3 46 0 Yes  No 





TS4 DHFR assay 





TS4_64_6 510  0 8 0 Yes  No 
TS4_64_4 3258 hfBR 00082 23 22 20 Yes Yes Possibly 
TS4_64_5 3259 hfBR 00086 8 8 8 Yes Yes Possibly 
TS4_64_5 3626 hfBTB 03261 13 5 3   Possibly 
TS4_64_5 3951 hfBTB 05541 11 24 19 Yes Yes Possibly 
TS4_64_5 3978 hfBTB 05727 17 0 1   Possibly 
TS4_64_4 4105 hfBTB 06669 6 20 2 Yes  No 
TS4_64_4 4321 hfBTB 08347 30 56 62 Yes Yes Possibly 
TS4_64_4 5173 hfCD 00513 0 16 0 Yes  No 
TS4_64_4 5422 hfCD 03421 29 44 28 Yes Yes Possibly 
TS4_64_4 5499 hfCD 04455 0 8 12  Yes No 
TS4_64_4 5506 hfCD 04510 20 23 15 Yes Yes Possibly 
TS4_64_4 5833 hfCD 08635 33 42 29 Yes Yes Possibly 
TS4_64_4 6247 hfDFP 00003 25 31 23 Yes Yes Possibly 
TS4_64_4 6461 hfDP 01920 12 13 10 Yes Yes Possibly 
TS4_64_5 6480 hfDSHS 00075 15 11 9 Yes Yes Possibly 
TS4_64_4 6875 hfGK 03162 31 32 26 Yes Yes Possibly 
TS4_64_4 7386 hfHTS 01930 14 23 17 Yes Yes Possibly 
TS4_64_4 7512 hfHTS 02571 0 26 0 Yes  No 
TS4_64_4 8440 hfHTS 08202 23 34 23 Yes Yes Possibly 
TS4_64_4 9048 hfHTS 11969 0 16 0 Yes  No 
TS4_64_5 9504 hfJFD 00823 0 8 12 Yes Yes No 
TS4_64_4 9621 hfJFD 01902 13 9 9   Possibly 
TS4_64_4 10041 hfKM 00407 10 16 11 Yes Yes Possibly 
TS4_64_4 10063 hfKM 00585 4 24 2 Yes  No 
TS4_64_4 10403 hfKM 03417 7 20 5 Yes  No 
TS4_64_4 10537 hfKM 04403 0 6 16  Yes No 
TS4_64_4 10764 hfKM 06044 25 31 23 Yes Yes Possibly 
TS4_64_5 10878 hfKM 06828 14 14 14 Yes Yes Possibly 
TS4_64_5 10885 hfKM 06897 9 12 8 Yes Yes Possibly 
TS4_64_4 11044 hfKM 08103 9 15 9 Yes  No 
TS4_64_5 11133 hfKM 08617 16 16 13 Yes Yes Possibly 
TS4_64_4 11164 hfKM 08832 32 16 9 Yes  Possibly 
TS4_64_5 11250 hfKM 09319 9 6 5   Possibly 
TS4_64_4 11614 hfMWP 00404 17 22 16 Yes Yes Possibly 
TS4_64_5 11822 hfNRB 00390 15 11 10 Yes Yes Possibly 
TS4_64_4 12000 hfNRB 02920 0 20 26 Yes Yes No 
TS4_64_4 12007 hfNRB 03047 14 18 9 Yes  Possibly 
TS4_64_4 12234 hfPD 00323 3 16 1 Yes  No 
TS4_64_4 12251 hfPD 00407 26 29 23 Yes Yes Possibly 










TS4_64_5 12803 hfRF 01744 5 16 16 Yes Yes No 
TS4_64_4 12868 hfRF 02895 10 15 12 Yes Yes Possibly 
TS4_64_4 14117 hfS 00540 32 31 25 Yes Yes Possibly 
TS4_64_4 14129 hfS 01394 2 18 1 Yes  No 
TS4_64_4 14244 hfS 05363 6 35 17 Yes Yes No 
TS4_64_4 14447 hfS 12623 25 34 23 Yes Yes Possibly 
TS4_64_4 14528 hfS 14125 0 16 0 Yes  No 
TS4_64_4 14874 hfSCR 01008 30 32 28 Yes Yes Possibly 
TS4_64_4 15309 hfSEW 02839 19 21 21 Yes Yes Possibly 
TS4_64_4 15360 hfSEW 03401 4 44 2 Yes  No 
TS4_64_4 15393 hfSEW 03591 12 14 12 Yes Yes Possibly 
TS4_64_5 16217 hfSPB 00506 19 11 9 Yes Yes Possibly 
TS4_64_5 16236 hfSPB 00625 10 8 4 Yes  Possibly 
TS4_64_4 16599 hfSPB 03238 14 18 14 Yes Yes Possibly 
TS4_64_5 16718 hfSPB 04137 9 8 6 Yes  Possibly 
TS4_64_4 16756 hfSPB 04438 19 28 17 Yes Yes Possibly 
 
TS5 DHFR assay 





TS5_71_2 510  0 0 74  Yes No 
TS5_71_2 3040 hfAW 00264 12 16 16 Yes Yes Possibly 
TS5_71_2 3594 hfBTB 02990 14 8 16 Yes Yes No 
TS5_71_2 3892 hfBTB 05160 0 17 42  Yes Possibly 
TS5_71_2 3978 hfBTB 05727 27 31 43 Yes Yes Possibly 
TS5_71_2 4321 hfBTB 08347 54 25 58 Yes Yes Possibly 
TS5_71_3 4321 hfBTB 08347 16 10 8 Yes Yes Possibly 
TS5_71_2 4606 hfBTB 10539 38 0 0 Yes  No 
TS5_71_2 4655 hfBTB 11167 38 15 40 Yes Yes Possibly 
TS5_71_2 4699 hfBTB 11765 30 18 24 Yes Yes Possibly 
TS5_71_2 4880 hfBTB 13766 42 28 43 Yes Yes Possibly 
TS5_71_2 4939 hfBTB 14154 46 9 16 Yes Yes No 
TS5_71_2 5322 hfCD 02264 35 24 37 Yes Yes Possibly 
TS5_71_2 5397 hfCD 03092 38 0 18 Yes Yes No 
TS5_71_2 5422 hfCD 03421 27 24 36 Yes Yes Possibly 
TS5_71_2 5499 hfCD 04455 0 0 42  Yes No 
TS5_71_2 6083 hfCD 10740 0 0 12  Yes No 
TS5_71_2 6480 hfDSHS 00075 30 32 32 Yes Yes Possibly 
TS5_71_2 6600 hfEN 00275 44 0 0 Yes  No 
TS5_71_2 6923 hfGK 03531 30 0 13 Yes Yes No 










TS5_71_2 7145 hfHTS 00480 58 0 0 Yes  No 
TS5_71_2 8286 hfHTS 07134 48 6 46 Yes Yes No 
TS5_71_2 8838 hfHTS 10391 36 0 0 Yes  No 
TS5_71_2 9444 hfJFD 00261 7 0 12  Yes No 
TS5_71_2 9499 hfJFD 00787 10 10 22 Yes Yes Possibly 
TS5_71_3 9504 hfJFD 00823 0 8 10  Yes Possibly 
TS5_71_2 9976 hfJP 00899 44 14 16 Yes Yes Possibly 
TS5_71_2 11133 hfKM 08617 27 30 47 Yes Yes Possibly 
TS5_71_2 11164 hfKM 08832 31 3 10 Yes Yes No 
TS5_71_2 11250 hfKM 09319 34 23 34 Yes Yes Possibly 
TS5_71_2 12054 hfNRB 03723 7 6 10  Yes No 
TS5_71_2 12395 hfRB 00158 24 24 32 Yes Yes Possibly 
TS5_71_2 12706 hfRF 00305 58 0 0 Yes  No 
TS5_71_3 12803 hfRF 01744 4 10 10  Yes Possibly 
TS5_71_2 12830 hfRF 02175 7 7 37  Yes No 
TS5_71_2 12868 hfRF 02895 9 7 22  Yes No 
TS5_71_2 12923 hfRF 03874 48 16 1 Yes  Possibly 
TS5_71_2 13162 hfRH 00731 30 6 38 Yes Yes No 
TS5_71_2 14244 hfS 05363 1 17 11  Yes Possibly 
TS5_71_2 14342 hfS 09668 56 8 17 Yes Yes No 
TS5_71_2 15179 hfSEW 01952 44 0 10 Yes Yes No 
TS5_71_2 15182 hfSEW 01975 46 0 17 Yes Yes No 
TS5_71_2 15469 hfSEW 03989 46 16 15 Yes Yes Possibly 
TS5_71_2 16207 hfSPB 00432 5 8 24  Yes No 
TS5_71_2 16213 hfSPB 00471 29 30 40 Yes Yes Possibly 
TS5_71_2 16222 hfSPB 00523 58 2 33 Yes Yes No 
TS5_71_2 16250 hfSPB 00828 22 0 0 Yes  No 
TS5_71_2 16252 hfSPB 00832 36 0 9 Yes  No 
TS5_71_2 16486 hfSPB 02590 14 0 0 Yes  No 
TS5_71_2 16490 hfSPB 02620 23 27 42 Yes Yes Possibly 
TS5_71_2 16830 hfSPB 05131 12 18 34 Yes Yes Possibly 





TS6 DHFR assay 
 Eve ID Maybridge 
ID 





TS6_c’pick 510  0 76 0 Yes  No 
TS6_c’pick 516  0 58 14 Yes Yes No 
TS6_c’pick 978  0 80 80 Yes Yes No 
TS6_77_8 978  0 24 2 Yes  No 
TS6_77_10 978  0 18 0 Yes  No 
TS6_77_11 978  0 30 4 Yes  No 
TS6_77_14 978  0 40 18 Yes Yes No 
TS6_77_15 978  0 40 14 Yes Yes No 
TS6_c’pick 3143 hfAW 00846 21 66 22 Yes Yes Possibly 
TS6_77_8 3259 hfBR 00086 8 0 7   Possibly 
TS6_77_7 3466 hfBTB 02152 16 36 18 Yes Yes Possibly 
TS6_77_16 3466 hfBTB 02152 8 8 8 Yes Yes Possibly 
TS6_c’pick 3548 hfBTB 02678 0 18 0 Yes  No 
TS6_77_7 3594 hfBTB 02990 8 30 16 Yes Yes No 
TS6_77_7 3740 hfBTB 04150 0 22 52 Yes Yes No 
TS6_77_5 3947 hfBTB 05522 17 6 17  Yes Possibly 
TS6_77_10 3951 hfBTB 05541 18 8 9 Yes Yes Possibly 
TS6_77_16 3951 hfBTB 05541 13 5 7   Possibly 
TS6_77_7 3978 hfBTB 05727 14 56 15 Yes Yes Possibly 
TS6_77_16 3978 hfBTB 05727 8 7 7   Possibly 
TS6_77_7 4584 hfBTB 10320 16 25 19 Yes Yes Possibly 
TS6_77_7 4662 hfBTB 11323 9 80 14 Yes Yes No 
TS6_77_7 4769 hfBTB 12704 0 0 26  Yes No 
TS6_77_3 4867 hfBTB 13657 14 46 8 Yes  Possibly 
TS6_77_10 4879 hfBTB 13762 12 1 0   Possibly 
TS6_77_10 4939 hfBTB 14154 8 0 0   Possibly 
TS6_77_7 5422 hfCD 03421 29 44 23 Yes Yes Possibly 
TS6_77_10 5422 hfCD 03421 0 0 16  Yes No 
TS6_77_8 5499 hfCD 04455 0 0 12  Yes No 
TS6_c’pick 5678 hfCD 06694 16 18 16 Yes Yes Possibly 
TS6_77_3 5678 hfCD 06694 16 24 16 Yes Yes Possibly 
TS6_77_16 5678 hfCD 06694 11 12 11 Yes Yes Possibly 
TS6_77_7 5829 hfCD 08585 0 72 0 Yes  No 
TS6_77_7 5833 hfCD 08635 30 36 21 Yes Yes Possibly 
TS6_77_7 5884 hfCD 09120 0 8 42  Yes No 
TS6_77_3 6049 hfCD 10467 12 0 18  Yes Possibly 
TS6_77_8 6480 hfDSHS 
00075 
12 9 12 Yes Yes Possibly 
TS6_77_7 7091 hfHTS 00223 0 22 0 Yes  No 
TS6_77_7 7283 hfHTS 01369 0 38 0 Yes  No 
TS6_77_7 7352 hfHTS 01717 10 13 8 Yes  Possibly 










TS6_77_7 8028 hfHTS 05561 0 14 32 Yes Yes No 
TS6_77_7 8751 hfHTS 09910 0 58 0 Yes  No 
TS6_77_7 8766 hfHTS 09988 0 80 2 Yes  No 
TS6_77_15 8853 hfHTS 10441 0 0 8  Yes No 
TS6_77_7 9082 hfHTS 12152 2 80 14 Yes Yes No 
TS6_c’pick 9156 hfHTS 12446 2 0 18  Yes No 
TS6_77_4 9156 hfHTS 12446 0 0 14  Yes No 
TS6_77_7 9186 hfHTS 12551 0 80 0 Yes  No 
TS6_77_4 9286 hfHTS 12958 20 0 8   Possibly 
TS6_77_5 9348 hfHTS 13283 8 2 14  Yes No 
TS6_77_4 9479 hfJFD 00597 0 36 0 Yes  No 
TS6_77_7 9499 hfJFD 00787 8 80 10 Yes Yes No 
TS6_77_16 9499 hfJFD 00787 10 10 10 Yes Yes Possibly 
TS6_77_7 9504 hfJFD 00823 20 44 60 Yes Yes Possibly 
TS6_77_8 9504 hfJFD 00823 0 8 28 Yes Yes No 
TS6_77_7 9525 hfJFD 00979 0 80 0 Yes  No 
TS6_77_7 9559 hfJFD 01325 0 68 0 Yes  No 
TS6_77_7 9762 hfJFD 02848 0 30 16 Yes Yes No 
TS6_77_7 9843 hfJFD 03375 0 78 18 Yes Yes No 
TS6_77_7 9853 hfJFD 03520 8 8 11  Yes No 
TS6_77_7 9892 hfJFD 03913 13 26 14 Yes Yes Possibly 
TS6_77_7 10371 hfKM 03205 0 80 76 Yes Yes No 
TS6_77_7 10655 hfKM 05251 0 62 0 Yes  No 
TS6_77_4 10684 hfKM 05413 0 24 6 Yes  No 
TS6_77_7 10708 hfKM 05576 12 74 52 Yes Yes Possibly 
TS6_77_7 10709 hfKM 05590 0 60 52 Yes Yes No 
TS6_77_7 10737 hfKM 05853 0 30 0 Yes  No 
TS6_77_7 10838 hfKM 06626 21 80 31 Yes Yes Possibly 
TS6_77_3 10874 hfKM 06811 15 11 8 Yes  Possibly 
TS6_77_7 10878 hfKM 06828 46 56 43 Yes Yes Possibly 
TS6_c’pick 10879 hfKM 06831 0 30 1 Yes  No 
TS6_77_7 10974 hfKM 07711 0 78 0 Yes  No 
TS6_77_7 11133 hfKM 08617 30 46 19 Yes Yes Possibly 
TS6_77_8 11250 hfKM 09319 12 2 5   Possibly 
TS6_77_7 11663 hfMWP 00824 0 44 3 Yes  No 
TS6_c’pick 11706 hfMWP 01127 0 74 60 Yes Yes No 
TS6_77_16 11783 hfNRB 00102 13 12 12 Yes Yes Possibly 
TS6_77_8 11822 hfNRB 00390 8 4 8  Yes Possibly 
TS6_77_3 12017 hfNRB 03257 0 16 0 Yes  No 
TS6_77_7 12054 hfNRB 03723 7 64 9 Yes  No 
TS6_77_7 12111 hfNRB 04514 0 78 0 Yes  No 









TS6_77_7 12588 hfRDR 02635 0 70 24 Yes Yes No 
TS6_77_7 12803 hfRF 01744 16 36 42 Yes Yes Possibly 
TS6_77_8 12803 hfRF 01744 4 4 16  Yes No 
TS6_c’pick 12830 hfRF 02175 19 22 33 Yes Yes Possibly 
TS6_77_4 12830 hfRF 02175 23 60 36 Yes Yes Possibly 
TS6_77_3 12913 hfRF 03548 10 80 17 Yes Yes Possibly 
TS6_77_7 13003 hfRF 04999 0 29 28 Yes Yes No 
TS6_77_7 13015 hfRF 05142 9 28 8 Yes  No 
TS6_77_3 13485 hfRJC 00408 8 16 26 Yes Yes No 
TS6_77_7 13664 hfRJC 02246 0 22 28 Yes Yes No 
TS6_77_7 14021 hfRJF 00951 0 80 14 Yes Yes No 
TS6_77_7 14238 hfS 05244 32 46 26 Yes Yes Possibly 
TS6_77_7 14244 hfS 05363 14 48 19 Yes Yes Possibly 
TS6_77_7 14246 hfS 05379 0 56 2 Yes  No 
TS6_77_7 14329 hfS 08684 0 2 28  Yes No 
TS6_77_7 14575 hfS 14676 0 56 0 Yes  No 
TS6_c’pick 14576 hfS 14685 0 30 0 Yes  No 
TS6_77_4 14952 hfSEW 00102 18 62 8 Yes  Possibly 
TS6_77_16 15254 hfSEW 02484 8 4 6   Possibly 
TS6_77_7 15497 hfSEW 04168 8 20 21 Yes Yes No 
TS6_77_7 15761 hfSEW 05596 0 70 0 Yes  No 
TS6_77_7 16169 hfSP 01458 39 46 39 Yes Yes Possibly 
TS6_77_15 16169 hfSP 01458 10 14 12 Yes Yes Possibly 
TS6_77_4 16172 hfSP 01461 0 12 4 Yes  No 
TS6_77_7 16211 hfSPB 00468 0 30 60 Yes Yes No 
TS6_77_7 16212 hfSPB 00470 10 34 62 Yes Yes Possibly 
TS6_77_16 16213 hfSPB 00471 16 16 16 Yes Yes Possibly 
TS6_77_8 16213 hfSPB 00471 9 1 5   Possibly 
TS6_77_10 16236 hfSPB 00625 8 1 5   Possibly 
TS6_77_4 16349 hfSPB 01622 0 32 0 Yes  No 
TS6_77_4 16350 hfSPB 01624 0 32 0 Yes  No 
TS6_c’pick 16490 hfSPB 02620 19 78 22 Yes Yes Possibly 
TS6_77_4 16490 hfSPB 02620 18 78 12 Yes Yes Possibly 
TS6_77_16 16490 hfSPB 02620 14 17 13 Yes Yes Possibly 
TS6_c’pick 16499 hfSPB 02669 0 62 0 Yes  No 
TS6_77_4 16499 hfSPB 02669 0 62 0 Yes  No 
TS6_77_4 16556 hfSPB 02947 0 0 18  Yes No 
TS6_77_7 16687 hfSPB 03954 0 55 3 Yes  No 
TS6_77_16 16718 hfSPB 04137 8 8 8 Yes Yes Possibly 
TS6_77_3 16830 hfSPB 05131 23 80 38 Yes Yes Possibly 
TS6_77_7 16914 hfSPB 05912 33 38 26 Yes Yes Possibly 
TS6_77_5 17095 hfSPB 07211 32 24 32 Yes Yes Possibly 










TS6_77_3 17167 hfSPB 07894 31 80 54 Yes Yes Possibly 
TS6_77_4 17170 hfSPB 07935 30 80 49 Yes Yes Possibly 
TS6_77_5 17217 hfSPB 08198 45 47 46 Yes Yes Possibly 
TS6_77_4 17226 hfSPB 08252 27 80 32 Yes Yes Possibly 
TS6_77_16 17226 hfSPB 08252 10 12 12 Yes Yes Possibly 
TS6_77_7 17302 hfTL 00165 0 54 0 Yes  No 
TS6_77_7 17329 hfXAX 00025 5 80 13 Yes Yes No 
TS6_77_16 18008 SMSPB06943SC 8 10 10 Yes Yes Possibly 
TS6_c’pick 18010 SMHTS12151SC 13 80 17 Yes Yes Possibly 
TS6_c’pick 18011 SMHTS12147SC 10 80 15 Yes Yes Possibly 
TS6_c’pick 18012 SMHTS07613SC 0 58 0 Yes  No 
TS6_c’pick 18014 SMHTS12150SC 48 80 44 Yes Yes Possibly 
 
TS7 DHFR assay 





TS7_80_3 978  0 0 28  Yes No 
TS7_80_4 4321 hfBTB 08347 16 12 20 Yes Yes Possibly 
TS7_80_6 4321 hfBTB 08347 12 10 14 Yes Yes Possibly 
TS7_80_3 4435 hfBTB 09154 0 0 18  Yes No 
TS7_80_6 4939 hfBTB 14154 8 0 8  Yes Possibly 
TS7_80_6 5403 hfCD 03158 16 16 8 Yes Yes Possibly 
TS7_80_3 5829 hfCD 08585 0 0 24  Yes No 
TS7_80_3 5833 hfCD 08635 12 8 12 Yes Yes Possibly 
TS7_80_3 6173 hfCD 11507 4 0 34  Yes No 
TS7_80_6 6173 hfCD 11507 12 5 8  Yes Possibly 
TS7_80_3 6480 hfDSHS 00075 8 8 3 Yes  Possibly 
TS7_80_3 6875 hfGK 03162 8 0 24  Yes Possibly 
TS7_80_3 8440 hfHTS 08202 3 0 12  Yes No 
TS7_80_3 9444 hfJFD 00261 0 0 22  Yes No 
TS7_80_3 9499 hfJFD 00787 0 0 26  Yes No 
TS7_80_6 9499 hfJFD 00787 9 9 3 Yes  Possibly 
TS7_80_3 9504 hfJFD 00823 0 8 30 Yes Yes No 
TS7_80_4 9504 hfJFD 00823 0 8 18 Yes Yes No 
TS7_80_6 9504 hfJFD 00823 0 8 22 Yes Yes No 
TS7_80_3 9525 hfJFD 00979 0 0 22  Yes No 
TS7_80_3 9876 hfJFD 03674 0 0 22  Yes No 
TS7_80_3 10371 hfKM 03205 2 16 22 Yes Yes No 
TS7_80_3 10608 hfKM 04905 0 4 10  Yes No 
TS7_80_3 10885 hfKM 06897 1 1 9  Yes No 
TS7_80_3 11636 hfMWP 00602 0 0 26  Yes No 










TS7_80_4 12803 hfRF 01744 6 16 0 Yes  No 
TS7_80_6 13361 hfRH 01876 26 32 13 Yes Yes Possibly 
TS7_80_3 13361 hfRH 01876 12 8 4 Yes  Possibly 
TS7_80_3 14246 hfS 05379 0 0 22  Yes No 
TS7_80_3 14371 hfS 10607 18 22 3 Yes  Possibly 
TS7_80_3 15254 hfSEW 02484 8 6 14  Yes Possibly 
TS7_80_6 15254 hfSEW 02484 9 4 16  Yes Possibly 
TS7_80_3 15667 hfSEW 05115 0 0 8  Yes No 
TS7_80_3 16211 hfSPB 00468 0 2 18  Yes No 
TS7_80_6 16211 hfSPB 00468 0 0 14  Yes No 
TS7_80_3 16212 hfSPB 00470 0 4 20  Yes No 
TS7_80_6 16212 hfSPB 00470 0 0 18  Yes No 
TS7_80_3 16217 hfSPB 00506 14 12 24 Yes Yes Possibly 
TS7_80_3 16219 hfSPB 00514 0 0 10  Yes No 
TS7_80_3 16499 hfSPB 02669 0 0 16  Yes No 
TS7_80_6 16718 hfSPB 04137 14 14 8 Yes Yes Possibly 
TS7_80_3 16718 hfSPB 04137 5 8 2 Yes  No 
TS7_80_6 16724 hfSPB 04186 10 8 6 Yes  Possibly 
TS7_80_3 16830 hfSPB 05131 2 1 26  Yes No 
TS7_80_3 17167 hfSPB 07894 4 2 28  Yes No 
TS7_80_3 17182 hfSPB 07993 0 0 16  Yes No 
TS7_80_3 17329 hfXAX 00025 0 0 36  Yes No 
TS7_80_3 18010 SMHTS12151SC 0 0 24  Yes No 
TS7_80_6 18010 SMHTS12151SC 5 8 0 Yes  No 
TS7_80_6 18011 SMHTS12147SC 22 22 0 Yes  Possibly 
TS7_80_3 18012 SMHTS07613SC 0 0 16  Yes No 
TS7_80_3 18014 SMHTS12150SC 0 0 24  Yes No 
 
NMT assay 1 





NMT_78_2 3259 hfBR 00086 1 8 6 Yes  No 
NMT_78_2 3320 hfBTB 00809 0 16 8 Yes Yes No 
NMT_78_2 3378 hfBTB 01383 0 30 32 Yes Yes No 
NMT_78_4 5422 hfCD 03421 0 2 30  Yes No 
NMT_78_2 5695 hfCD 06957 0 24 22 Yes Yes No 
NMT_78_2 5699 hfCD 07074 0 12 0 Yes  No 
NMT_78_2 5971 hfCD 09895 0 22 0 Yes  No 
NMT_78_2 6254 hfDFP 00054 0 12 10 Yes Yes No 
NMT_78_2 6353 hfDP 00892 3 12 12 Yes Yes No 










NMT_78_2 8028 hfHTS 05561 0 32 30 Yes Yes No 
NMT_78_6 9046 hfHTS 11966 18 0 18  Yes Possibly 
NMT_78_6 9080 hfHTS 12146 14 0 8  Yes Possibly 
NMT_78_6 9081 hfHTS 12148 0 12 0 Yes  No 
NMT_78_2 9694 hfJFD 02390 0 26 10 Yes Yes No 
NMT_78_4 9762 hfJFD 02848 14 14 20 Yes Yes Possibly 
NMT_78_2 9877 hfJFD 03675 0 14 0 Yes  No 
NMT_78_2 10708 hfKM 05576 0 10 3 Yes  No 
NMT_78_4 10838 hfKM 06626 0 8 0 Yes  No 
NMT_78_2 11133 hfKM 08617 5 28 26 Yes Yes No 
NMT_78_2 12506 hfRDR 01446 6 34 36 Yes Yes No 
NMT_78_2 12803 hfRF 01744 4 9 9 Yes Yes No 
NMT_78_4 12803 hfRF 01744 0 8 4 Yes  No 
NMT_78_2 12830 hfRF 02175 0 1 8  Yes No 
NMT_78_2 12868 hfRF 02895 0 10 8 Yes Yes No 
NMT_78_2 13003 hfRF 04999 3 24 16 Yes Yes No 
NMT_78_2 13664 hfRJC 02246 0 24 24 Yes Yes No 
NMT_78_2 13687 hfRJC 02395 0 4 16  Yes No 
NMT_78_2 14238 hfS 05244 5 14 8 Yes Yes No 
NMT_78_2 14345 hfS 09767 0 16 14 Yes Yes No 
NMT_78_2 16211 hfSPB 00468 0 18 28 Yes Yes No 
NMT_78_2 16212 hfSPB 00470 0 22 28 Yes Yes No 
NMT_78_2 16217 hfSPB 00506 5 26 30 Yes Yes No 
NMT_78_2 16718 hfSPB 04137 5 22 20 Yes Yes No 
NMT_78_2 16914 hfSPB 05912 6 16 12 Yes Yes No 
NMT_78_2 17196 hfSPB 08060 0 28 20 Yes Yes No 
NMT_78_2 17399 hfXBX 00332 0 12 6 Yes  No 
NMT_78_2 18004 SMSPB05423SC 0 22 0 Yes  No 
NMT_78_2 18009 SMSPB05424SC 0 8 0 Yes  No 
NMT_78_2 18010 SMHTS12151SC 0 24 12 Yes Yes No 
NMT_78_6 18010 SMHTS12151SC 0 12 0 Yes  No 
NMT_78_2 18011 SMHTS12147SC 0 36 26 Yes Yes No 
NMT_78_6 18011 SMHTS12147SC 0 20 0 Yes  No 






NMT assay 2 





NMT_79_2 3740 hfBTB 04150 0 10 22 Yes Yes No 
NMT_79_2 3951 hfBTB 05541 22 0 0   Possibly 
NMT_79_2 3999 hfBTB 05867 0 0 22  Yes No 
NMT_79_2 4495 hfBTB 09584 6 2 20  Yes No 
NMT_79_2 4496 hfBTB 09587 4 2 18  Yes No 
NMT_79_2 5499 hfCD 04455 0 0 12  Yes No 
NMT_79_2 5699 hfCD 07074 0 0 12  Yes No 
NMT_79_2 5809 hfCD 08381 16 24 22 Yes Yes Possibly 
NMT_79_2 5833 hfCD 08635 4 7 8  Yes No 
NMT_79_2 7107 hfHTS 00290 8 0 8  Yes Possibly 
NMT_79_2 8028 hfHTS 05561 0 4 26  Yes No 
NMT_79_6 9046 hfHTS 11966 16 0 14  Yes Possibly 
NMT_79_6 9080 hfHTS 12146 12 0 8  Yes Possibly 
NMT_79_6 9082 hfHTS 12152 10 0 0   Possibly 
NMT_79_2 9504 hfJFD 00823 8 20 34 Yes Yes Possibly 
NMT_79_2 9588 hfJFD 01579 2 0 12  Yes No 
NMT_79_2 10121 hfKM 01046 0 0 12  Yes No 
NMT_79_2 10764 hfKM 06044 2 0 8  Yes No 
NMT_79_2 10838 hfKM 06626 4 8 6 Yes  No 
NMT_79_2 11589 hfMWP 00123 8 6 16  Yes Possibly 
NMT_79_2 12005 hfNRB 03005 0 0 14  Yes No 
NMT_79_2 12630 hfRDR 03524 0 10 10 Yes Yes No 
NMT_79_2 12803 hfRF 01744 6 0 8  Yes No 
NMT_79_2 12978 hfRF 04603 0 0 10  Yes No 
NMT_79_2 13059 hfRH 00058 0 0 8  Yes No 
NMT_79_2 13664 hfRJC 02246 0 16 26 Yes Yes No 
NMT_79_2 14345 hfS 09767 0 4 14  Yes No 
NMT_79_2 14371 hfS 10607 14 20 16 Yes Yes Possibly 
NMT_79_2 15497 hfSEW 04168 0 0 22  Yes No 
NMT_79_2 15656 hfSEW 04978 0 8 28 Yes Yes No 
NMT_79_2 16211 hfSPB 00468 0 6 24  Yes No 
NMT_79_2 16212 hfSPB 00470 0 10 24 Yes Yes No 
NMT_79_2 17006 hfSPB 06520 8 8 14 Yes Yes Possibly 





PGK assay 1 





PGK1_72_2 3259 hfBR 00086 24 22 32 Yes Yes Possibly 
PGK1_72_2 3594 hfBTB 02990 14 16 16 Yes Yes Possibly 
PGK1_72_2 3951 hfBTB 05541 22 27 62 Yes Yes Possibly 
PGK1_72_2 4105 hfBTB 06669 0 14 0 Yes  No 
PGK1_72_2 4655 hfBTB 11167 16 17 48 Yes Yes Possibly 
PGK1_72_2 5403 hfCD 03158 33 37 25 Yes Yes Possibly 
PGK1_72_2 5422 hfCD 03421 31 32 31 Yes Yes Possibly 
PGK1_72_2 5595 hfCD 05564 44 20 31 Yes Yes Possibly 
PGK1_72_2 5909 hfCD 09340 0 0 30  Yes No 
PGK1_72_2 6173 hfCD 11507 24 16 16 Yes Yes Possibly 
PGK1_72_4 6777 hfGK 01974 1 0 16  Yes No 
PGK1_72_2 7259 hfHTS 01223 1 16 0 Yes  No 
PGK1_72_2 8028 hfHTS 05561 0 0 42  Yes No 
PGK1_72_2 8029 hfHTS 05567 0 0 28  Yes No 
PGK1_72_2 9203 hfHTS 12635 32 32 32 Yes Yes Possibly 
PGK1_72_2 9504 hfJFD 00823 0 16 16 Yes Yes No 
PGK1_72_2 9912 hfJFD 03992 2 0 22  Yes No 
PGK1_72_2 10294 hfKM 02595 0 12 0 Yes  No 
PGK1_72_2 10664 hfKM 05302 32 34 35 Yes Yes Possibly 
PGK1_72_2 10764 hfKM 06044 24 27 23 Yes Yes Possibly 
PGK1_72_2 10838 hfKM 06626 19 38 32 Yes Yes Possibly 
PGK1_72_4 10838 hfKM 06626 1 8 3 Yes  No 
PGK1_72_2 11044 hfKM 08103 9 15 10 Yes Yes No 
PGK1_72_2 11133 hfKM 08617 35 36 38 Yes Yes Possibly 
PGK1_72_2 12803 hfRF 01744 25 36 44 Yes Yes Possibly 
PGK1_72_2 12920 hfRF 03771 78 17 4 Yes  Possibly 
PGK1_72_2 13066 hfRH 00102 0 34 0 Yes  No 
PGK1_72_2 13309 hfRH 01609 14 16 26 Yes Yes Possibly 
PGK1_72_2 13670 hfRJC 02296 0 48 50 Yes Yes No 
PGK1_72_2 13894 hfRJC 03897 2 16 0 Yes  No 
PGK1_72_2 14488 hfS 13590 0 0 24  Yes No 
PGK1_72_2 14629 hfS 15380 42 50 40 Yes Yes Possibly 
PGK1_72_2 14809 hfSCR 00731 12 30 16 Yes Yes Possibly 
PGK1_72_2 15283 hfSEW 02660 0 0 26  Yes No 
PGK1_72_2 15394 hfSEW 03596 0 0 22  Yes No 
PGK1_72_2 16211 hfSPB 00468 2 22 32 Yes Yes No 
PGK1_72_2 16212 hfSPB 00470 2 10 46 Yes Yes No 
PGK1_72_2 16213 hfSPB 00471 30 31 32 Yes Yes Possibly 
PGK1_72_2 16490 hfSPB 02620 25 27 31 Yes Yes Possibly 
PGK1_72_2 17069 hfSPB 06981 2 21 16 Yes Yes No 
PGK1_72_2 17170 hfSPB 07935 19 32 32 Yes Yes Possibly 




PGK assay 2 





PGK2_74_4 510  24 0 18  Yes Possibly 
PGK2_74_4 516  20 0 12  Yes Possibly 
PGK2_74_4 3259 hfBR 00086 14 0 8  Yes Possibly 
PGK2_74_2 3466 hfBTB 02152 0 4 8  Yes No 
PGK2_74_2 3594 hfBTB 02990 0 8 8 Yes Yes No 
PGK2_74_2 3740 hfBTB 04150 0 2 8  Yes No 
PGK2_74_2 3951 hfBTB 05541 6 22 23 Yes Yes No 
PGK2_74_2 4344 hfBTB 08470 0 0 10  Yes No 
PGK2_74_4 4584 hfBTB 10320 25 0 20  Yes Possibly 
PGK2_74_4 4585 hfBTB 10323 26 0 22  Yes Possibly 
PGK2_74_2 4655 hfBTB 11167 4 14 0 Yes  No 
PGK2_74_2 6134 hfCD 11234 2 0 8  Yes No 
PGK2_74_4 6173 hfCD 11507 10 0 14  Yes Possibly 
PGK2_74_4 6365 hfDP 00986 10 0 10  Yes Possibly 
PGK2_74_2 7107 hfHTS 00290 0 8 12 Yes Yes No 
PGK2_74_2 8028 hfHTS 05561 0 0 10  Yes No 
PGK2_74_2 8029 hfHTS 05567 0 0 8  Yes No 
PGK2_74_2 9499 hfJFD 00787 10 0 0   Possibly 
PGK2_74_2 9504 hfJFD 00823 0 0 10  Yes No 
PGK2_74_4 10407 hfKM 03453 4 0 14  Yes No 
PGK2_74_2 10764 hfKM 06044 1 8 8 Yes Yes No 
PGK2_74_2 12201 hfPD 00168 0 0 12  Yes No 
PGK2_74_2 12506 hfRDR 01446 0 10 20 Yes Yes No 
PGK2_74_2 12803 hfRF 01744 12 16 13 Yes Yes Possibly 
PGK2_74_4 12803 hfRF 01744 16 2 16  Yes Possibly 
PGK2_74_2 12830 hfRF 02175 1 0 8  Yes No 
PGK2_74_2 13309 hfRH 01609 0 8 4 Yes  No 
PGK2_74_2 13670 hfRJC 02296 0 14 20 Yes Yes No 
PGK2_74_2 14371 hfS 10607 13 18 15 Yes Yes Possibly 
PGK2_74_2 14488 hfS 13590 0 0 12  Yes No 
PGK2_74_2 15661 hfSEW 04994 0 0 8  Yes No 
PGK2_74_2 16211 hfSPB 00468 0 0 8  Yes No 
PGK2_74_2 16212 hfSPB 00470 0 0 18  Yes No 





A.9  Confirmation: active JHCCL compounds  
DHFR TS3 assay 





TS3_63_7 20110 SM_JHU-520 11 12 16 Yes Yes Possibly 
TS3_63_7 20168 SM_JHU-904 8 8 22 Yes Yes Possibly 
TS3_63_2 20168 SM_JHU-904 16 0 15  Yes Possibly 
TS3_63_3 20248 SM_JHU-1305 10 16 36 Yes Yes Possibly 
TS3_63_7 20248 SM_JHU-1305 0 12 16 Yes Yes No 
TS3_63_2 20414 SM_JHU-2095 8 32 1 Yes  No 
TS3_63_7 20414 SM_JHU-2095 23 25 22 Yes Yes Possibly 
TS3_63_2 20484 SM_JHU-2524 13 58 46 Yes Yes Possibly 
TS3_63_2 21463 SM_JHU-9003 0 24 0 Yes  No 
 
DHFR TS4 assay 





TS4_64_6 20248 SM_JHU-1305 8 8 24 Yes Yes Possibly 
TS4_64_4 20516 SM_JHU-2766 0 4 12  Yes No 
TS4_64_4 20561 SM_JHU-3038 26 22 25 Yes Yes Possibly 
 
DHFR TS5 assay 





TS5_71_2 20110 SM_JHU-520 21 33 40 Yes Yes Possibly 
TS5_71_5 20110 SM_JHU-520 11 17 18 Yes Yes Possibly 
TS5_71_6 20110 SM_JHU-520 12 6 9  Yes No 
TS5_71_2 20168 SM_JHU-904 4 25 50  Yes Possibly 
TS5_71_5 20168 SM_JHU-904 7 22 26  Yes Possibly 
TS5_71_6 20168 SM_JHU-904 2 14 22  Yes Possibly 
TS5_71_3 20248 SM_JHU-1305 8 8 8 Yes Yes Possibly 
TS5_71_5 20248 SM_JHU-1305 8 10 16 Yes Yes Possibly 
TS5_71_6 20248 SM_JHU-1305 10 16 20 Yes Yes Possibly 
TS5_71_6 20414 SM_JHU-2095 14 21 19 Yes Yes Possibly 
TS5_71_2 20427 SM_JHU-2151 56 59 64 Yes Yes Possibly 
TS5_71_2 20561 SM_JHU-3038 16 12 18 Yes Yes Possibly 







DHFR TS6 assay 





TS6_77_11 20110 SM_JHU-520 17 11 14 Yes Yes Possibly 
TS6_77_14 20110 SM_JHU-520 16 13 16 Yes Yes Possibly 
TS6_c’pick 20141 SM_JHU-715 0 48 0 Yes  No 
TS6_77_11 20168 SM_JHU-904 12 14 26 Yes Yes Possibly 
TS6_77_16 20168 SM_JHU-904 14 13 18 Yes Yes Possibly 
TS6_77_14 20168 SM_JHU-904 4 3 18  Yes No 
TS6_c’pick 20245 SM_JHU-1293 0 40 0 Yes  No 
TS6_c’pick 20248 SM_JHU-1305 12 44 50 Yes Yes Possibly 
TS6_77_11 20248 SM_JHU-1305 8 16 16 Yes Yes Possibly 
TS6_77_14 20248 SM_JHU-1305 0 12 12 Yes Yes No 
TS6_c’pick 20414 SM_JHU-2095 6 30 8 Yes  No 
TS6_77_14 20414 SM_JHU-2095 20 24 24 Yes Yes Possibly 
TS6_77_16 20414 SM_JHU-2095 22 24 21 Yes Yes Possibly 
TS6_c’pick 20484 SM_JHU-2524 16 48 46 Yes Yes Possibly 
TS6_c’pick 20516 SM_JHU-2766 10 20 16 Yes Yes Possibly 
TS6_c’pick 20940 SM_JHU-5529 0 44 0 Yes  No 
TS6_c’pick 21389 SM_JHU-8509 0 80 80 Yes Yes No 
TS6_c’pick 21438 SM_JHU-8859 0 10 12 Yes Yes No 
TS6_c’pick 21463 SM_JHU-9003 0 12 0 Yes  No 
TS6_c’pick 21625 SM_JHU-10251 0 38 0 Yes  No 
TS6_c’pick 21658 SM_JHU-10450 20 40 23 Yes Yes Possibly 
TS6_77_14 21658 SM_JHU-10450 8 10 8 Yes Yes Possibly 
TS6_77_16 21658 SM_JHU-10450 8 8 6 Yes  Possibly 
TS6_77_11 21658 SM_JHU-10450 8 7 8  Yes Possibly 
TS6_77_16 21767 SM_JHU-12096 7 11 11 Yes Yes No 
TS6_c’pick 21767 SM_JHU-12096 8 9 12  Yes No 





DHFR TS7 assay 





TS7_80_4 20110 SM_JHU-520 8 8 0 Yes  Possibly 
TS7_80_6 20110 SM_JHU-520 22 20 0 Yes  Possibly 
TS7_80_3 20134 SM_JHU-657 20 12 0 Yes  Possibly 
TS7_80_4 20248 SM_JHU-1305 8 8 12 Yes Yes Possibly 
TS7_80_6 20248 SM_JHU-1305 0 8 10 Yes Yes No 
TS7_80_3 20449 SM_JHU-2317 40 40 0 Yes  Possibly 
TS7_80_3 20472 SM_JHU-2438 22 16 0 Yes  Possibly 
TS7_80_3 21619 SM_JHU-10190 40 40 16 Yes Yes Possibly 
TS7_80_6 21658 SM_JHU-10450 8 8 4 Yes  Possibly 
TS7_80_3 21767 SM_JHU-12096 0 0 16  Yes No 
TS7_80_6 21767 SM_JHU-12096 32 36 32 Yes Yes Possibly 
 
NMT assay 1 
 
 





NMT_78_6 20110 SM_JHU-520 14 8 8 Yes Yes Possibly 
NMT_78_4 20248 SM_JHU-1305 16 24 24 Yes Yes Possibly 
NMT_78_6 20248 SM_JHU-1305 4 18 12 Yes Yes No 
NMT_78_6 20414 SM_JHU-2095 16 19 19 Yes Yes Possibly 
NMT_78_2 20470 SM_JHU-2430 1 24 20 Yes Yes No 
NMT_78_2 20484 SM_JHU-2524 4 28 26 Yes Yes No 
NMT_78_2 20548 SM_JHU-2987 8 16 16 Yes Yes Possibly 
NMT_78_2 20626 SM_JHU-3353 0 32 2 Yes  No 
NMT_78_2 20633 SM_JHU-3415 0 10 0 Yes  No 
NMT_78_2 21006 SM_JHU-6047 0 32 0 Yes  No 
NMT_78_6 21006 SM_JHU-6047 0 40 30 Yes Yes No 
NMT_78_2 21400 SM_JHU-8555 1 20 14 Yes Yes No 
NMT_78_6 21658 SM_JHU-10450 6 8 7 Yes  No 




NMT assay 2 





NMT_79_6 20110 SM_JHU-520 16 11 11 Yes Yes Possibly 
NMT_79_6 20168 SM_JHU-904 3 0 17  Yes No 
NMT_79_2 20245 SM_JHU-1293 0 8 10 Yes Yes No 
NMT_79_6 20248 SM_JHU-1305 8 14 12 Yes Yes Possibly 
NMT_79_6 20414 SM_JHU-2095 20 21 20 Yes Yes Possibly 
NMT_79_2 20449 SM_JHU-2317 40 40 40 Yes Yes Possibly 
NMT_79_2 20472 SM_JHU-2438 26 24 20 Yes Yes Possibly 
NMT_79_2 20525 SM_JHU-2831 0 16 0 Yes  No 
NMT_79_2 20626 SM_JHU-3353 4 40 40 Yes Yes No 
NMT_79_6 21006 SM_JHU-6047 0 40 0 Yes  No 
NMT_79_2 21006 SM_JHU-6047 0 40 40 Yes Yes No 
NMT_79_2 21281 SM_JHU-7761 0 0 16  Yes No 
NMT_79_2 21390 SM_JHU-8513 10 8 10 Yes Yes Possibly 
NMT_79_2 21463 SM_JHU-9003 0 2 32  Yes No 
NMT_79_6 21658 SM_JHU-10450 8 8 8 Yes Yes Possibly 
NMT_79_6 21919  12 16 10 Yes Yes Possibly 
 
PGK assay 1 





PGK1_72_2 20070 SM_JHU-327 30 0 26  Yes Possibly 
PGK1_72_2 20110 SM_JHU-520 31 32 30 Yes Yes Possibly 
PGK1_72_2 20460 SM_JHU-2381 30 29 29 Yes Yes Possibly 
PGK1_72_2 20635 SM_JHU-3437 78 80 25 Yes Yes Possibly 
PGK1_72_2 20655 SM_JHU-3636 6 0 20  Yes No 
PGK1_72_2 20750 SM_JHU-4214 64 74 72 Yes Yes Possibly 
PGK1_72_2 21088 SM_JHU-6452 80 80 18 Yes Yes Possibly 
PGK1_72_2 21178 SM_JHU-7015 28 64 25 Yes Yes Possibly 
PGK1_72_2 21224 SM_JHU-7333 70 80 32 Yes Yes Possibly 
 
PGK assay 2 





PGK2_74_2 20110 SM_JHU-520 6 8 7 Yes  No 
PGK2_74_2 20134 SM_JHU-657 17 16 16 Yes Yes Possibly 
PGK2_74_2 20291 SM_JHU-1539 40 40 40 Yes Yes Possibly 
PGK2_74_2 20427 SM_JHU-2151 26 24 24 Yes Yes Possibly 
PGK2_74_2 20750 SM_JHU-4214 37 33 32 Yes Yes Possibly 
PGK2_74_2 21088 SM_JHU-6452 40 38 22 Yes Yes Possibly 























































































































































































































































































































Simulated Active Learning curves and rare category detection 
B.1 Active k-optimisation and SimplyGreedy learning curves B 2   
B.2 Pre-clustering learning curves B 19 
B.3 Rare category detection for B.1, last 5%/10% B 30 
B.4 Transfer Learning, with rare category detection comparison 
versus the SimplyGreedy curves 
B 39  
B.5 Deficiency results for combined Transfer Learning/preclustering 
strategy 
B 49 
B.6 Strain-by-strain analysis of Transfer Learning versus 
endogenous Active Learning algorithms 
B 55 
 
Descriptions and keys for the Active Learning curves and deficiency measurements are 




B.1 Active k-optimisation and SimplyGreedy learning curves 
TS3 PvDHFR 
 






































































TS6 PvDHFR (there were 8 other runs for each algorithm) 
 





























































































































Active k optimisation 
(#1 might have used 











































































































































































































































































































































































































































B.5 Deficiency results for combined Transfer Learning/preclustering strategy 
 





DHFR seeds NMT seeds 
Hs Pf Pv(TS6) Tb Tc Pv Tb Tc 
Pv 
DHFR-TS3 
 0.73  0.74 0.78 0.76 0.62 0.67 
PfR  0.73  0.92  0.77 0.82  
Tb DHFR-TS4  0.99 0.47  0.75 0.83  0.65 
Tc DHFR-TS5   0.55 0.77  0.63 0.63 0.57 
Pv 
DHFR-TS6 
   0.79 0.71 0.64 0.56 0.66 
Pf    0.86 0.55 0.60 0.66 0.60 
PvR DHFR-TS7  0.62  0.73  0.63 0.59 0.58 
Tb NMT-1  0.80 0.70 0.81 0.85   0.74 
Pv NMT-1  0.78 0.64 0.71 0.83 0.75  0.51 
Tc NMT-2  0.72 0.66 0.88 0.75 0.54 0.69  
Mean deficiency, all 
targets 
 0.77 0.60 0.88 0.75 0.68 0.65 0.62 
Mean of deficiencies: 0.70 
Mean of core PfDHFR/PvDHFR seed deficiencies: 0.73 
 
Table 2:  Rare category deficiencies (last 5%) for TL & preclustering (initial TS > 





DHFR seeds NMT seeds 
Hs Pf Pv(TS6) Tb Tc Pv Tb Tc 
Pv 
DHFR-TS3 
 0.60  0.64 0.42 0.56 0.40 0.54 
PfR  0.51  0.69  0.53 0.60  
Tb DHFR-TS4  0.60 0.69  0.46 0.59  0.51 
Tc DHFR-TS5   0.29 0.79   0.39 0.48 
Pv 
DHFR-TS6 
   0.76 0.41  0.53 0.56 
Pf    0.74 0.30  0.41 0.35 
PvR DHFR-TS7  0.46  0.58   0.40 0.48 
Tb NMT-1  0.63  0.74 0.53   0.54 
Pv NMT-1  0.62  0.72 0.62   0.52 
Tc NMT-2  0.65 0.59 0.63 0.65  0.53  
Mean deficiency, all 
targets 
 0.58 0.52 0.70 0.48 0.56 0.47 0.50 
Mean of deficiencies: 0.54 






Table 3:  Rare category deficiencies (last 10%) for TL & preclustering (initial TS > 




DHFR seeds NMT seeds 
Hs Pf Pv(TS6) Tb Tc Pv Tb Tc 
Pv 
DHFR-TS3 
 0.59  0.61 0.44 0.54 0.48 0.52 
PfR  0.50  0.68  0.54 0.58  
Tb DHFR-TS4  0.55 0.57  0.28 0.40  0.40 
Tc DHFR-TS5   0.42 0.78   0.45 0.38 
Pv 
DHFR-TS6 
   0.65 0.48  0.55 0.55 
Pf    0.71 0.38  0.42 0.40 
PvR DHFR-TS7  0.49  0.69   0.41 0.57 
Tb NMT-1  0.58  0.71 0.60   0.55 
Pv NMT-1  0.63  0.76 0.58   0.50 
Tc NMT-2  0.55 0.46 0.69 0.44  0.54  
Mean deficiency, all 
targets 
 0.56 0.48 0.70 0.46 0.49 0.49 0.48 
Mean of deficiencies: 0.52 
Mean of core PfDHFR/PvDHFR seed deficiencies: 0.53 
 




DHFR seeds NMT seeds 
Hs Pf Pv(TS6) Tb Tc Pv Tb Tc 
Pv 
DHFR-TS3 
 0.63 0.62      
PfR  0.65       
Tb DHFR-TS4  0.85       
Tc DHFR-TS5  0.47 0.54      
Pv 
DHFR-TS6 
        
Pf         
PvR DHFR-TS7  0.70 0.46      
Tb NMT-1  0.78 0.71      
Pv NMT-1  0.65 0.71      
Tc NMT-2  0.70 0.67      
Mean deficiency, all 
targets 
 
0.68 0.62     
 
Mean of deficiencies: 0.65 






Table 5: Rare category deficiencies (last 5%) for TL + preclustering (initial & body 




DHFR seeds NMT seeds 
Hs Pf Pv(TS6) Tb Tc Pv Tb Tc 
Pv 
DHFR-TS3 
 0.68 0.33      
PfR  0.53       
Tb DHFR-TS4  0.70       
Tc DHFR-TS5  0.41 0.28      
Pv 
DHFR-TS6 
        
Pf         
PvR DHFR-TS7  0.50 0.39      
Tb NMT-1  0.66 0.54      
Pv NMT-1  0.64 0.49      
Tc NMT-2  0.66 0.60      
Mean deficiency, all 
targets 
 0.60 0.44 
    
 
Mean of deficiencies: 0.52 
Mean of core PfDHFR/PvDHFR seed deficiencies: 0.58 
 
Table 6: Rare category deficiencies (last 10%) for TL + preclustering (initial & body 




DHFR seeds NMT seeds 
Hs Pf Pv(TS6) Tb Tc Pv Tb Tc 
Pv 
DHFR-TS3 
 0.62 0.34      
PfR  0.53       
Tb DHFR-TS4  0.59       
Tc DHFR-TS5  0.40 0.42      
Pv 
DHFR-TS6 
        
Pf         
PvR DHFR-TS7  0.49 0.47      
Tb NMT-1  0.60 0.54      
Pv NMT-1  0.66 0.58      
Tc NMT-2  0.55 0.49      
Mean deficiency, all 
targets 
 0.56 0.47 
    
 
Mean of deficiencies: 0.51 










DHFR seeds NMT seeds 
Hs Pf Pv(TS6) Tb Tc Pv Tb Tc 
Pv 
DHFR-TS3 
 -0.14  -0.16 -0.27 -0.16 -0.12 -0.12 
PfR  -0.08  -0.04  -0.03 -0.08  
Tb DHFR-TS4  -0.33 -0.04  -0.30 -0.23  -0.08 
Tc DHFR-TS5   -0.08 -0.11   -0.09 -0.07 
Pv 
DHFR-TS6 
   -0.20 -0.16 -0.06 -0.05 -0.07 
Pf     -0.12 -0.05 -0.09 -0.06 
PvR DHFR-TS7  -0.13  -0.08  -0.06 -0.07 -0.02 
Tb NMT-1  -0.14 -0.11 -0.09 -0.19   -0.07 
Pv NMT-1  -0.16 -0.01 -0.06 -0.18   -0.01 
Tc NMT-2  -0.10 -0.05 -0.12 -0.15 -0.05 -0.04  
Mean of deficiencies: -0.11 
Mean of core PfDHFR/PvDHFR seed deficiencies: -0.13 
 




DHFR seeds NMT seeds 
Hs Pf Pv(TS6) Tb Tc Pv Tb Tc 
Pv 
DHFR-TS3 
 0.46  0.43 0.34 0.43 0.28 0.37 
PfR  0.39  0.46  0.45 0.44  
Tb DHFR-TS4  0.63 0.63  0.37 0.64  0.38 
Tc DHFR-TS5   0.23 0.36   0.41 0.35 
Pv 
DHFR-TS6 
   0.31 0.34  0.37 0.35 
Pf     0.31  0.33 0.27 
PvR DHFR-TS7  0.33  0.31   0.29 0.57 
Tb NMT-1  0.41  0.38 0.35   0.57 
Pv NMT-1  0.52  0.43 0.43   0.43 
Tc NMT-2  0.43 0.38 0.35 0.43  0.44  
Mean of deficiencies: 0.40 










DHFR seeds NMT seeds 
Hs Pf Pv(TS6) Tb Tc Pv Tb Tc 
Pv 
DHFR-TS3 
 0.43  0.39 0.40 0.48 0.28 0.40 
PfR  0.42  0.43  0.48 0.43  
Tb DHFR-TS4  0.75 0.71  0.17 0.63  0.62 
Tc DHFR-TS5   0.25 0.37   0.35 0.38 
Pv 
DHFR-TS6 
   0.24 0.42  0.45 0.32 
Pf     0.32  0.30 0.32 
PvR DHFR-TS7  0.22  0.28   0.20 0.38 
Tb NMT-1  0.34  0.30 0.28   0.41 
Pv NMT-1  0.46  0.39 0.36   0.33 
Tc NMT-2  0.35 0.32 0.34 0.29  0.39  
Mean of deficiencies: 0.38 
Mean of core PfDHFR/PvDHFR seed deficiencies: 0.39 
 




DHFR seeds NMT seeds 
Hs Pf Pv(TS6) Tb Tc Pv Tb Tc 
Pv 
DHFR-TS3 
 -0.04 -0.33      
PfR   0.00       
Tb DHFR-TS4  -0.19       
Tc DHFR-TS5  -0.04 -0.07      
Pv 
DHFR-TS6 
        
Pf         
PvR DHFR-TS7  -0.18 -0.04      
Tb NMT-1  -0.12 -0.12      
Pv NMT-1  -0.03 -0.08      
Tc NMT-2  -0.08 -0.06      
Mean of deficiencies: -0.11 










DHFR seeds NMT seeds 
Hs Pf Pv(TS6) Tb Tc Pv Tb Tc 
Pv 
DHFR-TS3 
 0.38 0.34      
PfR  0.37       
Tb DHFR-TS4  0.53       
Tc DHFR-TS5  0.23 0.24      
Pv 
DHFR-TS6 
        
Pf         
PvR DHFR-TS7  0.29 0.22      
Tb NMT-1  0.38 0.41      
Pv NMT-1  0.50 0.45      
Tc NMT-2  0.42 0.37      
Mean of deficiencies: 0.37 
Mean of core PfDHFR/PvDHFR seed deficiencies: 0.39 
 




DHFR seeds NMT seeds 
Hs Pf Pv(TS6) Tb Tc Pv Tb Tc 
Pv 
DHFR-TS3 
 0.39 0.22      
PfR  0.39       
Tb DHFR-TS4  0.71       
Tc DHFR-TS5  0.18 0.25      
Pv 
DHFR-TS6 
        
Pf         
PvR DHFR-TS7  0.22 0.22      
Tb NMT-1  0.32 0.30      
Pv NMT-1  0.43 0.45      
Tc NMT-2  0.35 0.29      
Mean of deficiencies: 0.34 









General: The HsDHFR seed deficiency (0.68) is similar to that of SimplyGreedy (0.67) 
and active k-optimisation (0.64), indicating there is no significant TL impact from this 
seed group.  In comparison, there is a strong benefit from using the PvDHFR-TS6 seed 
(0.29), and weaker effects from TcDHFR (0.51) & TbNMT (0.50). 
5%/10% rare category:  The HsDHFR (0.98/1.01) seed has no significant effect on 
finding the rare actives.  Again, PvDHFR-TS6 is a strong seed (0.67/0.56), and TcDHFR 
(0.76/0.84) & TbNMT (0.68/0.76) are weaker seeds.  In comparison, active k-
optimisation (0.51/0.47) was a strong identifier of rare category compounds. 
PfRdhfr-TS3 
General: HsDHFR seed (0.35) versus SimplyGreedy (0.88) and active k-optimisation 
(0.91).  These results reflect the difficulty in identifying true active compounds against 
the PfR target (see Chapter 4), and there are no other TL seed groups that can offer 
obvious benefits. 
5%/10% rare category:  HsDHFR seed (0.36/0.34), active k-optimisation (0.40/0.48).  All 
the other TL seeds (deficiency ≥ 0.89/0.92) fail to predict the rare category compounds.  
These results further emphasise the lack of true active compounds for this target. 
TbDHFR-TS4 
General: HsDHFR (0.57), SimplyGreedy (0.63), active k-optimisation (0.69).  PvDHFR 
(0.43) and TcDHFR (0.45) are strong seeds; TbNMT(0.51) is weaker. 
5%/10% rare category:  HsDHFR (0.83/1.01), active k-optimisation (0.41/0.23).  





General: HsDHFR (0.55), SimplyGreedy (0.72), active k-optimisation (0.73).  PfDHFR 
(0.43) & PvDHFR (0.47) are strong seeds. 
5%/10% rare category:  HsDHFR (1.02/0.83), active k-optimisation (0.44/0.48).  
PfDHFR(0.64/0.58) and PvDHFR(0.52/0.67) are strong seeds. 
PvDHFR-TS6 
General: HsDHFR (0.66), SimplyGreedy (0.67), active k-optimisation (0.62).  
PfDHFR(0.49) is a strong seed. 
5%/10% rare category:  HsDHFR (1.06/1.06), active k-optimisation (0.45/0.40).  
PfDHFR (0.75/0.90), TcDHFR (0.75/0.90) and PvNMT (0.83/0.83) are weak seeds. 
PfDHFR-TS6 
General: HsDHFR (0.54), SimplyGreedy (0.74), active k-optimisation (0.83).  PvDHFR 
(0.45) and TcDHFR (0.43) are strong seeds. 
5%/10% rare category:  HsDHFR (0.88/0.86), active k-optimisation (0.42/0.44).  
PvDHFR (0.36/0.57) is a strong seed, and TcDHFR (0.61/0.70) and TcNMT (0.61/0.72) 
are weak seeds. 
PvRdhfr-TS7 
General: HsDHFR (0.63), SimplyGreedy (0.70), active k-optimisation (0.83).  PvDHFR 
(0.42) is a strong seed, and TcDHFR (0.50) is a weaker seed. 
5%/10% rare category:  HsDHFR (0.95/0.93), active k-optimisation (0.57/0.52).   





General: HsDHFR (0.74), SimplyGreedy (0.78), active k-optimisation (0.72).  
PvNMT (0.58) and PvDHFR (0.59) are weak seeds. 
5%/10% rare category:  HsDHFR (1.12/1.12), active k-optimisation (0.43/0.38).  PvNMT 
(0.58/0.80) is a fairly strong seed. 
PvNMT-1 
General: HsDHFR (0.74), SimplyGreedy (0.79), active k-optimisation (0.83).  
TbNMT (0.53) and TcNMT (0.50) are fairly strong seeds. 
5%/10% rare category:  HsDHFR (1.05/1.05), active k-optimisation (0.42/0.42).  TbNMT 
(0.85/0.83) is a weak seed. 
TcNMT-2 
General: HsDHFR (0.56), SimplyGreedy (0.80), active k-optimisation (0.80).  
PvNMT (0.49) is a weak seed. 
5%/10% rare category:  HsDHFR (0.76/0.73), active k-optimisation (0.40/0.36).  PvNMT 





C.1 Mass & cherrypick screen .csv files, column contents  
C.2 Hardware used during data analysis and simulations 
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C.1 Mass & cherrypick screen .csv files, column contents 
No. Data name Contents 
A/1 id_plate_instance numeric, plate number 
B/2 well_row letter, always A-P 
C/3 well_col numeric, always 1-24 
D/4 id_mixture string, two entries for each filled well, one entry for 
each negative control, no entries for empty wells, 
uses library name/code for substances on test 
E/5   id_chemical          numeric, Eve ID for chemicals in well, two entries for 
compounds (compound+DMSO), one entry for 
negative controls (#1313) 
F/6   name                 string, full compound name (or DMSO) 
G/7   smiles               SMILES code for F/6 
H/8   cherry_testname      alphanumeric 
I/9   cherry_hadError      numeric, should be zero 
J/10   cherry_startvalue   numeric, initial fluorescence 
K/11   cherry_endvalue     numeric, final fluorescence 
L/12   cherry_miylagtime   numeric 
M/13   cherry_doubletime   numeric 
N/14   sapphire_testname   alphanumeric 
O/15   sapphire_hadError   numeric, should be zero 
P/16   sapphire_startvalue numeric, initial fluorescence 
Q/17   sapphire_endvalue   numeric, final fluorescence 
R/18   sapphire_miylagtime numeric 
S/19   sapphire_doubletime numeric 
T/20   venus_testname      alphanumeric 
U/21   venus_hadError      numeric, should be zero 
V/22   venus_startvalue    numeric, initial fluorescence 
W/23   venus_endvalue      numeric, final fluorescence 
X/24   venus_miylagtime    numeric 
Y/25   venus_doubletime    numeric 
Z/26   id_plate_layout numeric 
AA/27   id_study            numeric 
AB/28   vol_cmpd_nl         numeric, for confirmation screen use 




C.2 Hardware used during data analysis and simulations 
Early prototype AL simulations, developed based on Kurt De Grave‟s active k-
optimisation algorithm (coded in Octave as multiSelOpt.m), were conducted using: 
(i) “Cledwall-testing” (processor 1: AMD Athlon MP 2000+ 1.67 GHz; 
processor 2: AMD Athlon MP 1000 – 1733 GHz; 2GB RAM). 
(ii) “Cledwall” (Intel Xeon quad core 2.80 GHz; 4 GB RAM). 
(iii) A desktop PC (Intel Core 2 Duo E8400 3.00 GHz; 4 GB RAM) running the 
Cygwin simulator. 
All three of these hardware setups ran into problems when attempting multiple loop 
simulations: Cledwall-testing would run three loops then slow rapidly due to insufficient 
memory; similar but less severe problems were seen with the desktop PC and Cledwall.  
It was also discovered that the 64-bit version of Octave is needed to process the larger 
data sets generated as the simulation progresses; this restricted the PC Cygwin Linux 
simulator as it did not support this software (August 2011). 
The Beowulf cluster (up to 40 units, Intel Pentium4 2.8 GHz with 1GB RAM) was also 
tentatively proposed as a possible resource for running simulations.  In addition to likely 
problems with computing capacity, this cluster didn‟t have appropriate software installed 
or any maintenance service contract. 
After tentatively exploring a couple of other external resources (cloud computing & HPC 
Wales), access to a computing facility (PINAC) at the Katholieke Universiteit Leuven 
was finally provided through our collaborator, Kurt de Grave. 
The PINAC cluster has developed over the period in use, with five older machines being 









5 Dual core E6600 processors (2.4 GHz, 4 MB 
cache), 4 GB RAM, 160 GB hard drive 
×  
10 Quad core Q9550 processors (2.83 GHz, 
12 MB cache), 8 GB RAM, 320 GB hard drive 
× × 
10 Intel Core i7-2600 3.4 GHz, 16 GB RAM  × 
The PINAC facility was used for all work on the active k-optimisation strategy. 
All other AL simulations were conducted using the HPC cluster run by IBERS, 
Aberystwyth University.  This facility has 152 processor cores available, with three 
discrete configurations: 
3 × AMD nodes 
AMD Opteron Processor 6220 @ 3 GHz 
32 cores 
100 GB memory available per node 
3 × Intel nodes 
Intel(R) Xeon(R) CPU X5647 @2.93 GHz 
8 cores 
190GB memory available per node 
1 × large memory node 






C.3 Software used during data analysis and simulations 
The data analysis steps were conducted using: 
 Microsoft Office Excel 2007. 
 WEKA (version 3.6.2) J48 decision trees. 
 R (version 2.12). 
 
The active k-optimisation simulations used: 
 R (version 2.12). 
 OpenBabel (version 2.2.3).  Note: some compatibility problems were 
encountered with later versions when used in conjunction with the Octave routine 
provided by Leuven. 
 Java. 
 Octave (64 bit Linux version 3.2.3 “x86_64-pc-linux-gnu” in Leuven; 32 bit 
Windows version 3.2.4 for testing purposes on a PC, in combination with the 
Cygwin Linux simulator). 
 
All other AL simulations used: 
 R 2.13.1 (including the following libraries: fingerprint 3.4.7, rcdk 3.1.7, rcdklibs 
1.4.7, rJava 0.9-3, rpubchem 1.4.3, car 2.0-11, rCurl 1.6-10.1, XML 3.4-2.2, 
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